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Thesis Abstract
The maintenance of the functional and structural integrity of our skeleton requires the
accurate spatial targeting of the activity of bone forming and resorbing cells, such that
functional adaptation occurs and microdamage is repaired. Osteocytes are thought to be
ideal candidates for targeting the remodeling process to specific sites, although little
evidence exists to support this. More recently they have been proposed to direct turnover
through their apoptotic death. Work in this thesis has focused on identifying a biological
role for osteocyte apoptosis, the identity of osteocyte-derived resorption targeting signals
and addresses the design of methods to blockade the excess apoptosis observed during
the use of glucocorticoids. High levels of osteocyte apoptosis have been seen to co-
localise with sites of bone resorption and to precede the resorption event, raising the
possibility that signals derived from dying osteocytes direct osteoclasts to bone requiring
remodeling; however the mechanism underlying this phenomenon is unknown. Many
osteoclastic activities have been shown previously to be controlled, not directly, but via
signals produced by osteoblastic cells. For this reason I have studied the effects of
osteocyte apoptotic bodies on osteoblastic cells. Apoptotic bodies derived from different
cell types were also used to determine behavioural responses in osteoblast and other
potential target cells. Osteoblasts were shown to undergo apoptosis upon contact with
osteocyte apoptotic bodies, while apoptotic products derived from different cell types,
did not induce osteoblast death. Furthermore, target cells other than osteoblasts, did not
undergo apoptosis in the presence of osteocyte or other cell type apoptotic products.
These data indicated a specific role for osteocyte apoptosis in the bone
microenvironment that might be directing the behaviour of osteoblasts in the bone
remodeling process. In addition, the demonstration of phenotypic specificity in the
apoptotic body-derived signals points to a further level of physiological "meaning" to
apoptosis. The physical interaction of apoptotic osteocytes with osteoblasts and the
resultant osteoblast death were dependent on membrane changes in the apoptotic body
and appeared to involve the phagocytic receptors CD 14 and scavenger receptor A as
evidenced by using gene knockout animal models.
Having identified an important potential role for apoptotic osteocytes in targeting
osteoblast removal at sites of remodeling, mechanisms that could interfere with the
induction of osteocyte apoptosis in response to Dexamethasone were investigated.
Dexamethasone-induced apoptosis was associated with activation of the Fas death
receptor and ERK1/2 pathways. Bisphosphonates suppressed the pro-apoptotic stimuli,
independently of their detailed structure and their in vivo anti-resorptive potency. These
data suggested that bisphosphonates could provide therapeutic approaches against excess
osteocytic death observed in glucocorticoid-induced osteoporosis in order to maintain a
balance between osteocyte viability and death, which might ultimately lead to stabilised
bone turnover activity and better bone quality.
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Bone is a rigid form of connective tissue that supports locomotion as a site for
muscle attachment, provides protection for vital organs, nurtures the bone marrow
and stores ions such as calcium and phosphate that participate in serum homeostasis
(Felsenfeld 1999, Rasmussen 1971, Einhorn 1996, Baron 1996). Bone is a dynamic
tissue that has the ability to adapt its architecture as a result of continuous modelling
and remodelling cycles throughout life according to structural and mechanical
requirements (Wolff 1892, Turner 1992, Parfitt 1994). The processes of bone
modelling and remodelling are regulated by a variety of osteotropic cytokines and
hormones, which influence the activity of bone cells in order to maintain coupling
between bone resorption and formation (Rodan 1992, Rodan and Fleisch 1996).
Imbalances in these interactions result in abnormal turnover cycles, characterised by
insufficient formation of bone resorbing or forming cells, increased resorptive or
forming activity or abnormal formation of mineral crystals, leading to diseases such
as osteoporosis, Paget's disease of bone, osteolytic and osteosclerotic bone diseases.
(Russell et al. 2001, Rodan and Martin 2000, Helfrich 2003).
Repair of damage and adaptation of bone to specific architectural requirements,
depends on the targeted activity of bone forming and resorbing cells (Parfitt 2002).
Osteocytes have been proposed to act as the mechanosensors and transducers in bone
(Lanyon 1993, Zhang et al. 1997, Noble et al. 2003); however very little is known
about the mechanism by which osteocytes direct the activity of bone resorbing or
forming cells, resulting in targeted remodelling of bone according to structural and
mechanical requirements. The aim of this thesis was to investigate the apoptosis of
osteocytes and discuss the significance of this death on the targeted remodelling and
the regulation of bone homeostasis. This section outlines the basic structural and
functional organisation of bone and describes aspects of osteocyte function. In
addition, it summarises the basic pathways of apoptosis and describes the current
knowledge on apoptotic bone cell death.
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1.2 Bone structure and modelling
Bones consist of hydroxyapatite crystals, collagenous and non-collagenous proteins
and can be categorised into flat bones formed by intramembranous ossification, and
long bones comprised of trabecular and cortical bone, which are formed by
endochondral ossification (Carter and Orr 1992, Parfitt 1994, Baron 1996). Cortical
bone encloses the medullary cavity and is composed of osteons oriented in the
direction of maximal stress, surrounded by lamellae and interstitial bone, while
macroscopically, trabecular bone has a spongy appearance and consists of a network
of thin bone bridges oriented to resist mechanical loading (Einhorn 1996, Weiner et
al. 1999, Sikavitsas et al. 2001). Spaces between trabeculae are filled with bone
marrow (Baron 1996). During intramembranous ossification, mesenchymal cells
differentiate into preosteoblasts and osteoblasts, which synthesise woven bone that is
characterised by irregular calcification and arrangement of collagen fibres, and high
osteocyte cell density, which is then progressively replaced by lamellar bone (Turner
1992, Weiner and Wagner 1998, Sikavitsas et al. 2001). During endochondral
ossification, mesenchymal cells differentiate into prechondroblasts and chondroblasts
that secrete cartilaginous matrix. Chondroblasts become embedded in their own
matrix and turn into chondrocytes, which engender longitudinal growth (Parfitt 1976,
Carter et al 1996). As chondroblasts continue to proliferate, more chondrocytes are
formed which move away from the proliferative zone and become larger, while the
matrix that surrounds them starts to calcify. This process is controlled by factors such
as parathyroid hormone-related protein (PTHrP), Indian Hedgehog (Ihh) and bone
morphogenetic proteins (BMPs) (Strewler 2001). Osteoclasts then, resorb the
calcified matrix, while osteoblasts form the woven bone. (Parfitt 1994, Weiner and
Wagner 1998, Boyde 1980).
1.3 Bone remodelling
Bone remodelling or turnover is the process by which old or damaged bone is
replaced by new bone (Mundy 1995). Bone turnover occurs in basic multicellular
units (BMUs) (Frost 1969) and involves a sequence of events, which include
formation and activation of osteoclasts which carry out bone resorption, recruitment
of osteoblasts which secrete new bone that eventually becomes mineralised, thus
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completing the remodelling process, while that particular site returns to a quiescent
state (Parfitt 1994, Parfitt 2002) (Figure 1).
Wolffs law has stated that changes in the form and function of bone are followed by
specific changes in the internal bone architecture and external conformation, in
accordance with quantitative laws (Wolff 1892). This law has provided the
fundamental basis for understanding the skeleton in both physiological and
pathological conditions and indicates that bone has the ability to sense structural and
mechanical requirements, repair any damage occurring as a result of everyday use
and adapt its architecture to maintain a constant reliability level, as a result of
continuous modelling and remodelling cycles throughout life (Turner 1992, Parfitt
1994). Bone turnover can be non-site dependent or directed against specific sites
(Parfitt 2002). Non-targeted remodelling could occur for example in order to restore
mineral balance, while the maintenance of structural and mechanical integrity in
bone is largely dependent on targeted remodelling (Burr 2002). The latter requires a
method to direct the activity of bone resorbing and bone forming cells to specific
sites, as it has been demonstrated by several studies which induced microdamage by
loading canine (Burr and Martin 1993) or rat bone (Verborgt et al. 2000, Noble et al.
2003), which was followed by increased remodelling activity. However, targeted
turnover also requires a method to detect the specific mechanical requirements,
which is further discussed in §1.5.3 and §2.8.4.
1.4 Bone forming and resorbing cells
Osteoclasts are large, multinucleated cells, formed by the fusion of mononuclear
progenitors (the CFU-GM, colony-forming unit for the granulocyte-macrophage
series) in the bone marrow, which have the capacity in response to appropriate
stimuli, to differentiate into a granulocyte, monocyte or osteoclast (Felix et al. 1994,
Mundy 1996). The osteoclast is characterised by a ruffled border that polarises the
cell on the bone surface (Mostov and Werb 1997). Acidification of bone is induced
by an electrogenic proton ATPase, whereas the abundant Golgi complexes and a
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Figure 1. Representation of bone turnover cycle. Osteoclasts are activated to
resorb bone at a particular bone surface, followed by bone formation by osteoblasts,
in a sequence of events known as activation-resorption-reversal-formation process.
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proteolytic enzymes, which are secreted via the ruffled border in the localised
environment and carry out bone degradation (Teitelbaum 2000). As members of the
monocyte/macrophage family of phagocytes described in §2.7, osteoclasts readily
phagocytose bone minerals through the protrusion of pseudopodia around the
particles followed by endophagosome formation and lysosomal degradation
(Wenisch et al. 2003, Wang et al. 1997). In addition, it has been proposed that
osteoclasts phagocytose apoptotic cells as demonstrated by the appearance of
apoptotic fragments possibly derived from osteoblasts and/or osteocytes in large
vacuoles within osteoclasts, in alveolar bone of young rats (Boabaid et al. 2001,
Cerri et al. 2003).
Formation and differentiation of osteoclast precursors is under the control of several
factors, including PTH, tumour necrosis factor a (TNFa), transforming growth factor
a (TGF-a), interleukin-1 (IL-1) and 1,25-dihydroxyvitamin D3 (Blair 1998).
However, osteoclastogenesis particularly depends on a soluble product known as the
macrophage colony-stimulating factor (M-CSF) and the receptor for activation of
nuclear factor kB (RANK) ligand, also known as osteoprotegerin ligand, which
requires contact with osteoblast progenitor cells and marrow stromal cells (Kong et
al. 1999, Miyamoto et al. 2000). These latter cells express the membrane-bound
molecule RANKL and OPG, a soluble decoy receptor that competes with RANK for
RANKL regulating osteoclast formation (Lacey et al. 2000, Teitelbaum 2000).
Osteoblasts are derived from bone marrow stromal cells or connective tissue
mesenchymal stem cells (Prockop 1997), and can appear as flat cells or be
characterised by a round nucleus, multiple Golgi stacks, and a well-developed
endoplasmic reticulum (Puzas 1996). In addition they are characterised by
cytoplasmic processes extending into the osteoid tissue, with which they
communicate with osteocytes in their canaliculi and gap junctions to communicate
with other osteoblasts (Baron 1996, Schiller et al. 2000). Central to osteoblast
differentiation is the transcription factor core-binding factor-1 (Cbfal), expressed in
mesenchymal cells destined to become chondrocytes or osteoblasts (Harada et al.
1999, Ducy et al. 2000) and Indian Hedgehog, which regulates expression of PTH
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and PTHrP controlling chondrocyte hypertrophy. Other growth factors involved in
osteogenesis include the BMPs, TGF-P and members of the fibroblast growth factor
family (FGF) and the insulin-like growth factor (IGF) family (Harada and Rodan
2003, Siddhanti and Quarles 1994). These factors are expressed during proliferation
of progenitor cells, along with matrix components, such as type I collagen and
fibronectin (Ducy et al. 2000, Puzas 1996). At the same time, gene products appear
that are associated with a mature matrix, such as alkaline phosphatase and matrix
gla-protein, followed by products such as osteopontin and osteocalcin which result in
hydroxyapatite accumulation and completion of mineralisation (Yamaguchi et al.
2000, Puzas 1996). Osteoblastic activity is also influenced by hormones such as
PTH, 1,25-dihydroxyvitamin D3, glucocorticoid hormones and gonadal steroids
(Strewler 2001). Recent studies have identified a role for LRP5 (low density
lipoprotein-receptor related protein 5), in the transcription control of bone formation,
also linked to Wnt signalling involved in developmental processes, as gain of
function mutation led to high bone mass while loss of function led to osteoporosis-
pseudoglioma syndrome (Little et al. 2002, Boyden et al. 2002). Furthermore, studies
have identified the gene Sclerostin (SOST), encoding for a protein that binds BMPs
and suppresses their activity in bone, decreasing bone formation (Balemans et al.
2001, Brunkow et al. 2001). Finally, evidence have suggested a role for the central
nervous system in the regulation of bone formation, as leptin deficiency induced high
bone mass independently of its anti-appetite effects (Ducy et al. 2000, Corral et al.
1998). At the end of the secretion period, mature osteoblasts are found on the bone
surface in clusters of cuboidal cells, as bone lining cells, undergo apoptosis or
become osteocytes (Jilka et al. 1998, Karsdal et al. 2002).
1.5 Osteocytes
1.5.1 Definition and morphology
Osteocytes are terminally differentiated, postmitotic cells that reside in lacunae
within the matrix of both cancellous and cortical bone (Aarden et al. 1994, Sikavitsas
et al. 2001). Osteocytes are formed from bone surface osteoblasts that have become
encased by their own matrix production, which eventually calcifies (Aarden et al.
1996). It has been suggested that a limited number of osteoblasts can become
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osteocytes (Palumbo et al. 1990a,b); however the signals that direct this
differentiation have not been identified yet. During their differentiation, osteocytes
acquire long dendritic-like processes, which extend through the matrix via the
canaliculi and form a communication network between other osteocytes and
osteoblasts lining the bone surface (Aarden et al 1996, Palumbo et al. 1990a,b Noble
et al 2000). Canaliculi are small channels, formed around previously existing
osteoblast processes and allow the diffusion of nutrients and waste products in and
out of the tissue.
Osteocytes have smaller cell volume than osteoblastic cells; however, they possess
most of the ultrastructural characteristics of an osteoblast including many
mitochondria and ribosomes and well-developed Golgi apparatus and endoplasmic
reticulum (Figure 2 and Figure 3) (Aarden et al. 1994). Osteocytes are embedded in
hard matrix and therefore are difficult to investigate. Very few studies using primary
osteocytes are available to date. Nijweide et al. have developed an antibody termed
mAb OB7.3 (see §1.5.3.3) that reacted specifically with avian osteocytes (Nijweide
and Mulder 1986). Isolation from chicken calvariae and investigation of these cells in
culture revealed that osteocytes remain postmitotic following their extraction and
retain some of the osteoblastic characteristics, such as alkaline phosphatase activity
and PTH receptors (Van der Plaas et al. 1994). Recently, an osteocytic-like cell line
called MLO-Y4, derived from murine long bones was developed enabling the
investigation of several signal transduction pathways, as discussed in §1.5.3. MLO-
Y4 osteocyte-like cells were isolated from transgenic mice, in which the SV40 large
T-antigen expression was under the control of the osteocalcin promoter (Kato et al.
1997). The cells were able to proliferate and express large amounts of osteocalcin
(Kato et al. 1997), a characteristic of osteocytes (Mikuni-Takagaki et al. 1995),
which possibly prevents mineralisation of the tissue around the cell body. The cell
line is also characterised by long cytoplasmic processes (Figure 3), low alkaline
phosphatase activity, low collagen type I mRNA expression, osteopontin and
connexin 43 mRNA expression, which is important for communication between cells
(Kato et al. 1997). Because of the abundance of osteocytes in bone and the
communication network that they form, several functions have been proposed for
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Figure 2. MLO-Y4 osteocytes in culture. Representative image of the MLO-Y4
osteocyte-like cell line, isolated and characterised by Kato et al. 1997, demonstrating
large cytoplasmic extensions which enable contact between neighbour osteocytes.
Image was taken using phase contrast light microscopy. Bar =10 pm.
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Figure 3. The osteocyte. The osteocyte contains a large Golgi apparatus (g), a
well developed endoplasmic reticuclum (er) and a basal nucleus. The osteocyte
expresses molecules involved in the targeting of bone formation and resorption and
are under the influence of hormones, neuronal factors and mechanical stimuli.
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these cells, as discussed in §1.5.2. Therefore it is important to investigate further and
characterise osteocytes, either through the establishment of new cell lines at various
differentiation stages or the development of antibodies against specific antigens,
discussed in §1.5.3.3 enabling the routine isolation of osteocytes following the
sequential digestion of bones from different species.
1.5.2 Function of osteocytes
Several theories have been proposed concerning the function of osteocytes and their
contribution to the process of bone remodelling. Osteocytes were initially thought to
contribute to the removal of bone matrix by resorbing calcified bone around them, a
phenomenon known as osteocyte osteolysis (Belanger et al. 1963, Parfitt 1976). This
belief was probably based on the size of the lacunae in particular diseases or to the
production of proteolytic enzymes, such as collagenase, capable of degrading bone
matrix. Later evidence however, suggested that osteocytes are not able to resorb bone
(Boyde 1980, Marotti et al. 1990, Van der Plaas et al. 1994). Osteocytes have also
been proposed to contribute to the mineralisation process, by secreting non-
collagenous proteins, such as osteocalcin and osteopontin (Ikeda et al. 1996).
Furthermore, osteocytes have been reported to produce inhibitory signals that
decrease the apposition rate of osteoblasts during refilling of BMUs and enable the
recruitment of osteoblasts to become osteocytes (Marotti 1996, Martin 2000).
Despite the evidence that enable osteocytes to contribute to the processes of bone
resorption and formation, these theories can not justify the existence of the extensive
network that these cells form within the bone matrix. Experiments in the last decade
have led to the conclusion that osteocytes sense the amount of strain applied in the
local environment either through changes in fluid flow or cell deformations (Lanyon
1993, Zhang et al. 1997, Noble et al. 2003). Osteocytes were shown to interact with
osteoblasts via gap junctions, as evidenced by the passage of calcein dye between
MLO-Y4 osteocytes and MC3T3-E1 osteoblasts, while mechanical deformation of
osteocyte cell membrane induced calcium signals in neighbouring osteocytes and
osteoblasts, suggesting that osteocytes are capable of communicating a mechanical
response (Yellowley et al. 2000). A reduced incidence of bone resorption has been
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correlated with osteonecrosis, characterised by death of bone cells (Kenzora et al.
1978), while examination of the lacunar occupancy at different stages of the
remodelling cycle, revealed that forming as well as resorbing osteons contained
higher osteocyte density and lacunar occupancy, compared to quiescent osteons
(Power et al. 2002). Other studies have demonstrated a decline in the osteocyte
lacunar density in human cortical bone, in association with microcracks and
increased porosity observed in aging (Vashishth et al. 2000). Finally, studies have
shown that apoptosis of osteocytes preceded bone resorption in rat ulna bone, in
response to mechanical loading (Noble et al. 2003). In summary, these findings
suggest that osteocytes constitute a signalling network capable of influencing the
remodelling activity of bone, following mechanical stimulation and might also
provide a candidate signal through their apoptosis for specific site-directed
remodelling, which forms the hypothesis tested in section 2. The nature of the control
that osteocytes' exert on the remodelling process might also be explained by
examining the response of osteocytes to hormonal or mechanically derived stimuli.
(Figure 3).
1.5.3 Hormonal and neuronal-related factors
Osteocytes are affected by a number of hormones and cytokines that are known to
regulate bone homeostasis. Estrogen loss induced by either gonadotrophin-releasing
hormone analogs or ovariectomy, increased the proportion of apoptotic osteocytes,
which could be reversed following estrogen administration (Tomkinson et al. 1997
and 1998), while glucocorticoid treatment also affected the viability of osteocytes in
the human and mouse (Weinstein et al. 1998 and 2000). Immunohistochemical
studies revealed the presence of receptors on osteocytes for mineralocorticoids,
glucocorticoids (Beavan et al. 2001) and l,25(OH)2D3 (Boivin et al. 1987). In
addition, osteocytes have demonstrated PTHrP and PTH binding (Rao et al. 1983,
Fermor et al. 1995), which were shown to alter cx43 expression and induce
apoptosis, regulating possibly osteocyte communication and survival (Divieti et al.
2001).
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Osteocytes also express receptors associated with the nervous system, such as
neurokinin-1 receptors, which bind to substance P released from axons of sensory
neurons and possibly regulate osteoclastic resorption (Goto et al. 1998). In addition,
they express the glutamate and aspartate transporter (GLAST) gene and mRNA,
which have been shown to be down-regulated in response to mechanical loading,
suggesting a paracrine role of glutamate in the communication between osteocytes
and osteoblasts (Mason et al. 1997). Binding of serotonin to the receptor 5-HT2B
reduced production of nitric oxide (NO) from mechanically stimulated mouse
osteoblasts, whereas the highest expression of 5-HT2b mRNA was found in
osteocytes, suggesting a role for serotonin in the modulation of mechanical stimuli in
bone (Westbroek et al. 2001).
1.5.4 Mechanotransduction and the osteocyte
Several studies have investigated signal transduction pathways in osteocytes in
response to mechanical loading. Pulsating fluid flow was shown to increase
intracellular Ca++ concentration, which further increased prostaglandin E2 (PGE2)
production in isolated chicken osteocytes (Ajubi et al. 1999) and in MLO-Y4
osteocytes (Hakeda et al. 2000). PGE2 production was associated with increased
levels of cx43 protein, in a cAMP-PKA-dependent manner (Cheng et al. 2001,
Cherian et al. 2003), while fluid shear stress led to rearrangement of Cx43 and Cx45,
disruption of junctional communication and disconnection of bone cells (Thi et al.
2003). These studies have indicated that in response to mechanical loading,
osteocytes could possibly transmit a metabolic signal, which could influence local
bone remodelling, since it has been shown that PGE2 is able to sustain recruitment
and maturation of osteoclasts and proliferation and differentiation of osteoblasts
(Suda et al. 1995, Samoto et al. 2003). Release of PGE2 from chicken osteocytes was
shown to be preceded by NO release from activated endothelial cell NO synthase
(ecNOS) (Klein-Nulend et al. 1995 and 1998). In addition, a reduced expression of
ecNOS on osteocytes has been observed in association with femoral neck fracture,
suggesting the importance of NO in directing osteoclast resorption depths and
orientation, in response to different magnitude strains sensed by the osteocytes
(Loveridge et al. 2002, Burger et al. 2003). Furthermore, in mouse alveolar
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osteocytes mechanical loading increased production of dentin matrix protein 1
(Gluhak-Heinrich 2003), while osteopontin production was associated with increased
number of osteoclasts and resorption pits on the site of pressure, indicating a role for
osteopontin in initiation of resorption (Terai et al. 1999).
1.5.5 Factors that affect osteocytic phenotype
Recent studies have identified a gene known as El 1, which encodes for a 17.4 kDa
protein, a type I transmembrane protein, preferentially expressed in mature
osteoblasts, preosteocytes and osteocytes, at regions of the cell membrane in contact
with the matrix. Expression was increased during intramembranous and
endochondral bone formation and during the early stages of fracture healing
(Wetterwald et al. 1996, Hadjiargyrou et al. 2001). Several studies have identified
Ell as an osteoblastic lineage differentiation marker, expressed in preosteoblasts,
mature osteoblasts, preosteocytes, mature osteocytes, osteoblastic cell lines and
MLO-Y4 osteocyte-like cells (Lian et al. 1999, Bonewald et al. 2000). However,
Schulze et al. showed that El 1 is present only on osteocytic cell membranes as well
as their processes, in calvariae, acting as a late osteogenic marker (Schulze et al.
1999).
El 1 is identical in amino acid sequence to a protein called podoplanin, in glomerular
epithelial cells (podocytes), which is involved in maintaining the shape of podocyte
foot processes and glomerular permeability, and also RT140, a protein isolated from
rat type I lung alveolar epithelial cells (Breiteneder-Geleff et al. 1997, Matsui et al.
1999, Vanderbilt et al.1999). In addition, El 1 shares 87% sequence homology to the
murine protein OTS-8 which has been reported to bind to the cell surface receptor
CD44, involved in cell adhesion and migration in tumour vascular endothelial cells
(Nose et al. 1990, Ohizumi et al. 2000). CD44 was also shown to be expressed
during fracture healing (Yamazaki et al. 1999). These findings imply that Ell is
associated with the formation and maintenance of osteoblastic and octeocytic cellular
processes, as well as in the adhesion of these cells to the bone matrix during fracture
repair.
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Osteocytes within trabecular and cortical rat bone were found to express high levels
of a bone-specific cDNA termed OF45 (osteoblast/osteocyte factor 45), encoding for
an RGD-containing protein (Petersen et al. 2000). Studies in the rat mandible using
in situ mRNA localization demonstrated OF45 expression in mature osteoblasts and
in osteocytes throughout ossification in the skeleton, hence it may represent an
important marker of the osteocyte phenotype (Igarashi et al. 2002). Skeletal
examination in OF45 knockout animals showed increased bone mass due to
increased osteoblast numbers and activity, while osteoclast recruitment and numbers
were not affected (Gowen et al. 2003). The authors have suggested that OF45 mRNA
is associated with differentiation into the osteocyte phenotype, possibly involved in
the regulation of bone mineralisation. The mouse OF45 gene sequence is
homologous to the human MEPE gene, implicated in oncogenic osteomalacia and
has been proposed as a downstream target in the phosphate pathway regulated by the
PHEX endoprotease (Gowen et al. 2003, MacDougall et al. 2001). Interestingly, it
has been shown that the PE1EX protein is the target of the antibody mAb OB7.3
(Westbroek et al. 2002), which is specifically used to isolate chicken osteocytes
(Nijweide and Mulder 1986). These observations suggest that osteocytes participate
in phosphate handling and regulation of mineralisation, since mutations in the PFIEX
gene result in bone mineralization abnormalities and X-linked hypopshosphataemia
(Sabbagh et al. 2003).
1.5.6 Osteocyte-derived factors that affect osteoclast survival and
function
Most of the studies described above propose that osteocytes are implicated in the
regulation of bone turnover events by acting as sensors and transducers of
mechanical-derived stimuli (§1.5.3.2) and by expressing osteotropic factors (§1.5.3.1
and 1.5.3.3). However, little is known about any direct effects of osteocyte-derived
factors on osteoclast recruitment and function. Studies have suggested that release of
TGF-P from MLO-Y4 osteocytes exerts direct inhibitory effects on osteoclast
resorption, in an estrogen-dependent manner (Heino et al. 2002), while generation of
ecNOS and NO by osteocytes directs orientation and depth of resorption by
osteoclasts (Loveridge et al. 2002, Burger et al. 2003).
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In addition, MLO-Y4 osteocytes have recently been suggested to support
osteoclastogenesis in co-culture experiments with spleen or marrow mouse cells, via
the production of RANKL (Zhao et al. 2002). The authors proposed that direct
contact is required between osteocytes and osteoclasts, in order to promote
osteoclastogenesis; however, this hypothesis has not yet been supported by in vivo
data that would show osteocytic cellular processes reaching the bone marrow and
interacting with osteoclast precursors. Ahuja et al. have shown that CD40L, which
serves as a survival factor for dendritic cells, protected MLO-Y4 osteocytes against
the antiapoptotic actions of Dexamethasone, TNFa or etoposide. The authors have
also suggested that CD40 may increase OPG production, as it does in B-lymphocytes
and that it may regulate production of matrix metalloproteinases by osteocytes and
osteoblasts participating in bone turnover (Ahuja et al. 2003).
1.6. Summary
Bone undergoes multiple cycles of remodelling during a lifetime in order to adapt to
specific requirements of strength and shape, according to Wolffs law (1892).
Osteocytes have been proposed to maintain bone quality by sensing mechanical
loading and transmitting signals that possibly target the activity of bone effector
cells, osteoclasts and osteoblasts through the canalicular network. In particular, the
bone resorptive activity of osteoclasts has been correlated with the incidence of
osteocyte apoptosis close to those areas (Noble et al. 1997). Apoptosis of osteocytes
is discussed in §2.8.4 and is investigated in detail in sections 2 and 3, which address






Cell death is an essential phenomenon conserved throughout evolution, and can be
characterised as necrotic cell death, which refers to the morphology seen when cells
or tissues die from severe and sudden injury and apoptotic cell death, which is the
focus of this section. Apoptosis can be initiated by a variety of stimuli and appears to
be an essential homeostatic mechanism for the healthy development and maintenance
of tissues (Kerr et al. 1972, Levine et al. 1994, Cotman and Anderson 1995). Recent
evidence has suggested that apoptosis of cells, rather than being a silent event
leading to the disposal of unwanted cells, could also result in specific
immunosuppressive or pro-inflammatory responses, when they interact with
monocytes/macrophages (Gao et al. 1998, Chen et al. 2001, Voll et al. 1997, Fadok
et al. 1998), or dendritic cells (Stuart et al. 2002, Albert et al. 1998, Belone et al.
1997, Inaba et al. 1998, Albert et al. 2001). These findings raise interesting issues as
to the consequences of phagocytosis of different apoptotic cells by various
phagocytes, which is the focus of section 2. This chapter outlines the basic apoptotic
events and describes in vivo and in vitro cases of apoptosis of bone cells.
2.2 Definition of apoptosis
Most of the knowledge concerning the genetic control of apoptosis comes from
studies on the nematode, Caenorhabditis elegans (Ellis and Florvitz 1986). Apoptosis
is the result of the induction of an internal suicide program and is characterised by
membrane blebbing, chromatin condensation, DNA cleavage and packaging of
cellular contents into apoptotic bodies. The contents of dying cells are eliminated by
phagocytosis, so that they do not generate an inflammatory response within the body
(Figure 4) (Kerr et al. 1972, Savill 1997). Apoptosis could be divided into four
stages, the initiating phase, the decision and execution phase and phagocytosis
(Dragovich et al. 1998). The roles of the Bcl-2 proteins, caspases and death receptors
throughout this four stage sequence are summarised in the following paragraphs.
2.3 Caspases (Cysteine Aspartate ProteASES)
Caspases disassemble the cell's structure, terminate DNA replication, attack the
nucleus, prevent repair mechanisms and prepare the cell for phagocytosis
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(Thornberry et al. 1998). Caspases include the initiator caspases (caspases 1, 2, 8, 9,
10), activated by functional changes occurring in the mitochondria and death
receptors, and effector caspases (caspases 3, 6, 7), which are mediators of the
execution phase, activating the DFF45 enzyme in humans or ICAD in mice
(Dragovich et al. 1998). These are Ca++/Mg+ dependent endonucleases, cleaving
DNA into oligomers of 180bp (Guchellaar et al. 1997). Other caspase targets include
the lamins, p21 activated kinase-2, gelsolin, PARP and replication factor C,
implicated in repair mechanisms (Thornberry et al. 1998, Allen et al. 1998).
2.4 Bcl-2 family of proteins and implication of mitochondria in
apoptosis.
During apoptosis, functional and structural changes occur in mitochondria, due to
disruption of the regulation of the permeability transition (PT) pore, a complex of
proteins located between the mitochondrial membranes (Kroemer 1997). Opening of
the PT pore induces changes in the mitochondrial inner transmembrane potential
Avgm and results in the generation of ceramide, reactive oxygen species and NO
(Green et al., 1998, Decaudin et al., 1998). These events lead to cytochrome c
release, disruption of the electron transfer chain and activation of caspase-9, which in
turn activates caspase-3 (Decaudin et al. 1998, Allen et al. 1998). The Bcl-2 family
of proteins includes the anti-apoptotic proteins the Bcl-2, Bc1-Xl, Bag, Mcl-1 and Al
and the pro-apoptotic proteins Bcl-xs, Bax, Bad, Bid and Bak,. The levels of these
proteins on the outer mitochondrial membrane and their ability to form homodimers
or heterodimers, regulate opening of the PT pore and the apoptotic threshold of the
cell. (Adams et al. 1998, Kroemer 1997).
2.5 Death Receptors
Death receptors are members of the TNF/NGF superfamily and include Fas and TNF
Receptors 1 and 2 (Figure 5), Death Receptor-3 and TRAIL receptors 1, 2, 3, and 4
(Ashkenazi et al. 1998). Binding of Fas L to Fas R or TNF L to TNF R1 causes
receptor oligomerisation (Figure 5). Death receptors interact through a death domain
with adapter molecules, such as FAS- or TNF-associated death domain-containing














Figure 4. The four stages of apoptosis: 1) Exposure to an apoptotic stimulus,
2) Decision to initiate survival or apoptotic cascades, 3) execution phase,
characterised by cytoplasmic and chromatin condensation, fragmentation of DNA
and membrane blebbing and 4) Clearance phase involving the engulftnent of the
apoptotic bodies by a nearby phagocyte, in order to avoid inflammation
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caspase-8 or caspase-10, activating the apoptotic cascade (Wehrli et al 2000). Fas
signalling can be inhibited by inhibitors of caspase-8 and downstream effector
caspases, or Bcl-2 proteins (Ashkenazi et al. 1998). TNF-R1 could also interact with
TRAFs (TNF-R-associated factors) and activate the JNK pathway, initiating
transcription of survival proteins (Rothe et al. 1995, Kitson et al. 1996, Ashkenazi et
al. 1998) (Figure 5). TNF and Fas receptors can also activate the sphingomyelin
pathway, which produces ceramide and initiates apoptosis through the JNK pathway
(Verheij et al. 1996).
2. 6 Membrane blebbing
Apoptotic cells fragment into membrane-bound bodies, which are rapidly ingested by
phagocytes, such as macrophages, or by neighbouring cells. The force that drives the
formation of apoptotic bodies is produced by actin-myosin II cytoskeletal structures
(Mills et al. 1999). Inhibition of the Rho kinase ROCK has been shown to prevent
formation of membrane blebs (Coleman et al. 2001), while activation of ROCK
resulted in stabilisation of actin-myosin interactions (Amano et al. 2001) and
generation of a hydrodynamic force, which leads to cell contraction. In addition
caspases cleave regulatory proteins, reducing the interaction between the plasma
membrane and the cytosleleton, leading to bleb protrusion (Fedier and Keeler 1997).
2.7 Phagocytosis
Phagocytosis is a rapid and efficient process that prevents leakage of contents that
would initiate an inflammatory response and which requires recognition of the
apoptotic bodies by phagocytes, in order to engulf them and degrade them, without
disturbing neighbouring living cells (Savill 1997) (Figure 6). Carbohydrate and
glycoprotein changes on the apoptotic cell membrane have been shown to enable
recognition of the apoptotic cells by the macrophage lectin receptors. (Savill et al
1992, Henson et al. 2001). Other markers on the apoptotic cell surface include
thrombospondin 1 (TSP1) binding sites and phosphatidylserine (PS). PS is a
phospholipid normally present on the inner leaflet of the membrane and is exposed
through a Ca++-dependent movement involving activation of a phospholipid













Figure 5. Death receptor signalling. Binding of Fas L to Fas R or TNF L to
TNF R1 causes receptor oligomerisation. The receptor interacts with adapter
molecules, such as FADD or TRADD, which interact with caspase-8 activating the
apoptotic cascade. Signalling from these receptors can be inhibited by caspase-8
inhibitors, Bcl-2 proteins or by x-linked inhibitors of apoptosis (x-IAP). TNF-R1 also
interacts with TRAFs (TNF-R-associated factors), which activate the inhibitor of kB
(I-kB) resulting in NF-kB activation and transcription of survival proteins. (Rothe et
al. 1995), or it can induce pro-survival signals through the JNK MAPK pathway.
stimulatory effect, 1 = inhibitory effect.
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translocase. Inhibition of phospholipid translocation has been shown to prevent
phagocytosis (Fadok et al. 2001). PS exposure occurs at the early stages of apoptosis,
as demonstrated by PS binding with Annexin V FITC, a rapid, sensitive and
quantitative assay (Shouman et al. 1998).
Phagocytic receptors (Figure 6) are also involved in the uptake of apoptotic cells,
such as the lectin and PS receptors (PtSerR) (Fadok et al. 2000) mentioned above.
Macrophages employ CD36 and avP3 integrin, which bind to apoptotic neutrophils,
eosinophils and lymphocytes through TSP1, as demonstrated by inhibition studies,
using monoclonal antibodies and RGD peptides (Savill et al. 1992). Scavenger
receptors of class A and class B and the ABC-1 membrane transporter have also been
shown to participate in the uptake of apoptotic cells (Piatt et al. 1996, Henson et al.
2001). Other recognition molecules include the CD 14, which has the ability to
interact with lipopolysaccharride on bacteria and also to induce apoptotic cell
tethering and uptake, in a noninflammatory manner (Devitt et al. 1998). CD14,
identified by the monoclonal antibody 61D3, has been proposed to act as a pattern
recognition receptor, interacting with a series of apoptotic cell associated molecular
patterns (ACAMPs) (Flora and Gregory 1994, Gregory 2000). Following recognition
of apoptotic bodies, phagocytes undertake pseudopodia extension possibly through
the involvement of PI3 kinase (Cox et al. 1999) and finally engulf apoptotic cells.
Studies in C. Elegans have identified two pathways implicated in engulfment, which
induce cytoskeletal changes, polymerisation of F actin and formation of a phagocytic
cup (Coleman et al. 2002, Leverrier et al. 2001, Henson et al. 2001, Tosello-
Trampont et al. 2001). Apoptotic body uptake is followed by endosomal fusion and
lysosomal degradation, brought about by F-actin dissociation and depolymerisation
(Bengtson et al. 1993).
2.8 Apoptosis in Bone
In bone tissue, necrosis occurs following exposure to radiation, steroid use and


























Figure 6. Mechanisms involved in the recognition of apoptotic cells by
phagocytes. Apoptotic cell changes include exposure of PS which is recognised by
the PS receptor on phagocytes, receptors for |32-glycoprotein and the Mer kinase
receptor for Gas6. In addition, scavenger receptors like CD36 and SRA recognise
oxidised sites on apoptotic cells, while CD36 may also enhance engulftnent through
formation ofCD36-TSPl-avP3 vitronectin receptor complex. ABC1 is implicated in
the rearrangement of phospholipids in both the prey and the phagocyte. The CD91-
calreticulin system is implicated in innate recognition, through binding to Clq, while
CD14 is implicated both in the recognition of self- and non-self components. (Image
adapted from Savill et al. 2002, Nat Rev, page 967).
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bone (Sugimoto et al. 1993, Wong et al. 1987). In addition, evidence is available for
apoptotic bone cell death during development and bone turnover as well as in disease
situations, as discussed below in further detail.
2.8.1 Chondrocyte apoptosis
During endochondral ossification and fracture healing, when cartilaginous tissue is
replaced by woven bone, chondrocytes become hypertrophic and undergo
programmed cell death, characterised by DNA fragmentation, condensation of the
nuclei and cell shrinkage (Lee et al. 1998). Hypertrophic chondrocytes that undergo
apoptosis have been suggested to signal to osteoclasts for their removal (Bronckers et
al. 2000), although the mechanism is unclear.
2.8.2 Osteoclast apoptosis
Osteoclasts have been shown to undergo apoptosis following completion of the
resorption. The process is characterised by cytoplasmic and nuclear condensation and
DNA fragmentation into nucleosomal-sized units (Roodman et al. 1996). Estrogen
exerts anti-resorptive activities through induction of osteoclast apoptosis, either
directly through estrogen receptor mediated pathways (Kameda et al. 1997), or
indirectly through the production of TGF-J3 from osteoblasts (Hughes et al. 1996). In
addition, bisphosphonates are well known anti-osteoclastic agents (reviewed in
section 3), which inhibit osteoclast survival and function following different routes,
depending on the absence or presence of a nitrogen group (Papapoulos 1997, Rodan
1998, Rogers et al. 1999). Glucocorticoids exert different effects on osteoclastic
activity, in different species. Glucocorticoids stimulate human and murine bone
resorption (Conaway et al. 1996, Hamdy 1997), whereas in rats (Tobias and
Chambers 1989, Dempster et al. 1997), glucocorticoids resulted in increased bone
mass and induction of osteoclast apoptosis.
Further studies have shown that Ca++ concentrations, at levels similar to those
produced during demineralisation, induce osteoclast apoptosis (Lorget et al. 2000),
while vitamin K2 also inhibited resorption through induction of osteoclast apoptotic
death (Kameda et al. 1996). Finally, mice "knockout" for the Bcl-2 gene had an
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osteopetrotic phenotype, implying that Bcl-2 levels might control osteoclast survival
and resorptive activity in active pits (McGill et al. 2002, Glantschnig et al. 2002).
Previous studies on Bcl-2"/" mice however, did not observe an osteopetrotic
phenotype but increased numbers of osteoblasts and disorganised appearance of
collagen fibres (Boot-Handford et al. 1998).
2.8.3 Osteoblast apoptosis
Osteoblast apoptosis has been evidenced by several in vitro studies. The Fas/FasL
death receptor pathway has been implicated in apoptosis of both human and murine
osteoblasts either through interaction with T cells (Kawakami et al. 1997) or
exposure to pro-inflammatory cytokines such as TNF-a, IL-1 and IFN-y (Ozeki et al.
2002). In addition, okadaic acid and caryculin A induce apoptosis in osteoblasts in
vitro, providing a possible role for protein phosphatases in regulation of osteoblastic
activity (Morimoto et al. 1997).
Inorganic phosphate has been shown to induce osteoblast apoptosis, which appeared
to be enhanced by increasing concentrations of Ca++, suggesting that these two ions,
which are major components of the bone extracellular matrix, act as local apoptogens
for osteoblasts (Adams et al. 2001). Landry et al. observed in vivo formation of
osteoblast apoptotic bodies in the callus of rat tibia, which was proposed as a
mechanism for eliminating excess osteoblasts from the injury site, following callus
formation (Landry et al. 1997). Furthermore, apoptosis of mature osteoblasts has
been shown to be influenced by cytokines and growth factors present in the bone
microenvironment such as IL-6 and TGF-P (Jilka et al. 1998), while survival and
differentiation of osteoblasts into osteocytes, was dependent on matrix
metalloproteinase activity and activation of latent TGF-P by MMPs, which was
mediated through the p44/42 MAPK pathway (Karsdal et al. 2002).
2.8.4 Osteocyte apoptosis
Death of osteocytes in vivo, was initially described by Frost, who observed an
increasing incidence of empty lacunae with increasing age (Frost 1960). Osteocyte
death appeared to occur in most types of bone, and could be associated with a range
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of diseases, including osteoporosis and osteoarthritis (Dunstan 1993). The
mechanism, by which osteocytes died under these conditions, was initially thought to
be due to necrosis. However, recent evidence suggests that osteocytes are capable of
apoptosis. Studies using both pathological and healthy human bone have provided
some insights into the apoptotic morphology of an osteocyte, suggesting the presence
of DNA fragmentation, intact nuclear envelope, chromatin condensation and cell
shrinkage (Noble et al. 1997). More recent studies in the ribs of premature infants
have identified the presence of tissue transglutaminase in apoptotic osteocytes, as
well as high expression of the anti-apoptotic protein Bcl-2, which appeared to
correlate with regions of low osteocyte apoptosis (Stevens et al. 2000). In addition,
osteocytes in the immediate vicinity of the microdamage site were shown to express
the pro-apoptotic protein Bax whereas, Bcl-2 was expressed at some distance from
microcracks, on osteocytes that appeared to create a wall around the apoptotic
osteocytes in the microcracks (Verborgt. et al. 2002), suggesting that the expression
pattern of anti-apoptotic and pro-apoptotic factors on osteocytes might be directing
the resorption process to specific areas following microdamage.
Several studies have reported that there may be an association between osteocyte
apoptosis and the regulation of bone turnover. For example, the viability of
osteocytes is affected by the presence or absence of hormones, which influence the
maintenance of bone homeostasis such as glucocorticoids (Weinstein et al. 1998 and
2000) or estrogen (Tomkinson et al. 1997 and 1998).
In addition, evidence is accumulating on the role of osteocyte apoptosis on the
targeted remodelling in response to mechanical stimuli and microdamage. Large
numbers of apoptotic osteocytes were found to surround resorption areas induced by
fatigue microdamage (Verborgt et al. 2000) or during orthodontic tooth movement
(Hamaya et al. 2002). More recently a direct association was demonstrated between
osteocyte apoptosis and mechanical loading, which was immediately followed by
intracortical remodelling, providing the first evidence that apoptotic death of
osteocytes might be an important mechanism for specific site-directed remodelling
(Noble et al 2003).
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2.9 Summary
Apoptosis is an essential homeostatic mechanism for the healthy development and
maintenance of tissues. Various diseases occur when apoptotic mechanisms
malfunction, including cancers, autoimmune disorders or neurodegenerative diseases
(Levine et al. 1994, Miyashita et al. 1994, Thompson 1995, Cotman and Anderson
1995). Apoptosis has been described in osteoblasts and osteoclasts, as well as
osteocytes, during bone growth and remodelling, in response to factors produced as a
normal consequence of the transition between bone resorption, reversal and bone
formation. These findings indicate that apoptosis is an important, routine mechanism
in the maintenance of bone homeostasis which forms the hypothesis investigated in
section 2 in which I demonstrate that products derived from the apoptosis of
osteocytes are capable of modifying the behaviour of bone effector cells.
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SECTION 2
The biological significance of osteocyte apoptosis
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Introduction to Section 2
Advanced age has been associated with imbalances between bone resorption and
formation and a substantial loss in bone mass, compared to the skeleton of young
individuals (Riggs et al. 1982). In addition, ageing has been correlated with increased
incidence of empty lacunae, indicating that there is an age-related dependency in the
viability of osteocytes (Frost 1960). Osteocytes have been proposed to receive
mechanical signals and to initiate biochemical responses that direct bone resorption
and formation, allowing bone to adapt to specific shape and strength requirements
(Noble et al. 2003), indicating that the quality of bone is very closely associated with
the presence of osteocytes and the communication network that they form through
their cytoplasmic processes, within the bone matrix (Dunstan et al. 1993). Studies
have shown that forming as well as resorbing osteons contain higher osteocyte
density and lacunar occupancy, compared to quiescent osteons, suggesting that
osteocytes might contribute to the process of bone remodelling (Power et al. 2002).
The process by which osteocytes control bone turnover is not understood yet.
However, there is accumulating evidence that controlled death of osteocytes through
apoptosis, might be providing the signals that direct turnover, since it has been
observed in close association with resorbing areas and most importantly prior to
initiation of bone resorption (Noble et al. 1997, Verborgt et al. 2000, Noble et al.
2003).
All these observations suggest that death of osteocytes via apoptosis is of
significance to the maintenance of bone homeostasis. This section focuses on the
effects of osteocyte apoptosis on cells of the osteogenic and other lineages as well as
on mechanisms that might mediate these effects.
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CHAPTER 3




Osteocyte apoptosis has been associated with targeting of the activity of specific
bone resorbing cell types. High levels of osteocyte apoptosis have been evidenced
prior to initiation of bone resorption raising the possibility that signals derived from
these dying cells direct osteoclasts to bone requiring remodelling (Noble et al. 2003).
Here we hypothesise that products form apoptotic osteocytes will significantly alter
the behaviour of osteoblastic cells. In particular this study has attempted to identify
the significance of osteocyte apoptosis by characterizing the responses of bone cells
and a variety of other target cells from various tissues, to the presence of osteocyte
apoptotic products.
TE85 human osteoblasts and primary mouse osteoblasts were shown to undergo
apoptosis in the presence of osteocyte apoptotic bodies compared to untreated
osteoblast cultures (p = 0.001 and p = 0.0001, respectively). Soluble apoptotic factors
as well as healthy or necrotic osteocyte products did not affect osteoblast viability,
pointing to the presence of a specific apoptotic body associated factor expressed
during osteocyte apoptosis, with death-inducing activity in osteoblasts. Apoptotic
bodies produced from other (non-osteocyte) cell types and lineages failed to induce
osteoblast apoptosis. In addition, different cell types used as target cells, did not
undergo apoptosis when challenged with osteocytic and a range of other cell
apoptotic products, indicating that there is phenotypic specificity in the death-
inducing signal delivered by apoptotic osteocytes to osteoblasts. Furthermore, in
macrophage cultures, prolonged incubation with osteocyte apoptotic bodies and their
conditioned medium increased cell number and induced morphological changes,
compared to control cultures.
This study provides evidence that apoptotic osteocytes are capable of being
recognized by different cell types and could carry a message able to elicit specific
responses, depending on the cell they encounter. Such phenotypic recognition of
apoptotic products provides a further level of "meaning" to apoptosis in general.
39
3.2 Introduction
Apoptosis, a form of programmed cell death conserved throughout evolution,
represents an essential part of life for a multicellular organism, fulfilling a need to
abolish supernumerary, hazardous or misplaced cells (Wylie et al. 1980). Everyday,
about 10 billion cells undergo apoptosis in our bodies and are effectively
phagocytosed by the macrophages residing in tissues or by neighboring cells acting
as semi-professional phagocytes (Savill 1997). Phagocytosis of dying cells is a safe
way of removing cells; however it might also suppress inflammation and modulate
immune responses (Savill et al. 2002). Recent studies have shown that apoptotic cells
can either directly exert immunosuppressive effects, by secreting IL-10 (Gao et al.
1998) or decrease production of pro-inflammatory cytokines such as IL-12, IL-1 and
TNFa, and increase production of IL-10 or TGF-P, when engulfed by activated
monocytes (Voll et al. 1997, Fadok et al. 1998). In addition, antigens on the
apoptotic cell membrane have been suggested to access the cytoplasm and be cross-
presented on MHC I and MHC II molecules on macrophages, inducing dendritic cell
maturation, and regulation of immune responses (Belone et al. 1997, Inaba et al.
1998). Apoptotic bodies may provide the catalytic surface for thrombin generation,
and lead to immunogenic responses, since changes in phospholipids and PS exposure
lead to coagulation events and generation of antibodies against phospholipids, in the
presence of cells normally found in circulating plasma (Casciola-Rosen et al. 1996).
Although most apoptotic cells share common characteristics (Kerr et al. 1972), cell-
specific membrane antigens are present on the surface of apoptotic bodies derived
from peripheral blood (Aupeix et al. 1997), highlighting the possibility that
phagocytes might recognise the cellular source of the apoptotic body and respond
differently to its ingestion. These findings imply that apoptotic cells could carry a
message able to elicit specific responses, depending on the cell they were derived
from and the phagocyte that engulfs them.
Bone is a rigid structural tissue, in which precise targeted activity of the effector cells
maintains its size and shape/strength. Association has been established between
apoptosis of the osteocytes and the targeting of the activity of specific bone resorbing
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cell types. Verborgt et al. observed large numbers of apoptotic osteocytes
surrounding resorption areas that were induced by fatigue microdamage (Verborgt et
al. 2000), while Noble et al. have demonstrated that very high levels of osteocyte
apoptosis were evident prior to initiation of bone resorption (Noble et al. 1997),
directing osteoclasts to bone requiring remodelling (Noble et al. 2003).
Bone appears as an ideal system for studying the geographically localised
phenotypes arising from the specific effects of phagocytosis of apoptotic vesicles.
This chapter examines whether osteocyte apoptosis might influence directly the bone
effector cells, and provides sufficient evidence that apoptotic osteocytes are capable
of inducing specific responses to bone cells and to a variety of other target cells from
various tissues.
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3.3 Materials and Methods
All chemicals were purchased from Sigma, UK and all tissue culture reagents were
purchased from Invitrogen, UK, unless otherwise stated. Tissue culture well plates
and petri dishes were purchased from Corning, UK. Tissue culture procedures were
performed in a laminar flow hood (class 2) receiving HEPA-filtered air, using sterile
equipment.
3.3.1 Culture of cell lines
The murine long-bone derived osteocyte-like MLO-Y4 cell line was cultured in
Modified Eagles Medium Alpha (aMEM) supplemented with 5% fetal bovine serum
(FBS), 5% newborn calf serum (NCS), 1% penicillin/streptomycin (P/S) and 1% L-
glutamine (Kato et al. 1997). The TE85 human osteosarcoma cell line was cultured
in Minimum Essential Medium Eagle (MEM) supplemented with 10% FBS, 1% P/S
and 1% L-glutamine (McAllister et al. 1971). The murine monocyte cell line IC21
was maintained in RPMI supplemented with 10% FBS, 1% P/S and 1% L-glutamine
(Mauel and Defendi, 1971). The T hybridoma cell line DOl 1 10 was provided by Dr
Sarah Howie and maintained in RPMI supplemented with 10% FBS, 1% P/S and 1%
L-glutamine as described by Underhill et al. 1999.
Cells were grown in continuous monolayer culture in sterile 75 cm tissue culture
flasks. For MLO-Y4 osteocytes, flasks were coated with 0.1 M collagen type I from
rat tail prior to use. Growth media were stored at 4 °C and warmed to 37 °C prior to
use. Cells were maintained in an incubator at 37 °C in a 95% humidified atmosphere
of CUCCL in the ratio of 95%: 5%. Subculturing was performed twice weekly upon
reaching 90% of confluency, maintaining the cells in the log phase of proliferation.
For adherent cultures (MLO-Y4, TE85 and IC21 cell cultures) the monolayer of cells
was detached with addition of 1 ml of trypsin solution at 2.5 gm/1 for 5-10 minutes,
followed by addition of 10 ml of growth medium. 1 ml of cell suspension was added
to a new flask containing 9 ml of fresh growth medium and placed in an incubator
for maintenance. Non-adherent cultures (T hybridoma cells) were subcultured twice
weekly by adding 1 ml of cell suspension to 29 ml of fresh growth medium and
placed in an incubator for maintenance.
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3.3.2 Isolation of primary mouse cell cultures.
Osteoblast and osteocyte cultures were isolated from 3-6 week-old female mice,
killed by CO2 asphyxiation. The mice were used at this age due to higher availability
within the university unit, while a wider range of ages did not indicate any age-
related differences in the responses studied in this thesis. Using sterile dissection
equipment, calvarial bones were removed. Following removal of the periosteum,
bones were digested in trypsin for 10 minutes at 37 °C. Bone tissue was then
sequentially digested in collagenase at a concentration of 0.75 mg/ml for 25 minutes,
which was repeated 10 times. After each individual digestion, cells were collected by
centrifugation at 500 g for 5 minutes and digestions were characterized as described
in §3.3.3, so that digestions 2-5, which stained positive for alkaline phosphatase, as
described in §3.3.3.2, were combined to provide the osteoblast population, while
digestions 6-10 provided the osteocyte population as described in §3.3.3.1. Cultures
were maintained in 24 or 96 well plates in aMEM supplemented with 5% FBS and
5% NCS for 8-10 days prior to experimental use. Bone marrow stromal cells were
isolated from 3-6 week old female mice as described by Thomson et al. 1993.Using
sterile equipment, femurs were removed and growth plates were cut open using a
scalpel to expose the marrow cavity. The bone marrow was removed by flushing the
cavity with aMEM using a syringe needle. Cells were maintained in same growth
medium (aMEM supplemented with 5% FBS and 5% NCS) for 5 days prior to
experimental use. Polymorphonuclear (PMN) cells and peripheral blood monocytes
(PBMCs) were supplied by Dr. Simon Brown and were cultured in Iscove's
Modified Eagle Medium supplemented with 10% FBS. Murine bone marrow
macrophages were prepared by Dr Jeremy Duffield and maintained in DMEM F12
supplemented with 10% FBS, as described by Duffield et al. 2000. CD4+ T
lymphocytes and spleen cell were isolated by Dr Sarah Flowie and maintained in
RPMI supplemented with 10% FBS, as described by Eagar et al. 2004.
3.3.3 Characterization of primary calvarial cultures
3.3.3.1 Proliferative capacity (5-bromo-2 deoxyuridine, BrdU)
In order to distinguish between proliferating fibroblasts, osteoblasts and non-
proliferating osteocyte cultures, cells from each collagenase digestion were analysed
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using BrdU incorporation into newly synthesized DNA (Thomson et al. 1993).
Cultures were transferred to growth medium supplemented with 0.1% serum for 24
h, to reduce proliferation and to synchronize cells to Go of the cell cycle. Cells were
then incubated with 50 pM BrdU, an analogue of thymidine which is taken up into
the DNA of cycling cells and 50 pM deoxycytidine, which inhibits DNA methylation
and results in heterochromatin decondensation, in normal 10% growth medium for
16 h, and were fixed in 4% paraformaldehyde for 10 minutes. Cells were then
washed in H2O and incubated with 3 M HC1 in order to permeabilise cells, for 30
minutes. Cells were washed thoroughly in PBS and incubated with anti-BrdU
antibody (DAKO) at 1:200, in the presence of 0.5% Tween 20 and 0.5% BSA, for 1
h at 37 °C, followed by incubation in goat anti-mouse FITC antibody at 1:50 in the
presence of 0.5% Tween 20 and 1% goat serum, for 1 h at 37 °C. Cells were washed
in PBS, mounted in fluorescence medium and analyzed by fluorescence microscopy.
Results were expressed as a percentage of proliferating BrdU positive cells against
total number of cells identified by DAPI nuclear staining.
3.3.3.2 Alkaline phosphatase Immunostaining
Alkaline phosphatase belongs to a family of proteins that are attached to the plasma
membrane via a glycosyl-phosphatidinositol linkage (Noda 1987) and catalyses the
hydrolysis of phosphate monoesters:
R-O- POT + H20 —> R-OH + HPO4"
Alkaline phosphatase is widely used as a marker of the osteoblast phenotype and has
been proposed to participate in bone mineralization (Waymire et al. 1995). Alkaline
phosphatase was detected in primary osteoblast cultures using light microscopy.
Cultures were washed in PBS and fixed in 4% paraformaldehyde for 10 minutes.
Cells were washed in PBS and were incubated with alkaline phosphatase staining
solution, consisting of 1 mg/ml Napthol-ASMX-mix and 1 mg/ml Fast Blue in 0.4%
MgCU solution, made in distilled water. The reaction mixture was filtered through a
0.2 pm sterile syringe filter prior to addition to cultures for 15 minutes at 37 °C. The
reaction was inhibited by washing the cultures in PBS, followed by 1% Acetic acid
solution. Osteoblasts expressing alkaline phosphatase were detected against total
number of cells in cultures identified by nuclear DAPI staining.
3.3.3.3 Mineralised nodule formation (Von Kossa stain)
Primary osteoblasts were induced to form mineralised nodules in confluent cultures
by addition of mineralisation solution containing 10 nM 1,25 dihydroxyvitamin D3,
lOOnM Dexamethasone (Calbiochem, UK), 50 pg/ml Ascorbic acid and lOmM |3-
glycerol phosphate in normal growth medium (Noble et al. 1995). The mixture was
filtered through a 0.2 pm sterile syringe filter prior to addition to cultures and was
replaced every 3 days for 3 weeks, after which time bone nodules were visible under
the light microscope in osteogenic cultures. After the mineralisation period, bone
nodules were identified using Von Kossa staining (Bills et al. 1974). Cultures were
fixed in 4% paraformaldehyde followed by incubation in 5% Silver Nitrate (AgNCft)
solution, exposed under strong light for 30 minutes at room temperature. Treatment
with silver solution replaces calcium and phosphates ions as they become reduced,
forming insoluble silver salts. The silver deposit becomes densely black after
prolonged exposure to light.
CaC03 + 2 A9NO3 —> Ag2C03 + CaN03
Ag2C03 (light treated)-)- Ag20 + C02
(Seen as black)
Cultures were then washed in PBS and incubated in 3% sodium thiosulphate solution
for 5 minutes, followed by Eosin staining for 3 minutes.
3.3.4 Induction of apoptosis and characterization of apoptotic bodies by
Annexin-V FITC binding and PI staining.
3.3.4.1 Production and characterisation of osteocyte apoptotic bodies.
A range of methods of apoptosis induction was used in order to determine any
specificity in response to osteocyte apoptotic products due to the specific mode of
engendering apoptosis. Osteocytes (primary and MLO-Y4 cell line) were either
incubated in 0.1% FBS media for 7-10 days, or in the presence of 0.4 mM H2O2 or
10"6 M Dexamethasone for 4-5 hours, at 37 °C. Following induction of apoptosis,
osteocyte cultures were characterized by fluorescein isothiocyanate (FITC)
conjugated Annexin-V and propidium iodide (PI) staining, in order to distinguish
between viable (FITC negative, PI negative), early apoptotic (FITC positive, PI
negative) and late apoptotic (FITC positive, PI positive) or necrotic cells (FITC
negative, PI positive). In addition, a sample from the supernatant of each culture was
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collected every hour during incubation with Dex and H2O2, or every 2 days during
incubation in low serum media and apoptotic bodies were characterised by Annexin-
V-FITC and PI staining to reveal the presence of early and late apoptotic changes.
3.3.4.2 Production and characterization of other apoptotic bodies
Apoptotic bodies derived from T hybridoma cells, IC21 monocyte-like cells and
osteoblast precursor cells were produced in low serum medium for 7-10 days at 37
°C, and characterized by Annexin-V-FITC and PI staining. PMN and PBMC-derived
apoptotic bodies were provided by Dr. Simon Brown.
3.3.5 Production of non-apoptotic osteocyte products
3.3.5.1 Induction of osteocyte necrosis and isolation of necrotic vesicles
Osteocytes were incubated in the presence of 0.8 mM H2O2 for 3 hours at 37 °C, to
produce necrotic vesicles. Following induction of necrosis, osteocyte cultures were
characterized by Annexin-V-FITC and PI, as described in §3.3.10.1 to distinguish
between viable (FITC negative, PI negative), early apoptotic (FITC positive, PI
negative) and late apoptotic or necrotic cells (FITC positive, PI positive and FITC
negative, PI positive). To investigate the effect of medium that nourished necrotic
vesicles, osteocyte cultures were incubated in 0.1% FBS media for more than 14
days. Medium was collected following isolation of the vesicles by centrifugation at
13,000 g and removal of cell debris by passing through a 0.2 pm sterile syringe filter.
More than 80% of the vesicles stained positive only for PI (indicative of necrotic but
not apoptotic cells) and were resuspended in growth medium appropriate for the
target cultures, according to their density, prior to presenting to target cell cultures.
3.3.5.2 Production and isolation of osteocyte lysis products
Osteocytes were incubated in solution containing 2 mM Tris-HCl, 2 mM EDTA, 2
mM EGTA and 0.1% Triton-X for 15 minutes on ice. Following lysis of cells, cell
fragments were collected by centrifugation at 3,000 g for 10 minutes. The pellet was
resuspended in aMEM medium and presented to target cell cultures at density
described in §3.3.8.
3.3.6 Purification of apoptotic bodies by Annexin V-biotin-streptavidin
complex.
Apoptotic bodies were purified on the basis of phosphatidylserine (PS) exposure on
the outer leaflet of the cell membrane, since this is one of the early changes that take
place in the apoptotic cell membranes, which can be visualised following binding to
FITC labelled Annexin V protein (Figure 7). The procedure followed comprised
modifications of the technique by Brown et al 2002. Following induction of
apoptosis, cells were incubated with CellTracker Orange dye (to facilitate their
identification at later experimental stages) (as described in §3.3.5), at 1 pg/ml or with
DAPI at 2.5 ng/ml for 20 minutes and washed in PBS to remove excess dye.
Apoptotic products were collected in universal tubes and incubated with 0.3 M of
biotinylated Annexin V (Roche, UK) at a density of 100,000 cells/ml, on ice for 5
minutes followed by incubation with 100 pi Streptavidin superparamagnetic beads
for 10 minutes on ice. Apoptotic products expressing PS were purified with the use
of a magnetic sorting device (magnetic activated cell sorting-MACS) (DAKO, UK)
and were washed in Flanks' Buffered Saline Solution to dissociate the apoptotic
body-magnetic bead complex. Prior to presenting vesicles to target cell cultures, they
were resuspended in growth medium appropriate for the target cultures, at measured
apoptotic body density. Samples of apoptotic bodies were also cytospan and stained
with Flematoxylin & Eosin, as described in §3.3.10.4 to characterize formation of
apoptotic body-magnetic bead complexes (Figure 8).
3.3.7 Visualization of apoptotic body and target cell morphology using
fluorescence microscopy.
Apoptotic bodies were readily visualised with Orange Cell Tracker CMTMR (5-(-6)-
(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine, which becomes absorbed at
540 nm and emitted at 566 nm (Molecular Probes), while target osteoblasts were
visualised with Green Cell Tracker CMFDA (5-choromethylfluorescein diacetate),
absorbed at 492 nm and emitted at 516 nm (Molecular Probes). Orange Cell Tracker
and Green Cell Tracker pass freely through the cell membrane and react with
intracellular thiols in glutathione S-transferase mediated reaction, producing a cell
impermeant fluorescent dye-thioether which can be retained for a long time, since it
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can be fixed with aldehydes. Orange Cell Tracker does not require enzymatic
cleavage by esterases to activate its fluorescence, while Green Cell Tracker is non-
fluorescent and colorless until inside the cytoplasm, where esterases cleave off its
acetate groups, releasing a highly fluorescent product. Cell were incubated for 20
minutes with either compound at a concentration of 1 pg/ml in DMSO followed by
thorough washing to remove excess unconjugated probe. In addition, both the target
cells and phagocytic prey were stained with DAPI (4',6-Diamidino-2-phenylindole),
which is stimulated at 344 nm and emitted at 488 nm. DAPI is rapidly taken up by
cells, and forms fluorescent complexes with double-stranded DNA. Binding to DNA
enhances the fluorescence of DAPI because it is a highly energetic interaction or
because it forms stable hydrogen bonds with the minor groove of the double helix as
well. The exact staining method with either the Cell Tracker or DAPI varies
according to experimental requirements and is indicated for individual experiments
in the figure legends.
3.3.8 Phagocytosis assay
Phagocytosis was determined using minor modifications of the technique by Tosello-
Trampont et al. 2001. Briefly, target cells were plated at a density of 30,000
cells/well for primary osteoblasts, 15,000 cell/well for TE85 human osteoblasts,
20,000 cells/well for bone marrow stromal cells, 30,000 cells/well for primary bone
marrow macrophages, 200,000 cells/well for primary CD4+ T lymphocytes and
20,000 cells/well for T hybridoma lymphocytes, in 96 well plates (Corning, UK). For
apoptotic products, density varied according to target cell density in order to achieve
an average of 5x more apoptotic bodies than cells in a well (5 bodies/per target cell)
(Fadok et al. 1998, Moodley et al. 2003). Target cells were stained with CellTracker
Green dye at 1 pg/ml for 20 minutes or with DAPI at 2.5 ng/ml for 20 min at 37 °C,
and were washed in PBS to remove excess dye prior to incubation with apoptotic
bodies for the time points (range of 1 h-48 h) indicated in the figure legends. Media
conditioned by both healthy and apoptotic prey cell cultures were also collected and
presented to target cell cultures after centrifugation at 13,000 g and purification
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Figure 7. Purification of osteocyte apoptotic bodies displaying
phosphatidyl serine. Osteocytes in cultures were incubated with agents inducing
apoptosis. Primary and secondary apoptotic products as well as necrotic products
were collected in universal tubes and incubated with 0.3 M of biotinylated Annexin
V on ice for 5 minutes, followed by incubation with 100 pi Streptavidin
superparamagnetic beads for 10 minutes on ice. Apoptotic vesicles expressing PS on
the surface were purified with the use of a magnetic device, washed in Hanks'
Buffered Saline Solution and were centrifuged to dissociate the apoptotic body-











Figure 8. Purification of osteocyte apoptotic bodies. A. Apoptotic osteocyte
displaying apoptotic bodies. B. Apoptotic bodies were purified on the basis of
phosphatidyl serine (PS) exposure, as one of the early changes that take place in the
apoptotic cell membranes, which can be identified following binding to Annexin V
protein, through the formation of Annexin-V-biotin-streptavidin complex with the
use of a magnetic device. Samples were cytospan and stained with H&E.
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Experiments were carried out a minimum of 3 times, and each treatment group was
represented by 3 wells in each independent experiment. Cells were observed in 3
fields per well resulting in 9 fields per treatment group. Control treatments comprised
vehicle treatments using the medium in which vesicles were resuspended, which was
the growth medium used for each target cell culture. For experiments investigating
the response of target cells to media that nourished apoptotic vesicles (CM), vehicle
treatments include the addition of an equal volume of growth medium used to
maintain the cells producing the particular apoptotic vesicles.
3.3.9 Interaction and Engulfment assays
Following incubation of target cells with apoptotic bodies for the appropriate time
intervals, indicated in the figure legends, medium was removed and cultures were
washed twice in ice-cold PBS to remove apoptotic bodies with low affinity
interactions with the target cells. For estimation of engulfment of apoptotic bodies by
target cells, cultures were washed for 2 minutes in trypsin at 2.5 gm/1, so that the
apoptotic bodies would be removed from the surface of target cells and after
appropriate staining, as described above, would only appear inside target cells.
Engulfment was expressed as percentage of cells with 0, 1, 2, 3, 4 or more apoptotic
bodies. Experiments were carried out a minimum of 3 times, and each treatment
group was represented by 3 wells in each independent experiment. Cells were
observed in 3 fields per well resulting in 9 fields per treatment group.
3.3.10 Determination of Apoptotic State
A range of techniques were used to assess the apoptotic state, for all the independent
experimental culture setups. Cells were observed in 3 fields per well (x20
magnification lens, approximately 40-100 cells per field) resulting in 9 fields per
treatment group. Identical magnifications were used for all apoptosis estimates
allowing similar numbers of cells to be counted per field in all experiments.
3.3.10.1 Annexin-V-FITC Assay
One of the earliest changes that occur in cells undergoing apoptosis is the appearance
of negatively charged phospholipids on the outer leaflet of the membrane bilayer,
which can be detected with fluorescently labelled Annexin V; a Ca2+-dependent
phospholipid binding protein with high affinity for phosphatidyl serine (PS) (Martin
et al. 1995). Cells were washed in PBS and incubated with Annexin-V-FITC at a
concentration of 1 pg/ml for 15 minutes at RT, followed by PI at 2.5 ng/ml to
identify necrotic cells in the culture. Analysis by fluorescence microscopy, allowed
discrimination between viable (FITC negative, PI negative), apoptotic (FITC
positive) or necrotic cells (FITC negative). Apoptotic cells were expressed as the
percentage of the ratio of annexin positive and PI negative cells estimated from 9
fields (3 wells per treatment and 3 fields per well) over the total number of cells
estimated from those fields. Total number of cells was estimated using brightfield
microscopy. Average number of apoptotic cells from 9 fields
_ x 100
Percentage of apoptotic cells = „ , „ r ,
Average number of cells from 9 fields
3.3.10.2 DNA fragmentation using in situ Nick Translation
The percentage of target cells demonstrating DNA breaks was investigated on
samples fixed in 4% paraformaldehyde, using a sensitive DNA nick translation
technique detecting single DNA breaks (Noble et al. 1997). In situ nick translation
staining allows the determination of early DNA breaks, prior to the loss of any DNA
content or morphological variations and prior to plasma membrane permeabilisation
(Petit et al 1995). Positive controls were established through pre-treatment with
DNasel (Roche, UK) at 0.2 mg/ml in PBS, for 30 minutes. Cells were exposed to
nick translation mixture which consisted of 3 pM Digoxigenin (DIG) labelled dUTP
(DIG-11-dUTP), 3 pM each of dATP, dGTP, dCTP, 50 mM Tris HC1, pH 7.5, 5 mM
MgCf and 0.1 mM dithiotreitol and 0.5 pl/100 pi DNA polymerase for 1 hour at 37
°C, in a humidified chamber (Roche, UK). Negative controls were established by
omitting from the NT mixture. Wells were washed in PBS and incubated for 1 hour
at RT with FITC-labelled anti-DIG antibody (Roche, UK) and 5% normal sheep
serum. Wells were washed in PBS, counter stained with PI at 2.5 ng/ml and mounted
in DAKO mounting medium (DAKO, UK). Target cells staining positive for FITC
label and PI, were considered as cells containing fragmented DNA. The ratio of total
52
cells (PI positive) to apoptotic (FITC positive) was determined using fluorescence
microscopy and digital image capture.
Average number of FITC cells from 9 fields
Percentage of apoptotic cells = x 100
Average number of PI cells from 9 fields
3.3.10.3 DAPI staining for healthy and apoptotic cell morphology
DAPI (4',6-Diamidino-2-phenylindole) staining reveals chromatin condensation,
shrinkage of nuclei and the fragmentation of the nuclear material into smaller blebs,
representing late stages during the apoptotic cascades (Cowden et al. 1981).
Following experimental treatment, cells were fixed in 4% paraformaldehyde, washed
in PBS and air-dried. Cells were then incubated with DAPI at 2.5 ng/ml for 20
minutes, washed in PBS and examined by fluorescence microscopy and digital image
capture. Healthy cells were characterised by intact nucleus and normal cytoplasmic
appearance. Results were expressed as the percentage of the ratio of apoptotic to
non-apoptotic cells , r „ r. ,
Average number of apoptotic cells from 9 fields
Percentage of apoptotic cells = x 100
Average number of cells from 9 fields
3.3.10.4 Cytospin and H&E staining
For non-adherent CD4+ T lymphocyte and T hybridoma cell cultures, apoptotic and
healthy morphology were investigated, in addition to the above methods, with
Haematoxylin & Eosin staining. H&E staining enabled the visualisation of nuclei as
they stain deep blue-black with haematoxylin detecting morphological nuclear
changes during late stages of apoptosis, while the cytoplasm is stained pink after
counterstaining with eosin. Following completion of the experiment, samples of 100
pi were collected from the supernatant of experimental samples and were placed into
cytospin chambers. Samples were cytospan onto slides after being centrifuged for 3
minutes at 300 rpm. Samples were immediately fixed for 5 minutes in methanol and
were stained with H&E for 2 minutes, after which samples were thoroughly washed
in distilled water. Samples were left to air-dry and were mounted in pertex mounting
medium (CellPath, UK). Apoptotic and healthy morphology were characterized
under the light microscope.
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3.3.11 Inhibition of apoptosis using caspase inhibitors
Caspases are involved at various stages in apoptotic cascades, mediating either death
receptor pathways or cleavage of intracellular components in order to disassemble
the cell's structure (Thornberry et al. 1998). In order to determine whether osteoblast
apoptosis in response to OAB was a caspase-dependent process, target cells were
incubated with caspase 3/7 inhibitor (Glaxosmithkline, USA), a non-peptide selective
inhibitor of caspases 3 and 7 based on sulphanylamide derivatives (Lee et al. 2000),
mediating mainly end-stage cytoskeletal and nuclear changes in the apoptotic cell at
1 pM for 1 hour prior to addition of apoptotic bodies.
3.3.12 Statistical Analysis
All statistical analyses were performed using quantitative data analysis with SPSS
release 10.1 for Windows. The distribution of the data within the sampling
population they were obtained from was determined by applying the Kolmogorov-
Smirnov test. In cases where the randomly selected sample data were shown to have
a normal (Gaussian) distribution (95% of data would fall within plus or minus 1.96
standard deviations from the mean value) parametric statistical tests such as two-
tailed Analysis of Variance (ANOVA) and the post-hoc Tukey test and Dunnett test
were performed directly to determine statistical significance between the treatment
groups. For comparison between percentages or proportions, the square root of each
proportion was transformed into its arcsine, which enabled the distribution of the
data to be nearly normal allowing therefore the use of parametric tests. The Tukey
test was used to compare more than two means at once since this reduces the error
associated with multiple t-tests (Zar 1984), while the Dunnett test was used to
compare the control mean to all the other group means (Zar 1984). In order to
determine the functional dependence of one variable (e.g. the proportion of apoptotic
osteoblasts) on another (number of OAB phagocytosed), simple linear regression
analysis was used and the correlation coefficient and slope of the regression line)
were calculated to determine the significance of the regression. Results are expressed
as means ± S.D. p<0.05 was considered to be statistically significant.
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3.4 Results
3.4.1 Characterization of osteocyte apoptotic bodies (OAB) and bodies
derived from other cells types
Osteocytes were induced to undergo apoptosis as described in §3.3.4 (Figure 9A
and 9C) and OAB were collected and characterized based on the exposure of PS on
the plasma membrane detected with fluorescently labeled Annexin V. The staining
was combined with PI to allow differentiation between apoptotic, secondary necrotic
and necrotic vesicles. Following incubation with Dex and H202 for 4-5 hours or in
low serum media for 7-10 days, more than 80% of the vesicles collected from the
supernatant of cultures were positive for Annexin V (Figure 9B and 9D). OAB were
spherical vesicles, which varied in diameter ranging between 0.02 pm to 0.5 pm.
(Figure 10). Although the presence of necrotic osteocyte debris in the primary
extraction was considered negligible, since less than 5% were positive for PI
(indicative of necrotic cells and/or late stage leaky apoptotic particles), osteocyte
apoptotic bodies were further purified based on the exposure of Annexin V, (by
MACS, as described in §3.3.6) to ensure the absence of necrotic factors (Figure 10).
In a similar manner to OAB, vesicles derived from T hybridoma cells, IC21
monocytes and fibroblastic/osteoblast precursor cells were characterised and stained
for PS exposure with Annexin V FITC and further purified by MACS (Figure 11).
3.4.2 Characterization of primary osteoblast and osteocyte cultures
Cultures obtained from calvarial digestions number 2-5 had the morphological
characteristics of osteoblasts, with cuboidal appearance and polarized nuclei (Baron
1996). In addition osteoblast cultures were characterized as positive for alkaline
phosphatase staining (Figure 12A) and formation of bone nodules (Figure 12B),
which are indicative of osteoblast function (Wong et al. 1983, Lomri et al. 1988).
Osteocyte cultures were isolated from calvarial digestions above number 6 and
characterised based on proliferation, since primary osteocytes are non-proliferating
cells, identified by BrdU staining as described in §3.3.3. The majority of the cells did
not stain positive for BrdU (Figure 12C), while they also had the characteristic
morphology of osteocytes, with long cytoplasmic processes and relatively small cell
body (Figure 12D).
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Figure 9. Characterisation of osteocyte apoptotic bodies (OAB). OAB
were obtained from cultures incubated in low serum or in the presence ofDex at 10"6
M and 0.4 mM H2O2. A. Time course induction of osteocyte apoptosis in the
presence of Dex at 10"6 M and H2O2. B. Mean percentages of apoptotic vesicles
collected from the supernatant of apoptotic osteocyte cultures, staining positive for
Annexin V and PI after 5 hours incubation with Dex or H2O2. C. Time course
induction of osteocyte apoptosis incubated in low serum growth medium. D. Mean
percentages of apoptotic vesicles collected from the supernatant of apoptotic
osteocyte cultures staining positive for Annexin V and PI after 7 days incubation in
low serum. Error bars represent ± S.D. *** = p<0.0001, ** = p<0.001, compared to
(A, C) control cultures and (B, D) Annexin negative vesicles. Annexin positive =
early apoptotic, Annexin positive, PI positive = late apoptotic or secondary necrotic
bodies and Annexin negative = necrotic bodies.
Figure 10. Osteocyte Apoptotic Bodies. OAB were stained with Annexin V-
FITC (green) to indicate exposure of phosphatidyl serine on the plasma membrane,
and counterstained with PI (red) to indicate late apoptosis or necrosis. A.Unpurified
bodies contained early apoptotic (AnV+ve -Pl-ve), late apoptotic (AnV+ve -Pl+ve)
or necrotic bodies (AnV-ve -Pl+ve) B. Purified bodies contained early apoptotic
(AnV+ve -Pl-ve) and late apoptotic bodies (AnV+ve —Pl+ve) and C. Necrotic bodies
(AnV-ve -Pl+ve). D. DAPI staining of OAB to show the presence of nuclear
osteocyte fragments...Bar =10 pm
► =AnV+ve -Pl-ve >.= AnV+ve -Pl+ve — . •*» =AnV-ve-PI+ve
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Figure 11. Characterisation of apoptotic bodies from other cell types.
Apoptotic products were obtained from cultures incubated in growth medium
containing 0.1% FBS serum for 7 days. Graphs represent mean percentages of
apoptotic bodies ± SD, collected from the supernatant of apoptotic cultures A. T
hybridoma cell cultures, B. IC21 cell cultures and C. fibroblast/osteoblast precursor
cultures staining positive for Annexin V and PI after 7 days incubation in low serum.
Error bars represent ± SD. *** = p<0.0001, compared to Annexin negative bodies.
Annexin V positive = early apoptotic, Annexin V positive, PI positive = late
apoptotic or secondary necrotic bodies and Annexin V negative = necrotic bodies.
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C. %BrdU positive cell cultures D. Primary calvarial osteocytes
3 4 5
□gestions
Figure 12. Isolation of primary osteoblast and osteocyte cultures by
sequential digestions of mouse calvariae. Osteoblast cultures were
characterised by A. Alkaline phosphatase staining and B. Formation of mineralised
nodules identified by Von Kossa staining. C. Estimation of mean percentages of
BrdU positive cells. D. Osteocyte cultures were isolated from digestions above
number 6, which did not contain many proliferating cells, compared to cultures
isolated from the first 5 digestions. Osteocyte cultures did not display mineralization
in vitro using von kossa staining, while they were characterised by very low alkaline
phosphatase activity. Osteoblast cultures were isolated from digestions 2-5, while




3.4.3 Apoptotic osteocytes induce osteoblast apoptosis
Since osteocytes are located close to the surface-resident osteoblasts in bone,
osteocyte apoptotic bodies (OAB) were initially presented to TE85 human
osteoblasts and primary mouse osteoblasts in culture for various time periods.
Following incubation with apoptotic osteocytes, both types of osteoblasts were
shown to undergo apoptosis (Figure 13A and 14A). In vivo studies have shown that
control levels of apoptosis in osteoblasts would be around 0.66% and would increase
for example to 2% (Weinstein 1998) and 19% (Plotkin 1999) following prednisolone
treatment for 27 and 56 days respectively. In this thesis, mean percentage of
apoptotic osteoblasts was increased from 2 ± 0.1% S.D. in untreated TE85
osteoblasts cultures and 2.6 ± 0.6% S.D. in untreated primary mouse osteoblast
cultures to 20 ± 0.9 % S.D. and 24.5 ± 3.5% S.D. respectively in the presence of
OAB (p < 0.0001 compared to control cultures in both cases), as evidenced by DAPI
staining of cultures. Induction of apoptosis was accompanied by significant cell loss
(Figure 13B and 14B) by 5 hours and 24 hours of incubation, whereas by 48 hours
both increased apoptosis and cell reduction were minimised, compared to control
cultures, indicating further proliferation of surviving cells.
Osteoblast apoptosis at 24 hours incubation with OAB was further characterised by
externalisation of PS as evidenced by Annexin-V FITC staining (15 ± 2% S.D.
compared to 0.31 ± 0.31% S.D. in untreated cultures) (Figure 15A-15C). In
addition, Nick Translation identified fragmented DNA (Figure 16A), while DAPI
staining showed chromatin condensation (Figure 16B). Confocal microscopy
showed that numerous OAB were localised on the surface or inside osteoblasts
which appeared apoptotic (Figure 17A). In addition, estimation of the percentage of
apoptotic osteoblasts associated with OAB either engulfed or bound to their surface
showed that osteoblasts appeared more likely to be apoptotic the more OAB were
associated with them (Figure 17B). Indeed, regression analysis showed that there
was a significant (p = 0.039) dependency of the proportion of apoptotic osteoblasts
on the number of OAB phagocytosed by osteoblasts that appeared apoptotic (Figure
17B).
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TE85 osteoblasts and OAB
1h 3h 5h 24h
Time (h)
48h
Figure 13. TE85 osteoblast apoptosis in relation to time. Osteoblast
cultures were incubated in the presence of OAB for 1-48 h. Apoptotic osteoblasts
were evidenced by DAPI nuclear staining and fluorescence microscopy. Graphs
represent A. Mean percentages of apoptotic osteoblasts and B. Number of osteoblasts
in culture, in relation to time, in the presence of OAB. *** = p < 0.0001, ** = p <
0.001, * = p < 0.05, compared to control. Error bars represent ± S.D. Control cultures
represent treatment with vehicle for OAB (aMEM).
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A. %Apoptotic osteoblasts stained with DAPI
B. Number of cells per field
1h 3h 5h 24h 48h
Time (h)
Figure 14. Primary mouse osteoblast apoptosis in relation to time.
Osteoblast cultures were incubated in the presence of osteocyte apoptotic bodies for
1-48 h. Apoptotic osteoblasts were evidenced by DAPI nuclear staining. A. Mean
percentages of apoptotic osteoblasts B. Osteoblast cell number in cultures, in relation
to time, in the presence of osteocyte apoptotic bodies. *** = p < 0.0001, ** = p <
0.001, * = p <0.05, compared to control. Error bars represent ± SD. Control cultures
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C. Apoptotic Osteoblast Healthy Osteoblast
PS exposure
Figure 15. Osteoblast apoptosis in the presence of osteocyte apoptotic
bodies. Osteoblast cultures were fed with OAB and apoptosis was evidenced in a
time course of 1-48 hours by Annexin-V FITC binding and fluorescence microscopy.
Graphs represent mean percentages of apoptotic A. TE85 osteoblasts and B. primary
osteoblasts ± SD, in the presence ofOAB. *** = p < 0.0001, ** = p < 0.001, * = p <
0.05, compared to control. Control cultures represent treatment with vehicle for OAB
(aMEM). C. Apoptotic osteoblast (left image) exhibiting membrane blebbing and PS
exposure evidenced by Annexin-V FITC staining (green), having phagocytosed OAB
(DAPI blue) and healthy osteoblast not exposed to OAB (right image). Bar = 10 pm
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Figure 16. Osteoblast apoptosis in the presence of osteocyte apoptotic
bodies. Primary osteoblast cultures were incubated in the absence (top panel) and
presence (top panel) of OAB and apoptosis was evidenced after 24 hours incubation
with A. DAPI nuclear staining and B. Nick Translation DNA staining which
identified formation of apoptotic bodies and fragmented DNA, in contact with OAB.
(Green =NT staining, Blue =DAPI staining and Red =OAB).
A. Control Osteoblasts and OAB
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Figure 17. Osteoblast apoptosis in the presence of osteocyte apoptotic
bodies. A. Representative images of confocal microscopy of osteoblast cultures
(Green Cell tracker) fed with osteocyte apoptotic bodies (Orange Cell tracker). Left
panel shows control osteoblast cultures and right panel shows cultures fed with OAB.
Bar = 20 pm. B. Osteoblasts were incubated with OAB and the percentage of
apoptotic osteoblasts that carried none, 1, 2, 3 or > 4 OAB was determined. Error
bars represent ± S.D., n=3, r = correlation coefficient.
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3.4.4 Induction of osteoblast apoptosis is dependent on caspases 3 and
7
In order to determine whether OAB-induced osteoblast apoptosis involved activation
of caspases to mediate end-stage cytoskeletal and nuclear fragmentation, a selective
inhibitor of caspases 3 and 7 based on sulphanylamide derivatives (Lee et al. 2000)
was used to treat osteoblast cultures prior to presentation of OAB. Treatment with
caspase 3,7 inhibitor prevented DNA breakdown and formation of membrane blebs
as evidenced by Nick translation (Figure 18A) and DAPI (Figure 18B) staining of
osteoblast cultures, in the presence of OAB (p = 0.01 and p = 0.003, respectively
compared to treatment with OAB alone).
3.4.5 Induction of osteoblast apoptosis is independent of the stimulus
that induced osteocyte apoptosis
To characterise the ability of apoptotic osteocytes to induce osteoblast apoptosis,
OAB were prepared by stimulation with different inducers of apoptosis, including
absence of growth factors, Dex and H2O2 as described in §3.3.4 (Figure 19). DAPI
staining of osteoblast cultures, 24 hours after incubation with OAB, showed that
osteoblasts efficiently phagocytosed OAB. Mean percentages of apoptotic
osteoblasts were significantly increased compared to control cultures (p < 0.0001 in
all cases) independently of the stimulus that induced apoptotic osteocyte death.
3.4.6 Soluble osteocyte apoptotic products do not affect osteoblast
survival
In order to determine the effect of soluble rather than apoptotic body-associated
apoptotic products on osteoblast survival, medium that nourished the apoptotic
osteocytes was introduced to osteoblast cultures. Estimation of mean percentages of
apoptotic osteoblasts by DAPI staining of cultures indicated that soluble apoptotic
products failed to induce osteoblast apoptosis (p > 0.05 compared to control) (Figure
20). In addition, medium that conditioned healthy osteocyte cultures had no effect on
osteoblast survival, indicating that osteoblasts were only sensitive to the presence of
osteocyte apoptotic bodies (Figure 20 and 21).
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Figure 18. Caspase 3, 7-dependent induction of osteoblast apoptosis.
Incubation of osteoblast cultures with an inhibitor of caspases 3 and 7 reduced mean
percentages of apoptosis in the presence ofOAB as estimated by A. Nick Translation
staining and B. DAPI staining of cultures. Control treatments represent vehicle
treatments for the medium in which OAB were prepared (aMEM) and percentages of
apoptotic osteoblasts are statistically indifferent from untreated cultures (0.97 ± 0.1
S.D., p > 0.05) and vehicle cultures (DMSO) for caspase inhibitors (0.97 ± 0.65



























Figure 19. Osteoblasts undergo apoptosis in the presence of apoptotic
osteocytes independently of the stimulus that induced apoptotic
osteocyte death. OAB were prepared in response to absence of growth factors,
Dexamethasone and H2O2, and were fed to TE85 osteoblasts in culture. Graphs
represent mean percentages of apoptotic osteoblasts ± S.D., as estimated with DAPI
staining of cultures. *** = p < 0.0001, compared to control. Control cultures
represent treatment with vehicle for OAB (aMEM) and are similar to untreated
cultures in percentages of apoptotic osteocytes (1.12 ± 0.33 S.D., p > 0.05).
3.4.7 Non-apoptotic osteocyte products do not induce osteoblast
apoptosis
Osteoblast viability was also investigated in the presence of necrotic osteocyte
products, lysed osteocyte products and streptavidin beads (Figure 21). Estimation of
mean percentages of apoptotic osteoblasts by DAPI staining of cultures showed that
necrotic or lysed vesicles did not induce osteoblast apoptosis, compared to control
cultures (p > 0.05), pointing to differences between the responses induced by healthy,
necrotic and apoptotic osteocytes on osteoblast cultures (Figure 21). In addition,
streptavidin beads did not affect osteoblast viability compared to control cultures (p
> 0.05). Osteoblast cell loss and apoptosis were observed however, following
incubation with soluble factors released from cultures containing large numbers of
necrotic osteocytes (Figure 21).
3.4.8 Apoptotic products from other cells fail to induce osteoblast
apoptosis.
In light of the close proximity of osteoblasts to cells in the bone marrow, besides
bone cells, apoptotic products derived from a variety of marrow cell phenotypes as
well as from distant tissues were compared to osteocyte apoptotic bodies, in terms of
their response on osteoblasts. Primary osteoblast cultures were incubated with
apoptotic products of mesenchymal (primary calvarial osteocytes and MLO-Y4 long-
bone osteocytes, periosteal fibroblasts and renal fibroblasts) and haematopoietic
origin (IC21 monocytes and T hybridoma cells) and also the conditioned media in
which they were produced (Figure 22A). Apoptosis, estimated by DAPI staining was
observed only in the presence of OAB (p = 0.0001 compared to control), while the
media that nourished apoptotic osteocytes as well as apoptotic products either soluble
or membrane-bound derived from other cell types, did not affect osteoblast survival,
compared to control cultures (p > 0.05 in all cases, compared to control).
In addition, incubation of TE85 human osteoblasts with a range of apoptotic cell
products of haematopoietic origin, including primary human PMNs and PBMCs,
indicated again that apoptotic osteoblast death occurred only in the presence of OAB
(Figure 22B).
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Figure 20. Soluble osteocyte apoptotic products do not induce
osteoblast apoptosis. Time course of primary mouse osteoblast cultures
incubated in the presence of OAB and their conditioned medium (CM). Graphs
represent mean percentages of apoptotic osteoblasts ± SD as evidenced by DAPI
staining of cultures. Results indicated that apoptotic osteocyte CM did not increase
mean percentages of apoptosis or osteoblast cell numbers, compared to control
cultures. *** - p < 0.0001, ** = p < 0.001, * = p < 0.05, compared to control.
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Figure 21. Osteocyte necrotic vesicles do not induce osteoblast
apoptosis. A. Time course of primary mouse osteoblast apoptosis in culture in the
presence of necrotic osteocyte vesicles, their conditioned medium (necrotic CM),
medium that nourished healthy osteocyte cultures and OAB. B. Incubation of
primary osteoblasts with lysed MLO-Y4 particles and streptavidin magnetic beads
for 24 hours. Graphs represent mean percentages of apoptotic osteoblasts ± S.D., as
evidenced by DAPI staining of cultures. Control cultures represent treatment with
vehicle for OAB (aMEM).
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3.4.9 Different target cell phenotypes do not undergo apoptosis in the
presence of apoptotic osteocyte products
Seeking additional evidence for the specificity in the response observed in osteoblast
cultures, other potential target cell systems were investigated in the presence of
osteocyte apoptotic bodies (Figure 23 and 24).
3.4.9.1 Macrophages
Bone marrow macrophages were incubated with a range of different apoptotic bodies
derived from osteocytes, IC21 monocytes and T hybridoma cells. Mean percentages
of apoptotic macrophages were not significant with any of the different apoptotic cell
sources, compared to untreated macrophage cultures (p > 0.05), indicating that
apoptotic osteocytes do not induce apoptosis in macrophage cultures (Figure 23B
and 24B). In contrast, both OAB and their conditioned media increased number of
macrophages in culture and induced changes in macrophage morphology, which
acquired long dendritic processes, by 72 and 96 hours of incubation (p = 0.0001,
compared to control cultures) (Figure 25). Soluble factors released from healthy
osteocytes did not affect macrophage numbers in culture and did not alter cell
morphology.
3.4.9.2 CD4+ T lymphocytes and T hybridoma cells
T lymphocyte-lymphoma mouse cells (Figure 23C and 24C) and CD4+ T helper
lymphocytes (Figure 23D and 24D) did not undergo apoptosis in the presence of
OAB (p > 0.05, compared to control cultures, in both cell types), or other apoptotic
bodies and their conditioned media. In both types of lymphocyte cultures however,
cells were physically associated more commonly with osteocyte apoptotic bodies
than with other apoptotic bodies.
3.4.9.3 Spleen cells
No reduction in cell number or induction of apoptosis by apoptotic osteocyte
products was observed in mouse spleen cells (p > 0.05 compared to control cultures)
(Figure 24E), indicating that apoptotic osteocytes might deliver specific signals and
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Figure 22. Apoptotic bodies derived from different cell types, do not
induce osteoblast apoptosis. Osteoblasts were incubated with a range of
apoptotic vesicles produced from different cell types for 24 hours. Graphs represent
mean percentages of apoptotic osteoblasts ± S.D., as evidenced by DAPI staining of
cultures A. mean percentages of apoptotic primary osteoblasts fed with MLO-Y4
osteocyte apoptotic bodies, primary OAB, IC21 monocyte, T hybridoma, periosteal
and renal fibroblast apoptotic bodies (AB), and their conditioned media. B. mean
percentages of TE85 human osteoblasts incubated with AB derived from MLO-Y4
osteocyte, TE85 osteoblasts, PBMCs and PMNs. Control cultures represent treatment
with vehicle for OAB and are similar to untreated cultures in percentages of
apoptotic osteocytes (0.58 ± 0.58% S.D. and 1.15 ± 0.3% S.D. for primary and TE85
osteoblasts respectively). Error bars represent ± S.D. *** = p < 0.0001, compared to
control cultures (Dunnets test).


















Figure 23. Response of various cell systems to osteocyte apoptotic
bodies after 24h of incubation. A. primary osteoblasts, and B. macrophages,
observed using combined images of phase contrast microscopy and fluorescence
microscopy (DAPI blue = cell nuclei and Orange Cell Tracker = OAB). C. T
hybridomas and D. CD4+ T lymphocyte cultures incubated in the presence and
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Figure 24. Different target cells do not undergo apoptosis in response
to OAB. Target cells were incubated with OAB for 24 hours. Graphs show mean
number of cells and percentages of apoptotic cells ± SD as estimated by DAPI
staining of cultures A. Osteoblast, B. Macrophages, C. T hybridomas, D. CD4+ T
lymphocytes and E. Spleen cells. Error bars represent ± S.D. *** = p < 0.0001, ** =
p < 0.001, compared to control cultures.
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B. Macrophage cultures in response to AOB treatment after 72 hours
a control + osteocyte apoptotic bodies + apoptotic osteocyte CM
Figure 25. Increase in cell number in macrophage cultures in response
to osteocyte apoptotic bodies. Macrophage cultures were incubated with OAB
for 24 to 96 h. A. Estimation of number of cells in cultures revealed that OAB and
their conditioned media (CM) significantly increased cells numbers, after 72 h and
96 h of incubation. B. Representative images of macrophage cultures showing
increased number of cells in culture and morphological changes after 72 h of
incubation with OAB and CM. Error bars represent ± S.D. *** = p < 0.0001,
compared to control cultures . 20x magnification.
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3.5 Discussion
This study has identified several aspects of osteocyte function relevant to the
biological significance of osteocyte apoptosis in bone and has shown that apoptotic
osteocytes are capable of inducing specific and unique responses in the different
target cell systems investigated. Osteoblasts, both primary cells and a cell line, were
shown to undergo apoptosis following phagocytosis of osteocyte apoptotic bodies
produced either from primary murine osteocyte-like cultures or MLO-Y4 osteocyte
cell line cultures. OAB-induced apoptosis of osteoblasts was characterised by
externalisation of phosphatidylserine on the outer leaflet of the plasma membrane,
cytoplasmic and nuclear condensation, fragmentation of the DNA and formation of
apoptotic bodies. In addition, induction of osteoblast apoptosis was shown to be
caspase-dependent. Treatment of osteoblast cultures with a non-peptide selective
inhibitor of caspases 3 and 7 mediating mainly end-stage cytoskeletal and nuclear
changes in the apoptotic pathways, based on sulphanylamide derivatives (Lee et al.
2000), managed to prevent osteoblast apoptosis indicating that blockade of these two
caspases was sufficient to prevent apoptotic death. Soluble factors released during
osteocyte apoptosis did not induce the same response as apoptotic bodies, indicating
that a membrane-bound or OAB resident factor is responsible for initiation of
osteoblast apoptosis. In addition, healthy or necrotic osteocytes were not able to
induce osteoblast apoptosis pointing to the existence of a specific factor or factors
expressed during the process of osteocyte apoptosis and persisting after the
production of apoptotic bodies.
Significant osteoblast cell loss and apoptotic death of about 15% were observed as
early as 5 hours after addition of OAB, and reached a peak after 24 hours of
incubation. However, at 48 hours after treatment, both apoptosis and loss of cell
number were reduced compared to values at 24 hours possibly due to the transient
nature of the apoptotic response and the proliferation of the healthy cells remaining
in the cultures after OAB challenge, respectively. Alternatively the reduced apoptotic
response could be due to limitations of in vitro culture systems related to movement
and distribution of the apoptotic bodies to new target cells. It is possible that having
being delivered in the cultures, apoptotic bodies land on a proportion of cells that
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subsequently die, but they do not ever encounter other cells due to the static nature of
the cell culture environment. On the other hand, our time lapse microscopy data
which included image capture in control and OAB-treated osteoblast cultures, every
10 minutes for 24 hours using a Nikon ECLIPSE TE2000-U time-lapse microscope,
suggest that this is not the case since we witnessed significant (Brownian / thermal
motion derived) movement of apoptotic bodies within the cultures.
Phagocytosis of OAB and the subsequent death of osteoblasts did not appear to be
dependent on the stimulus that induced apoptosis in the osteocyte cell cultures. OAB
prepared in response to treatment with three different apoptosis-inducing stimuli,
namely Dexamethasone, H2O2 and serum deprived conditions, were equally
efficiently engulfed by osteoblasts and induced similar levels of osteoblast apoptotic
death. Studies by others have shown however that the efficient recognition and
engulfment of apoptotic epithelial cells by homotypic neighbors was dependent on
the stimulus that triggered apoptotic death (Wiegand et al. 2001). These current data
suggest that it is unlikely that the different pathways leading to apoptosis of
osteocytes engendered by different apoptotic stimuli, determine the efficiency of
phagocytosis by osteoblasts and the subsequent induction of osteoblast apoptosis. A
possible explanation for this finding could be that the death inducing factor/factors
associated with OAB are produced at a late stage in the pathway to death, at a point
downstream of the stimulus dependent on the specificity of the pathways.
Alternatively, the factor responsible for the efficient phagocytosis of OAB by
osteoblasts and the induction of osteoblast apoptosis might not be related to apoptotic
characteristics per se but it might be specifically related to the osteocytic nature of
the apoptotic bodies. This would seem unlikely since similar outcomes could not be
derived from live or necrotic cells. Elowever, it remains possible that it is an
osteocyte derived factor which is either normally unlikely to be delivered to an
osteoblast or that is exposed to the external environment during the formation of
apoptotic bodies that is likely responsible for the effect. Actually, it is likely to be
both apoptotic and osteocyte specific molecules involved, as suggested by the data
discussed in the following paragraphs.
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The current studies demonstrate the clear ability of osteoblasts to phagocytose
apoptotic bodies from a variety of cell sources. Despite the osteoblast not being
traditionally viewed as an important phagocyte in bone, there are examples of this
behaviour in literature. A number of studies have previously reported that osteoblasts
are capable of phagocytosing non-biological particles, which affect their viability and
function (for review see Vermes et al. 2001). For example, it has been shown that
MG63 osteoblasts and primary human osteoblast-like cells phagocytose particles
smaller than 3 pm, which are frequently generated during wear of surgical implants
(Lohmann et al. 2000, Lohmann et al. 2002). Phagocytosis of these non-biological
particles induced alterations in osteoblast cell morphology, proliferation and
differentiation as well as production of PGE2 in a concentration and particle-
dependent manner, inhibiting bone formation and contributing possibly to aseptic
loosening of orthopaedic implants. Other studies have also shown that titanium
particles derived from prosthetic devices induced cytotoxic effects on osteoblasts,
which affected the adhesive properties of osteoblasts (Kwon et al. 2001), their
viability (Pioletti et al. 1999) and proliferation (O'Connor et al. 2004) with particles
ranging between 1.5 to 4 pm inducing the greatest effect as soon as 4 hours after
introduction to cultures. Phagocytosis of these particles resulted both in necrotic and
apoptotic cell death and the release of products that were cytotoxic when presented to
other osteoblast cultures (Pioletti et al. 1999). Furthermore osteoblasts were observed
to acquire a phagocytic phenotype upon engulfment of titanium alloy particles,
resulting in the expression of the macrophage marker CD68, associated with fine
granules in the cytoplasm (Heinemann et al. 2000).
Besides engulfing non-biological particles, osteoblasts have also been reported to
phagocytose apoptotic bodies (Landry et al. 1997). Apoptotic bodies produced from
osteoblasts in the callus of rat tibia that were fractured following a surgical operation
were phagocytosed by homotypic cells. This observation was proposed to be a
mechanism for eliminating excess osteoblasts from the injury site, following callus
formation (Landry et al. 1997). These studies demonstrate that osteoblasts are
capable of phagocytosis of biological and non-biological particles, both in vivo and
in vitro conditions. Although phagocytosis of non-biological particles has been
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reported to affect osteoblast function and viability, induction of apoptosis upon
phagocytosis of biological particles by osteoblasts has not been previously reported.
The specificity of the response seen in these experiments would explain why this is
the case.
In the current studies, a comparison was carried out between the response of
osteoblast cultures to apoptotic bodies produced from different cell types of
mesenchymal (primary calvarial osteocytes and MLO-Y4 long-bone osteocytes,
periosteal fibroblasts and renal fibroblasts) and haematopoietic origin (IC21
monocytes and T hybridoma cells). The findings indicated that osteoblasts
phagocytosed apoptotic bodies efficiently from all cell phenotypes presented to them,
suggesting that osteoblasts are capable of efficiently binding, recognising and
engulfing apoptotic bodies derived from cells of various origins. However, of great
significance to these studies was the observation that osteoblasts only underwent
apoptosis following interaction with osteocyte apoptotic bodies, while uptake of
other apoptotic bodies used in this study did not affect viability or osteoblast cell
number in cultures. These data pointed to the existence of a very specific difference
between the response of osteoblasts to OAB rather than other apoptotic bodies. The
specificity of the response could possibly be attributed to the presence of an
osteocytic specific factor delivered by OAB to osteoblasts and that is responsible for
the induction of osteoblast apoptosis. The possible identity of these factors is dealt
with in chapter 4.
Detailed investigation of the in vitro cultures following completion of delivery of the
phagocytic meals and subsequent target cell response allowed the study of the
importance of the physical interaction with and /or phagocytosis of the apoptotic
bodies by the osteoblastic rather than other target cells in the ensuing response. The
data suggested there was a higher probability of individual osteoblasts being
apoptotic when they were physically associated with apoptotic bodies. In addition, it
was shown that the majority of apoptotic osteoblasts were associated with more than
four apoptotic bodies. Quantification of the phagocytic index in other studies has also
shown that not all phagocytes in a culture interact with the same number of apoptotic
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bodies, as phagocytes have appeared to interact more frequently on average with
more than two (Sexton et al. 2001), three (Hanamaya et al. 2002) or more than four
apoptotic bodies (Hamon et al. 2000). These findings have indicated that the
induction of apoptosis was also related to the number of apoptotic bodies interacting
with the target osteoblasts and that there was a requirement for a threshold amount of
osteocyte apoptotic bodies that would interact with osteoblasts and engender their
apoptotic death. In fact it might be possible that phagocytosis of osteocyte apoptotic
bodies by osteoblasts was necessary for induction of osteoblast apoptosis, since most
of the OAB interacting with apoptotic osteoblasts appeared to be engulfed, rather
than bound on the surface of the apoptotic cells. Other studies have also reported the
dependency on engulfment of apoptotic bodies by phagocytes in order to obtain
particular responses. For example, production of TGF-(3 by human stellate cells
(Canbay et al. 2003a) as well as generation of TNF-a and Fas by Kupffer cells
(Canbay et al. 2003b) and the subsequent induction of their fibrogenic activity
appeared to depend upon engulfment of hepatocyte apoptotic bodies.
Additional support for the specificity of the signal delivered by OAB to osteoblasts
as well as the requirement of phagocytosis in the ensuing response was obtained
through the comparison of the response induced by OAB in osteoblasts with that
induced in other cell types used as target cells, such as macrophages, spleen cells,
CD4+ T lymphocytes and T hybridoma cells. Having established that OAB induce
death in osteoblasts, these studies sought to determine whether OAB might induce
the same response in all cell types. Macrophages appeared readily to bind and
phagocytose multiple osteocyte apoptotic bodies, without however undergoing any
apoptotic changes. In spleen cell cultures, osteocyte apoptotic bodies were also
readily engulfed by cells with a macrophage-like and dendritic cell-like appearance,
however without any evidence of apoptosis in the target cell cultures. In addition, I
used primary CD4* T lymphocytes and a T hybridoma cell line, which have been
shown not to demonstrate phagocytic capacity and presented them with OAB in
culture. In the presence of OAB, both lymphocytic cell types did not undergo any
apoptotic changes, despite close interaction of the OAB with the cells (see below).
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Physical interaction of osteocyte apoptotic bodies with all the target cells used in this
study indicated the existence of mechanisms involved in recognition, binding and/or
phagocytosis of osteocyte apoptotic bodies. This finding would imply that OAB are
associated with specific apoptotic changes in molecules expressed on their plasma
membrane which are implicated in their efficient recognition, binding and
engulfment by phagocytes. Such changes are likely to be of the type shown to be
characteristic of a large number of apoptotic cells types (for review see §2.7). For
example, OAB were clearly demonstrated to express phosphatidyl serine on the outer
leaflet of the plasma membrane, as shown by binding of fluorescently labelled
Annexin V, while their purification was also enabled by biotinylated Annexin V-
streptavidin magnetic bead-conjugates. The role of phosphatidyl serine in recognition
of osteocyte apoptotic bodies by phagocytes, as well as the involvement of other
classical apoptotic cell recognition features such as loss of terminal sialic acid
9+ •
residues or the requirement of Ca in the phagocytic process are investigated in
more detail in chapter 4. Interestingly, it was also observed that a proportion of
osteoblasts in cell culture would not be physically associated with any OAB, which
might not necessarily be attributed to lack of movement of apoptotic bodies, as
discussed above, but possibly to the fact that there exist subsets of osteoblasts
incapable of binding OAB, since the primary osteoblast cultures are of course
representative of a mixed population at different stages in the osteoblast lineage. In
addition, it might be possible that binding of multiple OAB on a single osteoblast
could be enabling the binding of additional OAB on the same cell. This phenomenon
could be due to altered signaling mechanisms on osteoblasts following the binding of
OAB, associated with possible changes induced in phagocytes in order to bind and
internalise apoptotic bodies. Studies by others have also suggested that there is a
requirement for alterations in membrane-related molecules, such as phosphatidyl
serine, in both the phagocyte and the prey in order for efficient recognition and
engulfment to occur (Marguet et al. 1999). These possibilities are investigated in
chapter 4.
Data obtained from the different target cell systems used in this study suggested that
neither engulfment of OAB by phagocytes, as observed in macrophage and spleen
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cell cultures, nor binding as observed in the lymphocyte cultures are alone sufficient
to induce apoptotic death in these target cells. The comparison between the response
of osteoblasts and that of the other target cells to OAB, indicated that non-osteoblast
lineage related cell phenotypes did not undergo apoptosis in response to osteocytic
and a range of other cell apoptotic bodies. These data indicated a clear specificity in
this system, in which unique recognition mechanisms are involved between OAB
and osteoblasts, allowing OAB to induce apoptosis only to osteoblasts, while
osteoblasts only undergo apoptosis in response to OAB. This would tend to suggest
that not only do OAB carry a potent osteoblast death inducing signal but that this
signal is not recognised in cell phenotypes other than those of the osteoblastic
lineage. The relevance of such specificity to the functioning bone environment is
likely to be large. The ability to send out apoptotic body derived death signals to
specific cell types would represent an elegant signaling pathway in bone. The
significance of this specificity is discussed further in the following paragraphs, while
the identification of unique factors on OAB implicated in the ensuing response, is the
subject investigated in chapter 4 and also of further work currently undertaken in our
laboratory.
Although interaction of OAB with target cells other than osteoblasts did not lead to
apoptotic death, morphological behavioural changes were observed in some of these
cell types. For example, CD4+ T lymphocytes appeared closely arranged around
apoptotic osteocytes, with multiple lymphocytes physically interacting with a single
osteocyte. This behaviour was in distinct contrast to that demonstrated by
lymphocytes when they were challenged with apoptotic products produced by other
lymphocytes and hybridoma cells. In T hybridoma cultures, cells were seen forming
a phagocytic cap at multiple sites of interaction with apoptotic osteocytes, indicating
clearly a preference for lymphocytes to physically interact with apoptotic osteocyte
bodies. Furthermore, prolonged incubation of macrophages with apoptotic osteocytes
and/or their conditioned medium resulted in an increase in cell number and a change
in morphology, including the formation of long cytoplasmic extensions which
resembled dendritic cell processes, compared to control cultures. Although not
determined experimentally, macrophages appeared morphologically activated and
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were characterised by the presence of large vacuoles in the cytoplasm, with single
cells being physically associated with up to 20 OAB either internalised or bound on
the cell surface. This might indicate that OAB promote at some level a pro¬
inflammatory response by modulating the behavior of macrophages. Engulfment of
apoptotic cells by splenic macrophages has been shown to lead to infiltration of
neutrophils (Lorimore et al. 2001), possibly through the release of the neutrophil
chemoattractant molecules IL-8 and FasL (Kurosaka et al. 1998, Brown and Savill,
1999). In addition, inefficient clearance of apoptotic cells has been suggested to
contribute to the inflammatory response observed in acute lung injury (Mantell et al.
1997), indicating that induction of pro-inflammatory responses following ingestion
of intact apoptotic bodies might be directing the activity of macrophages to specific
sites in order to efficiently clear apoptotic cells from these sites. For example,
macrophages have been reported to accumulate at sites of inflammation in bone in
response to chemoattractant molecules (Rahimi et al. 1995) and to carry out bone
resorption following release of IL-1 and TNF-a and production of matrix
metalloproteinase-1 in response to LPS (Hong et al. 2004). However, further
investigation is required in order to determine whether OAB promote pro¬
inflammatory responses or the release of anti-inflammatory cytokines such as TGF-
|31 and IL-10 in osteoblasts in a similar way to that seen in macrophages (Voll et al.
1997, Newman et al. 1982, Fadok et al. 1998, Huyhn et al. 2002), following their
engulfment by macrophages. The appearance of dendritic-like cells following
incubation of macrophages with OAB is being followed up in the laboratory and
demonstrated the ability of apoptotic osteocytes to induce a specific response, other
than apoptosis in a particular cell phenotype since it was not observed upon addition
of apoptotic bodies and soluble apoptotic products derived from other cell types,
such as IC21 monocytes and T hybridoma cells. Dendritic cells are known to modify
and present antigens to cells of the immune system, while engulfment of apoptotic
cells by dendritic cells has been shown to exert anti-inflammatory effects by
suppressing their maturation (Stuart et al. 2002). In addition, it has also been
suggested that antigens on the apoptotic cell membrane could access the cytoplasm
and be cross-presented on MHC I and MHC II molecules on macrophages, inducing
dendritic cell maturation, and regulation of immune responses (Bellone et al. 1997,
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Inaba et al. 1998). At present, it is not clear how production of dendritic-like cells in
the presence of OAB might contribute in the bone resorption process or in the
modulation of the local immune system, while there is also no evidence to suggest or
relate the possibility that OAB might travel any further than the osteoblasts on the
bone surface.
This phenomenon, along with the induction of apoptosis specifically in osteoblastic
cells, (which is the main response induced by OAB investigated in this thesis), might
imply the possible existence of a range of phenotype specific molecular patterns
carried by apoptotic bodies from a range of cell types. Such as possibility would be
supported by the work of Aupeix et al. in which they demonstrated phenotype
specific molecular markers on apoptotic bodies generated during AIDS (Aupeix et al.
1997). In these studies, apoptotic bodies could by way of their molecular signatures
be traced back to their cell of origin. These observations imply that it is possible for
apoptotic bodies, which carry on their surfaces specific cell-type antigens to elicit
specific cell/tissue-related responses, depending on the cell they were derived from
and the phagocyte that engulfs them, assigning novel functional significance to the
circulation of apoptotic bodies derived from various tissues in peripheral blood as
demonstrated by Aupeix et al. Overall, the possibility that a wide range of apoptotic
and target cell signaling combinations might exist provides further significance and
physiological meaning to the apoptotic process as a whole. We might now consider
that there is not one but many cell phenotype dependent outcomes related to a cell's
death and phagocytic removal from a tissue.
Prior to initiation of resorption, osteoblasts lining the bone surface are removed in
order to expose the underlying bone mineral to osteoclasts, resulting in the activation
of a quiescent bone surface (Parfitt 1994). In addition, osteoblasts produce signals
such as RANKL that can both induce osteoclast maturation and mediate osteoclast
formation in the presence of MCSF-1 (Lacey et al. 2000, Kong et al. 1999), and the
soluble decoy receptor OPG, which inhibits differentiation and activation of
osteoclasts by competing against RANKL (Yasuda et al. 1999), indicating that
osteoblasts participate directly in the activation of bone turnover. Interestingly,
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apoptosis of osteocytes has been reported to target the activity of osteoclasts, the
bone resorbing cells, by directing them to sites that require to be resorbed in order to
maintain the appropriate structure and strength of bone (Noble et al. 2003). However,
the mechanisms underlying this phenomenon remain unclear. Data provided in this
thesis show that apoptotic osteocytes induce the apoptotic death of osteoblasts in
vitro and ex vivo. In normal physiology, apoptosis in osteoblasts has been suggested
to contribute to the maintenance of the osteocytic population, since following the end
of the bone formation period in the turnover process, osteoblasts have been observed
to undergo apoptosis or to become incorporated into the mineralising bone matrix
and differentiate into osteocytes (Parfitt 1994). Induction of osteoblast apoptosis
upon interaction with apoptotic osteocyte products, as suggested in this thesis, is of
particular importance for the bone tissue microenvironment, since osteocytes are in
close contact with osteoblasts (the bone forming cells) through the canalicular
system. In addition, osteocytic processes have been shown to be in contact with
osteoblasts via gap junctions (Doty 1981, Shapiro 1997), while removal of lining
cells from the bone surface could possibly allow osteocytes to come in contact with
cells in the bone marrow (Kamioka et al. 2001). Palazzini et al. have suggested that a
functional syncytium is present between the cells of osteogenic origin, which is
enabled by the presence of gap junctions, allowing osteocytes to communicate with
cells in the vascular endothelium, through contact with osteoblasts and stromal cells,
indicating that signals passing through this network could be regulating the function
of these cells.
Since osteocytes are located within the bone matrix, we should consider how
osteocyte apoptotic bodies could induce the apoptotic death of bone surface resident
osteoblasts in vivo. It might be possible that osteocyte apoptotic bodies could be
delivered through the syncytial network to neighbor osteocytes and osteoblasts
inducing apoptosis. Recent studies have shown that tracer molecules like reactive
red, microperoxidase and horseradish peroxidase ranging between 1-6 nm in size,
could readily pass through the lacuno-canalicular system, while transport of ferritin
which is 10 nm in size, could not be achieved, in rat long bone, in the absence of
mechanical loading, possibly due to the theoretical presence of fiber matrix of 7 nm
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pore size in the lacuno-canalicular channels (Wang et al. 2004). Osteocyte apoptotic
bodies produced in these studies ranged in size between 0.02 pm to 0.5 pm,
indicating that it might be possible for some osteocyte apoptotic bodies to be
transported through the canaliculi which are approximately 0.2 pm radius. Although
there are no studies available to show presence of apoptotic bodies in canaliculi, we
have noted their presence in our laboratory. Transport could also possibly be
increased by mechanical loading (Wang et al. 2000). In addition, there might be
alterations in the lacuno-canalicular channels in response to death of an osteocyte,
which might be allowing more communication between neighbour cells.
Alternatively, if apoptotic bodies could not be delivered through the canalicular
system, apoptotic osteocytes could be inducing the bystander death of other
osteocytes reaching eventually osteoblasts on the surface. In conclusion, data
provided in this chapter, suggest that osteocyte apoptotic death might play a primary
role in the maintenance of bone quality, through initiation of bone turnover at
particular areas through the induction of apoptosis in osteoblasts lining the bone
surface. Death of the osteoblasts might possibly provide the signals for initiation of
resorption by osteoclasts or alternatively facilitate the removal of anti-resorptive
signals, such as OPG. Induction of apoptosis only to cells of osteoblast origin
indicates that identification and subsequent manipulation of the signals responsible
for osteoblast apoptosis could possibly allow the initiation of turnover at sites of
interest without however altering the viability of non-osteoblast lineage cells present
in the bone microenvironment. In addition, these data raise interesting issues with
regard to the functional significance of apoptosis, other than in developmental and
inflammatory processes, indicating that functional activity of cells in tissues might be
regulated through encounter of apoptotic bodies derived from homotypic cells, cells
that are close by or at distant sites, following their circulation in peripheral blood.
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CHAPTER 4
Mechanisms of phagocytosis of osteocyte apoptotic
bodies and induction of osteoblast apoptosis
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4.1 Abstract
Phagocytosis of apoptotic cells is an efficient and complex process that requires
specific changes to occur on the apoptotic cell membrane as well as co-operation
between phagocyte receptors in order to achieve recognition and phagocytosis. Data
in chapter 3 demonstrated that osteocyte apoptotic bodies can induce apoptosis in
osteoblasts but not in other target cells investigated. This study attempts to identify
mechanisms by which osteoblasts recognise OAB and undergo apoptosis.
OAB-induced osteoblast apoptosis was shown to be caspase-driven and associated
with increased presence of the Fas death receptor on osteoblast cell membranes. In
addition, initiation of osteoblast apoptosis was shown to depend on some level upon
physical interaction with OAB. Agents that interfered with membrane composition
on the osteoblast reduced the uptake of osteocyte apoptotic bodies and the induction
• 2d"of osteoblast apoptosis indicating that the osteoblast response to OAB was a Ca -
dependent process that required specific phospholipid and carbohydrate changes in
both the phagocyte and the prey. Furthermore, OAB appeared to increase the
production of nitric oxide in osteoblast cultures. Gene knockout animal models
demonstrated partial blockade of ingestion but not apoptosis in the absence of
scavenger receptor A (SRA). In addition, absence of CD 14 in osteoblasts derived
from knock out mice not only impaired the uptake of OAB, but also reduced
osteoblast apoptosis by 50% possibly indicating that CD14 is acting at initial




Phagocytosis is a complex process that involves multiple changes on the apoptotic
cell surface to allow rapid and efficient recognition by the phagocytes. Changes on
the apoptotic cell membrane commonly involve loss of terminal sialic acid residues
from glycoproteins such as N-acetylglucosamine, galactose and N-
acetylgalactosamine, which become recognised by the macrophage lectin receptors.
(Savill et al. 2000). Other apoptotic markers involved in the recognition process
include anionic sites such as thrombospondin 1 (TSP1) binding sites and
phosphatidyl serine (PS) (Fadok et al. 1998), which becomes exposed on the outer
leaflet of the plasma membrane through a calcium dependent mechanism that
involves activation of a phospholipid scramblase and downregulation of an ATP-
dependent aminophospholipid translocase (Savill 1997).
Professional phagocytes usually engage different receptors to recognise and engulf
apoptotic cells, at different phases of the apoptotic program, so that a variety of first-
line and back-up mechanisms arise to ensure rapid clearance (Gregory 2000). The
scavenger receptors A (SRA) and CD36, act as endocytic receptors in the clearance
of oxidised low density-lipoprotein (oxLDL), while they have also been implicated
in the mechanism of uptake of apoptotic cells (Piatt et al. 1996, Piatt et al. 1998).
CD36 binds to oxidised residues on apoptotic cells. In addition it co-operates with
the vitronectin receptor avP3 and the bridging molecule, TSP1, via the TPS1- 0^3
interaction, which can be inhibited by antibodies and RGD (Arg-Gly-Glu) peptides,
preventing both recognition of apoptotic cells by phagocytes and adhesion of TSP to
phagocytes. (Savill et al. 1992).
Other recognition mechanisms involve the ABC-1 membrane transporter, (Luciani
and Chimini 1996) and CD 14, which may be found in soluble form in the plasma or
as a membrane-bound receptor on the macrophage cell surface. CD 14 interacts with
LPS on bacteria, but also mediates tethering and uptake of apoptotic cells, in a non¬
inflammatory manner. CD 14 has been proposed to act as a pattern recognition
receptor (PRR), interacting with a series of apoptotic cell associated molecular
patterns (ACAMPs). (Guchelaar et al. 1997, Gregory 2000).
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As discussed in chapter 3, osteocyte apoptotic bodies induce apoptosis in osteoblast
cultures. Confocal microscopy of osteoblast cultures (Figure 17) indicated that OAB
both bind onto the surface of osteoblasts and become engulfed by them. This study
attempts to investigate mechanisms involved in the recognition and engulfment of
the apoptotic osteocyte by phagocytic osteoblasts, and to identify molecules that
might be implicated in the induction of osteoblast apoptosis. In addition, we have
attempted to identify the molecular "reason" for phenotypic specificity in the
apoptotic body/phagocyte interaction with a view to clarifying any further "meaning"
to apoptotic body production.
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4.3 Materials and Methods
Unless otherwise stated, all chemicals were purchased from Sigma, UK and all
culture reagents were purchased from Invitrogen, UK. Tissue culture well plates and
petri dishes were purchased from Corning, UK. Tissue culture procedures were
performed in a laminar flow hood (class 2) receiving HEPA-filtered air, using sterile
equipment.
4.3.1 Cell line culture
Cell line culture was carried out as described in §3.3.1. Briefly, MLO-Y4 osteocyte-
like cells were cultured in aMEM supplemented with 5% fetal bovine serum (FBS),
5% newborn calf serum (NCS), 1% penicillin/streptomycin (P/S) and 1% L-
glutamine while TE85 osteosarcoma cells were cultured in MEM supplemented with
10% FBS, 1% P/S and 1% L-glutamine.
4.3.2 Isolation of primary mouse osteoblast and osteocyte cultures.
Osteoblast and osteocyte cultures were isolated from 3-6 week old female mice as
described in §3.3.2, and killed by CO2 asphyxiation in a closed chamber. Briefly,
calvarial bones were digested in trypsin at 2.5 gm/1 for 10 minutes at 37 °C, followed
by 10 sequential collagenase digestions at a concentration of 0.75 mg/ml, which
provided the osteoblast and osteocyte populations as described in § 3.3.2. Murine
bone marrow macrophages were supplied by Dr Jeremy Duffield and maintained in
DMEM F12 supplemented with 10% FBS as described by Duffield et al. 2000.
Isolation of primary osteoblasts from CD14 and SRA transgenic mice
CD 14 knockout mice were supplied by Prof. Chris Gregory and were generated as
described by Haziot et al. 1996. Briefly, the CD 14 gene was disrupted by removal of
a 272 bp segment including the CD14 initiation codon in exon 1, the 97 bp intron and
172 bp of the coding region in exon 2, and by replacement with a neomycin
resistance gene. This replacement resulted in a frame-shift mutation in the remaining
CD14 sequence. The construct was electroporated to W9.5 ES cells and cells
carrying the disrupted gene were injected to C57BL/6 mice blastocysts. Male
chimaeras were bred with wild-type mice and offspring interbred to produce
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homozygous CD14-deficient mice. Scavenger receptor A (SRA) knockout mice were
supplied by Dr. Adam Lacy-Hulbert. Mice deficient in type I and II SR-A were
generated by homologous recombination as described by Suzuki et al. 1997. The
mice were bred onto the 129/ICR genetic background. Brother-sister matings were
subsequently used to create homozygous receptor-deficient and wild-type mice on
the same genetic background. All mice used in this study were housed in the animal
facility (Edinburgh, UK) and were used between 2 and 8 week of age. Osteoblast
cultures from the transgenic mice were isolated as described above.
4.3.3 Isolation of mouse calvariae for ex vivo experimental conditions
Mouse calvariae were aseptically isolated from 3 pure C57BL/6 mice and 3 CD 14
knockout mice. Calvariae were carefully broken across the suture line in order to
provide controls from each animal for each of the treatments and were kept in
individual wells in a 24-well plate in aMEM medium supplemented with 10% FBS,
1% P/S and 1% 1-glutamine. OAB from MLO-Y4 osteocytes were presented to the
calvariae for 24 hours at 37 °C. After that period, the bones were submerged
immediately in 5% polyvinyl alcohol and snap frozen in a hexane-chilling bath
before being stored at -70 °C prior to cryostat sectioning. Cryostat sections of 8pm
thickness were cut from the chilled material and transferred to 3-
aminopropylnethoxy-silane (TESPA) coated slides to aid adhesion of the bone
section to the slide by creating a highly charged surface. Three sections were used
per treatment group (per half scull).
4.3.4 Characterization of primary calvarial cultures
4.3.4.1 Proliferative capacity (5-bromo-2 deoxyuridine, BrdU)
Proliferating fibroblasts, osteoblasts and non-proliferating osteocyte cultures were
distinguished using BrdU incorporation into newly synthesized DNA, as described in
§3.3.3.1.
4.3.4 2 Alkaline phosphatase Immunostaining
Alkaline phosphatase is widely used as a marker of the osteoblast phenotype and has
been proposed to participate in bone mineralization (Waymire et al. 1995). Alkaline
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phosphatase was detected in primary osteoblast cultures following incubation in
Napthol-ASMX-mix and Fast Blue using light microscopy, as described in §3.3.3.2.
Osteoblasts expressing alkaline phosphatase were detected against total number of
cells in cultures identified by nuclear DAPI staining.
4.3.4.3 Mineralised nodule formation (Von Kossa stain)
Primary osteoblasts were induced to form mineralised nodules in confluent cultures,
by addition of mineralisation solution for 3 weeks (Noble et al. 1995), followed by
incubation in silver nitrate solution and exposure to light, as described in §3.3.3.3.
4.3.5 Induction of osteocyte apoptosis and characterization of apoptotic
bodies by Annexin-V FITC binding and PI staining.
Osteocyte apoptotic bodies (OAB) were produced and characterised as described in
chapter 3. Briefly, osteocytes were either incubated in 0.1% FBS media for 7-10
days, or in the presence of 0.4 mM H2O2 or Dexamethasone at 10"6 M for 4-5 hours,
at 37 °C. Apoptotic osteocyte cultures were characterized by Annexin-V-FITC and
Propidium Iodide staining, in order to distinguish between viable (FITC negative, PI
negative), early apoptotic (FITC positive, PI negative) and late apoptotic or necrotic
cells (FITC negative, PI positive), as described in §3.3.4.1.
4.3.6 Induction of osteocyte necrosis and isolation of necrotic vesicles
by Annexin-V FITC binding and PI staining.
Necrotic osteocyte vesicles as well as the medium that nourished the necrotic
vesicles was produced by incubating osteocyte cultures in 0.8 mM H2O2 for 3-5
hours at 37 °C, as described in §3.3.5.1.
4.3.7 Purification of apoptotic bodies by Annexin-biotin-streptavidin
complex.
Apoptotic bodies were purified on the basis of phosphatidylserine (PS) exposure on
the outer leaflet of the cell membrane, (Figure 7) as described in §3.3.6. Briefly,
apoptotic cells were incubated in biotinylated Annexin V and Streptavidin magnetic
beads, which enabled the purification of apoptotic bodies expressing PS with the use
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of a magnetic sorting device. Apoptotic bodies were then resuspended in growth
medium appropriate for the target cultures, at measured apoptotic body density.
4.3.8 Visualization of apoptotic body and target cell morphology with
fluorescence staining.
Apoptotic bodies were readily visualised with Orange Cell Tracker CMTMR which
becomes absorbed at 540 nm and emitted at 566 nm (Molecular Probes), while target
osteoblasts were visualised with Green Cell Tracker CMFDA absorbed at 492 nm
and emitted at 516 nm (Molecular Probes), as described in §3.3.7. In addition, both
the target cells and phagocytic prey were stained with DAPI, which is stimulated at
344 nm and emitted at 488 nm, as described in §3.3.10.3. The exact staining method
with either the Cell Tracker or DAPI varies according to experimental requirements
and is indicated for individual experiments in the figure legends.
4.3.9 Phagocytosis assay
Phagocytosis was determined as described in §3.3.8. Briefly, target cells stained with
CellTracker Green dye or DAPI were plated at a density of 30,000 cells/well for
primary osteoblasts, 15,000 cell/well for TE85 human osteoblasts and 30,000
cells/well for primary bone marrow macrophages, in 96 well plates. Apoptotic
products and media conditioned by both healthy and apoptotic prey cell cultures
were collected and presented to target cell cultures as described in §3.3.8.
4.3.10 Interaction and Engulfment assays
Following incubation of target cells with apoptotic bodies for the appropriate time
intervals indicated in the figure legends, medium was removed and cultures were
analysed for low affinity interactions with apoptotic bodies or for engulfment of
apoptotic bodies by target cells, as described in §3.3.9. Cells were observed in 3
fields per well resulting in 9 fields per treatment group.
4.3.11 Inhibition of phagocytosis
The process of phagocytosis involves alterations in the plasma membrane
composition, such as exposure of negatively charged phospholipids on the outer
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leaflet of the membrane and loss of terminal sialic acid residues, which enable
recognition of apoptotic cells by phagocytes (Savill 1997), which also undergo
membrane and cytoskeletal changes in order for engulfment to occur.
4.3.11.1 Inhibitors of plasma membrane components
Glyburide
Glyburide is a sulfonylurea compound that has been used to affect phagocytosis due
to its ability to interfere with phospholipid efflux by inhibiting ABCA1 transporter
activity (Becq et al. 1997, Marguet et al. 1999). Target cell cultures and osteocytes,
prior to production of apoptotic bodies were incubated with glyburide for 4 h at 50
pM in DMSO. Target cultures were then presented with OAB, in order to determine
the involvement of phospholipid changes in the interaction of target cells with OAB.
Oligomycin
Oligomycin is an inhibitor of the mitochondrial FoFl-ATPase but has also been
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shown to affect Ca -dependent transbilayer movement of phospholipids (Cho et al.
1997, Catz et al. 1998, Marguet et al. 1999). Target cell cultures and osteocytes, prior
to production of apoptotic bodies, were incubated with Oligomycin for 4 h at 6 pM
in DMSO, in order to determine the involvement of phospholipid changes and the
9+ •
requirement of Ca in the interaction of target cells with OAB.
Ethylenediaminetetraacetic acid (EDTA)
EDTA is a synthetic amino acid that forms chelates with both transition metal ions
and main-group ions. EDTA binds Ca2+ and prevents its availability. EDTA has been
• 94- • •
widely used to reduce the availability of Ca resulting in decreased phagocytosis
(Yuan et al. 2001). OAB were incubated with EDTA at 5 mM in PBS for 5 minutes
• 94-
followed by incubation with OAB, in order to determine the requirement of Ca in
the interaction of target cells with OAB.
Trypsin
Trypsin is a widely used proteolytic enzyme that has also been shown to prevent
glycoprotein-dependent recognition and engulfment by macrophages (Leiro et al.
1997). OAB were incubated with trypsin at 2.5 gm/1 for 10 minutes in order to




N-acetylglucosamine is a cationic amino sugar that can competitively bind to lectin
receptors on the macrophage which recognise modified surface glycoproteins on
apoptotic cells (Dini et al. 1995). Target cells were incubated with N-
acetylglucosamine for 1 hour at 1 mg/ml, prior to incubation with OAB, in order to
determine the involvement of glycoprotein moieties on recognition of OAB by
phagocytes.
4.3.11.2 Inhibitors of cytoskeletal components
Nocodazole
Nocodazole induces depolymerisation of microtubules and has been shown to
interfere with engulfment of apoptotic cells by macrophages (Cannon and Swanson
1992). Target cells were incubated with Nocodazole for 15 minutes at 7 pM in
DMSO, prior to incubation with OAB, in order to investigate the cytoskeletal
changes on target cells upon engulfment of OAB.
4.3.12 Inhibition of nitric oxide (NO) production by phagocytes and OAB
NO is involved in the phagocytic process by macrophages (Corradin et al. 1991)
while in addition it is produced by osteoblasts, osteoclasts and osteocytes and plays a
central role in the regulation of bone turnover (van't Hof et al. 1997). Target cells
and OAB were incubated with the nitric oxide synthase inhibitor L-NAME for 30
minutes at 0.1 mM prior to preparation of phagocytic meals in order to study the
effect of nitric oxide upon engulfment ofOAB by phagocytes.
4.3.13 Determination of Apoptotic State
A range of techniques were used to assess the apoptotic state as described in chapter
3. Cells were observed in 3 fields per well (x20 magnification lens, approximately
40-100 cells per field) resulting in 9 fields per treatment group. Identical
magnifications were used for all apoptosis estimates allowing similar numbers of
cells to be counted per field in all experiments.
4.3.13.1 Annexin-V-FITC Assay
The appearance of phosphatidylserine (PS) on the outer leaflet of the membrane
bilayer can be detected with fluorescently labelled Annexin V; (Martin et al 1995).
Cells were incubated with Annexin-V-FITC followed by propidium iodide (PI) as
described in §3.3.10.1 in order to distinguish between viable (FITC negative, PI
negative), early apoptotic (FITC positive, PI negative) and late apoptotic or necrotic
cells (FITC negative, PI positive).
4.3.13.2 DNA fragmentation using in situ Nick Translation
The percentage of target cells demonstrating DNA breaks was investigated using in
situ nick translation staining (Noble et al. 1997), which allows the determination of
DNA breaks following the incorporation of DIG-labelled dUTP as described in
§3.3.10.2. The ratio of total cells (PI positive) to apoptotic (FITC positive) was
determined using fluorescence microscopy and digital image capture.
4.3.13.3 DAPI staining for healthy and apoptotic cell morphology
DAPI (4',6-Diamidino-2-phenylindole) staining which reveals chromatin
condensation and nuclear fragmentation was performed as described in §3.3.10.3.
4.3.14 Nitrite assay (Griess assay)
In aqueous solutions, nitric oxide (NO) rapidly degrades to nitrate and nitrite making
direct measurement of this compound difficult. Spectrophotometric quantitation of
nitrite using Griess Reagent is straightforward and sensitive, but it might cause a
possible underestimation of NO. Initially nitrate is reduced to nitrite, which is
converted to nitrous acid (FINO2) which then diazotizes sulfanilamide. This
sulfanilamide-diazonium salt is then reacted with N-(l-Naphthyl)-ethylenediamine
(NED) to produce a chromophore which is measured at 540 nm. This assay was
modified from a previously described method (Green et al. 1982) in order to measure
nitrite in up to 200 pi of biological fluids. Concentration of nitrite in the samples and
blank controls was calculated against a series of sodium nitrite (1 mM) dilutions
providing two standard curves of 0-100 pM (1:10 dilution) and 0-10 pM (1:100)
dilution respectively. Samples were pipetted onto a microtitre plate and were
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incubated with the Griess reagent made up with equal volumes of Reagent A (2%
sulphanilamide in orthophosphoric acid) and Reagent B (0.2% N-l-napthyl
ethylenediamine dihydrochloride, NED, in H2O). The assay colour was left to
develop at room temperature for 15 minutes and the concentrations were estimated
using a microplate reader at 540 nm. Dilutions, where appropriate were made in the
same medium used in the experimental samples.
4.3.15 Inhibition of apoptosis using caspase 8 inhibitor
Caspases are involved at various stages in apoptotic cascades, mediating either death
receptor pathways or cleavage of intracellular components in order to disassemble
the cell's structure (Thornberry et al. 1998). In order to determine whether osteoblast
apoptosis in response to OAB involved the activation of death receptor pathways
target cells were incubated with caspase 8 inhibitor II Z-IETD-FMK (Calbiochem,
UK) (Martin et al. 1998), which is activated mainly by death receptors, at 1 pM for 1
hour prior to addition of apoptotic bodies.
4.3.16 Determination of Fas expression by immunocytochemical
staining
The Fas pathway is a death receptor pathway that mediates apoptosis in cells of the
immune system (Ashkenazi et al. 1998); in addition, osteoblasts have also been
shown to undergo apoptosis in response to Fas activation (Kawakami et al. 1997,
Ozeki et al. 2002). Immunocytochemical staining for Fas was used in order to
determine the percentage of target cells that were expressing Fas on the cell surface
in response to OAB. Following incubation with various agents, cells in 24-well
plates were fixed in 4% paraformaldehyde and subsequently washed in PBS. Cells
were incubated for 5 minutes with 0.1% SDS, and were washed in PBS thoroughly.
Cells were then nourished for 20 minutes in goat serum followed by 1 h incubation
with anti-Fas monoclonal antibody (BD Transduction labs, UK) at RT. After
washing in PBS, cells were incubated with secondary anti-mouse FITC antibody for
1 hour and were counter-stained with PI. Cells were visualised by fluorescence
microscopy and digital image capture. The ratio of total cells (PI positive) to Fas
positive (FITC positive) was detected based on 9 fields from a total of 3 wells.
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4.3.17 Reverse Transcription-polymerase chain reaction
Total RNA was isolated from cultures of MLO-Y4 cells using RNA-B™
(Biogenesis) according to the manufacturer's instruction. cDNA was synthesized
from 3 gig of total RNA using oligo dT primers, and RNA was converted into cDNA
by Superscript II RNaseH" reverse transcriptase first strand synthesis system for RT-
PCR (Invitrogen). The PCR reaction was performed using Qiagen Taq PCR core kit
(10X reaction buffer, Taq 5 u/pl, Q buffer and dNTP 10 mM each) in a total of 25 pi
reaction containing 5 pM each forward and reverse primers. Mouse CD 14 specific
primers were designed against sequence accession number BC057889 and mouse (3-
Actin specific primers against sequence accession number X03765 from HGMP
database as shown below. The resulting PCR products for CD 14 and Actin were 290
bp and 290 bp respectively. The PCR reaction was carried out for 40 cycles with
PTC-200 Peltier thermal cycler (MJ Research). PCR conditions were denaturation at
94 °C for 4 minutes, annealing at 57 °C for 1 minute and extension at 72 °C for 1
minute and 30 seconds. The PCR products were analysed in 1.2% agarose gel




Actin reverse 5 -GCTACGTACATGGCTGGGGTG-3'
PCR products were cut from the gel, the DNA gel extracted using Qiagen Kit and
sequencing was carried out by the sequencing service (Edinburgh University) who
use Big Dye version 2 run on a ABI 3730 capillary sequencing machine.
4.3.18 Statistical Analysis
Statistical analysis was performed with SPSS release ll.5 for Windows, using
Analysis of Variance (ANOVA), Tukey test and Dunnett test for comparison
between the treatment groups or simple regression analysis as described in §3.3.11.




4.4.1 Characterization of osteocyte apoptotic bodies (OAB)
Osteocyte apoptotic bodies, ranging between 0.02-0.5 pm in diameter were isolated
from osteocyte apoptotic cultures as described in §4.3.7 and 3.4.1
4.4.2 Characterization of primary osteoblast and osteocyte cultures
Osteoblast and osteocyte cultures obtained from murine calvaria were characterised
as described in §3.3.3 and 3.4.2
4.4.3 Modification of binding/ingestion of OAB by phagocytes
In order to identify molecules that might be implicated in the interaction of
osteoblasts with OAB, the latter were treated with several compounds that modify
plasma membrane composition.
4.4.3.1 EDTA
EDTA is Ca2+ chelator that has been widely used to reduce the availability of Ca2+
resulting in decreased phagocytosis (Yuan et al. 2001). OAB were incubated in
EDTA and introduced to osteoblast cultures for 24 h. Mean percentages of apoptotic
osteoblasts estimated by Nick Translation (Figure 26A) and DAPI (Figure 26B)
staining of cultures, were significantly reduced following incubation of apoptotic
osteocytes with EDTA (p = 0.008, compared to cultures fed with OAB). In addition,
treatment of OAB with EDTA significantly reduced their interaction both with
osteoblasts and macrophages (Figure 27A and 27B) (p = 0.001 and p = 0.03
respectively compared to cultures fed with OAB), indicating that the availability of
Ca2+ is important in mediating the interaction between apoptotic osteocytes and
phagocytes.
4.4.3.2 Trypsin
OAB were incubated with the proteolytic enzyme trypsin prior to introduction to
osteoblast cultures for 24 h, in order to determine the importance of binding of OAB
to osteoblasts on protein-protein interactions. Mean percentages of apoptotic
osteoblasts estimated by Nick Translation (Figure 26A) and DAPI (Figure 26B)
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staining of cultures, were significantly reduced following incubation of apoptotic
osteocytes with trypsin (p = 0.001 respectively, compared to cultures fed with OAB).
Furthermore, incubation of OAB with trypsin significantly reduced phagocytosis of
OAB by osteoblasts (Figure 27A) (p = 0.03) and macrophages (Figure 27B) (p =
0.002), compared to cultures treated with OAB alone, indicating possibly a
glycoprotein-dependent binding and engulfment ofOAB by phagocytes.
4.4.3.3 Glyburide
Glyburide, is a potent sulfonylurea compound that can inhibit ABCA1 transporter
activity, block ATP-sensitive potassium channel (Becq et al. 1997), induces
membrane depolarisation, and affects phospholipid efflux and PS externalisation
(Marguet et al. 1999). The compound has been used to effectively block PS
externalisation in a number of studies (Zha et al. 2001, Marguet et al. 1999, Hamon
et al. 2000). Treatment of osteoblast cultures with glyburide prior to incubation with
OAB, reduced the percentage of apoptotic osteoblasts (Figure 28C) by 4-fold,
compared to cultures incubated with OAB alone as shown by DAPI staining (p =
0.02) (Figure 29A) and Nick Translation staining (Figure 29B). In addition,
estimation of the mean percentages of osteoblasts and macrophages physically
associated with OAB showed a significant reduction in cultures pre-treated with
Glyburide (p = 0.001) (Figure 30), indicating that phospholipid changes and/or
ABCA-1 transporter activity is mediating the interaction of osteoblasts with OAB
which results in osteoblast apoptosis.
4.4.3.4 Oligomycin
Oligomycin is an antibiotic which inhibits the mitochondrial FoF"-ATPase and the
Na+,K+-ATPase, and has also been shown to interfere with Ca2+-influx mediated by
9+
store-operated channels (Cho et al. 1997) and to impair Ca -induced transmembrane
randomization of phospholipids (Marguet et al. 1999). The compound has been used
previously to modify phospholipid activity in a number of studies (Catz et al. 1998,
Marguet et al. 1999, Kamp et al. 2001). Pre-treatment of osteoblast cultures with
oligomycin also resulted in decreased percentage of apoptotic osteoblasts in response
to OAB (Figure 28D) as shown by DAPI staining (Figure 29A) (p = 0.001,
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compared to cultures incubated with OAB alone) and Nick Translation staining
(Figure 29B). Reduced osteoblast apoptosis was associated with reduced interaction
between osteoblasts and OAB (p = 0.0009) (Figure 30A), while similar reduction
was observed in the physical association of OAB with macrophage cultures pre-
treated with Oligomycin (p = 0.0004) (Figure 30B), further supporting the
importance of phospholipid asymmetry in the phagocyte for the recognition of OAB.
The mean percentage of apoptotic osteoblasts was also reduced when osteocytes
rather than osteoblasts were pre-treated with glyburide and oligomycin prior to
production of OAB (p = 0.01 and p = 0.002, respectively compared to treatment with
OAB alone) (Figure 29A and 29B) pointing to the fact that phospholipid changes in
both the target osteoblast and the osteocytic prey could affect induction of osteoblast
apoptosis.
4.4.3.5 N-acetylglucosamine
Osteoblast cultures were incubated with N-acetylglucosamine, a compound which
competitively binds to cell surface glycoproteins, in the presence of OAB, since it
has been shown that loss of terminal sialic acid residues from cell surface
glycoproteins is involved in the recognition of the apoptotic cells by lectin receptors.
(Tarnowski et al. 1987, Savill et al. 2000). Incubation of osteoblast cultures with N-
acetylglucosamine reduced the mean percentage of osteoblast apoptosis compared to
cultures incubated with OAB alone estimated by DAPI staining (p = 0.001) (Figure
29C) and Nick Translation staining (Figure 29D). Treatment of osteoblast and
macrophage cultures with N-acetylglucosamine also decreased the percentages of
phagocytes physically associated with OAB, compared to cultures incubated with
OAB alone (p = 0.0001 and p = 0.0003, respectively) (Figure 30A and 30B).
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Figure 26. Ca++ and protein-dependent induction of osteoblast
apoptosis. Osteoblast cultures were incubated with OAB that were pre-treated
with Trypsin and EDTA. Graphs represent mean percentages of cells associated with
OAB after 24 hours of incubation, estimated by A. Nick Translation staining and B.
DAPI staining of cultures. Control treatments represent vehicle treatments for the
medium in which OAB were prepared (aMEM) and percentages of apoptotic
osteoblasts are statistically indifferent from untreated cultures (1.27 ± 0.64 S.D., p >
0.05). Error bars represent ± S.D. *** = p < 0.0001, ** = p < 0.001, compared to
control cultures (Dunnetts test).
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Figure 27. Ca++ and protein-dependent interaction of OAB with target
cells. Osteoblast and macrophage cultures were incubated for 24 h with OAB that
were pre-treated with Trypsin and EDTA. Association between OAB and A.
osteoblasts and B. macrophages was estimated using combined images of
fluorescence staining of both the phagocyte and the prey. Error bars represent ± S.D.
** = p < 0.0001, * = p < 0.001, compared to cultures incubated with OAB (Dunnetts
test).
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4.4.4 Modification of engulfment of OAB by phagocytes with
Nocodazole
Incubation of osteoblast cultures with nocodazole, an agent that induces
depolymerisation of actin filaments and impairs engulfment of apoptotic bodies
(Cannon and Swanson 1992) also reduced OAB-induced pro-apoptotic activity
(Figure 28E) as shown by DAPI staining (p = 0.0001) (Figure 29C) and Nick
Translation staining (Figure 29D). In addition, upon pre-treatment of osteoblasts
with Nocodazole, physical interaction between OAB and osteoblasts was also
reduced (p = 0.0003) compared to treatment with OAB alone, indicating that
blockade of the upstream binding and engulfment of OAB might be sufficient to
regulate the apoptosis inducing activity of OAB. (Figure 30A). Furthermore, pre-
treatment of macrophage cultures with nocodazole also reduced the mean
percentages of phagocytosis of OAB by macrophages (p = 0.0002) compared to
treatment with OAB alone (Figure 30B).
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A. Control B. OAB C. Glyburide and OAB
Figure 28. Inhibition of phagocytosis prevents osteoblast apoptosis.
Osteoblast cultures were treated with agents and incubated with OAB for 24 hours.
A. control cultures, B. cultures in presence of OAB, and cultures treated with C.
Glyburide, D. Oligomycin and E. Nocodazole in the presence of OAB. Control
treatments represent vehicle treatments for the medium in which OAB were prepared
(aMEM). Green = target osteoblast cultures, Red = OAB. 20x magnification.
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Figure 29. Inhibition of osteoblast apoptosis. Osteoblasts were incubated
with OAB for 24 hours and apoptosis was estimated with DAPI and Nick Translation
nuclear staining, using fluorescent microscopy. Graphs represent reduced
percentages of osteoblast apoptosis in cultures in which A and B. both the phagocyte
and the prey were incubated with Glyburide (Gly) and Oligomycin (Oli) and C and
D. osteoblast cultures were pre-treated with N-acetylglucosamine (Nacetyl) and
Nocodazole (Noco). Control treatments represent vehicle treatments for the medium
in which OAB were prepared (aMEM) and percentages of apoptotic osteoblasts are
statistically indifferent from untreated cultures (1.3 ± 0.21 S.D., p > 0.05). Error bars
represent ± SD. *** = p < 0.0001, compared to control cultures (Dunnetts test).
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Figure 30. Glyburide, Oligomycin, N-acetylglucosamine and Nocodazole
impair the interaction of OAB with phagocytes. Reduced percentages of A.
osteoblasts and B. macrophages associated with OAB following the pre-treatment of
cultures with Glyburide, Oligomycin, Nocodazole and N-acetylglucosamine.
Association between OAB and osteoblasts was estimated using combined images of
fluorescence staining of both the phagocyte and the prey. Error bars represent ± S.D.
*** = p < 0.0001, ** = p < 0.001, compared to cultures incubated with OAB
(Dunnetts test).
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4.4.5 Apoptotic osteocytes increase production of nitric oxide (NO) in
osteoblasts.
NO plays a central role that has biphasic effects on bone formation and resorption
activity and is a potential inducer and inhibitor of apoptosis (Van't Hof et al. 1997).
To establish any role of NO in the induction of osteoblast apoptosis by apoptotic
osteocytes, we exposed the osteoblast and osteocyte cultures to L-NAME, an
inhibitor of NO production, prior to preparation of phagocytic meals. Inhibition of
NO production by osteocytes did not reduce apoptosis of osteoblasts. However,
apoptosis (Figure 31A) as well as association of osteoblasts with OAB (Figure 31B)
were reduced in osteoblast cultures in which NO production was inhibited by L-
NAME treatment. To determine whether osteocyte apoptotic bodies affect NO
production by osteoblasts, media were collected and analysed from phagocytic meals
by Griess assay. This finding confirmed firstly that OAB induced production of NO
by osteoblasts and that the increase in NO production induced by apoptotic
osteocytes was partially inhibited by L-NAME (Figure 32). Necrotic debris did not
induce NO production, pointing again to differences in the response of osteoblasts to
products of the two different types of cell death, as discussed in chapter 3.
In addition, in macrophage cultures, the presence of apoptotic osteocytes was also
associated with increased production of NO by macrophages, indicating that
phagocytosis of apoptotic osteocytes could be mediated or associated with NO
production by the target cells and that production of NO alone is not necessarily
responsible for induction of death in the phagocyte (Figure 31C).
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Figure 31. NO mediated induction of osteoblast apoptosis and
interaction of OAB with target cells. A. Pre-treatment of osteoblast cultures
with L-NAME reduced mean percentages of osteoblast apoptosis as estimated by
DAPI staining. Control treatment represents vehicle treatments for the medium in
which OAB were prepared (aMEM) and percentages of apoptotic osteoblasts are
statistically non-significant from untreated cultures (1.01 ±0.11 S.D., p > 0.05). Pre-
treatment of B. osteoblast and C. macrophage cultures with L-NAME reduced mean
percentages of cells associated with OAB. Association between OAB and osteoblasts
was estimated using combined images of fluorescence staining of both the phagocyte
and the prey. Error bars represent ± SD. ** = p < 0.001, * = p < 0.05, compared to




















Figure 32. OAB increase production of NO by osteoblasts. Osteoblast
cultures were incubated with L-NAME prior to OAB. Griess assay showed reduced
NO concentration in the presence of OAB in cultures pre-treated with L-NAME.
Control treatment represents vehicle treatments for the medium in which OAB were
prepared (aMEM) and NO concentration is statistically indifferent from blank
cultures (0.68 ± 0.452 S.D., p > 0.05). Error bars represent ± S.D. ** = p < 0.001,
compared to control cultures (Dunnetts test).
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4.4.6 Scavenger receptor A mediates interaction between OAB and
osteoblasts
The involvement of scavenger receptor A (SRA) in the recognition of apoptotic
bodies has been demonstrated in several studies (Piatt et al. 1998, Yamamoto et al.
1999). Osteoblasts were isolated from mice that were transgenically modified to not
express the scavenger receptor A gene and were incubated with OAB and the
medium in which they were produced (CM). Physical interaction of osteoblasts with
OAB was significantly reduced by about 50% in SRA null mice (Figure 33) (p =
0.001), compared to wild type mice. However the absence of the scavenger receptor
A did not reduce mean percentages of apoptotic osteoblasts in response to OAB (p >
0.05), as shown by DAPI (Figure 34A) and Nick Translation staining of cultures
(Figure 34B). In addition, there was no reduction in the percentage of osteoblasts
(Figure 34D) and apoptotic osteoblasts (Figure 34D) associated with OAB either
engulfed or bound to their surface, indicating that osteoblasts isolated either from
wild-type or SRA null mice appeared equally likely to be apoptotic the more OAB
were associated with them, as shown by regression analysis. In both wild-type and
SRA null osteoblast cultures, the proportion of apoptotic osteoblasts appeared to
depend on the number ofOAB engulfed (Figure 34D) (p = 0.045 in both cultures).
4.4.7 Absence of CD14 reduces osteoblast apoptosis in vitro and ex
vivo.
CD 14 has been shown to interact with LPS on bacteria, but also to mediate tethering
and uptake of apoptotic cells, in a noninflammatory manner (Devitt et al. 1998). RT-
PCR studies and subsequent gene sequencing confirmed the presence of CD 14
mRNA in osteoblasts (Figure 35A). In this study CD 14 null mice were used to
determine the effect of CD 14 in mediating recognition of OAB by osteoblasts. In a
similar way to SRA knockout cells, engulfment of osteocyte apoptotic bodies by
osteoblasts was reduced by 50% compared to wild-type cultures (p = 0.002),
indicating that the absence of CD 14 might affect interaction ofOAB with osteoblasts
(Figure 35B). In addition, a significant reduction was observed in apoptosis of
osteoblasts isolated from CD14 null mice (p = 0.0001 compared to wild type
cultures) (Figure 36A and 36B and 37), indicating that CD 14 might mediate
113
pathways that involve initiation of apoptotic osteoblast death in response to OAB.
Furthermore, there was a reduction in the percentage both of total osteoblasts
(Figure 36C) and apoptotic osteoblasts (Figure 36D) associated with OAB either
engulfed or bound to their surface, isolated from CD 14 null mice compared to wild-
type osteoblast cultures. Regression analysis showed that the absence of CD 14 from
osteoblasts reduced the dependence of the proportion of apoptotic osteoblasts on the
number of OAB engulfed (Figure 36D) (p = 0.039 in wild-type osteoblast cultures
and p = 0.08 in CD14 knockout osteoblast cultures).
Ex vivo studies using calvaria derived from CD 14 null mice, which were incubated
with OAB for 24 hours, confirmed the reduction in OAB-engendered osteoblast
apoptosis in the absence of CD14, compared to mean percentages of osteoblast
apoptosis estimated from wild-type calvarial sections (p = 0.0001) (Figure 38A). In
addition, estimation of osteocyte apoptosis indicated that the presence of OAB
induced bone resident osteocytes to undergo apoptosis, which was however reduced
in the absence of CD14 (p = 0.001) (Figure 38B).














Control OAB CM OAB + CM
Figure 33. Scavenger receptor A-dependent uptake of OAB. Osteoblasts
were isolated from wild-type and SRA null mice and incubated with OAB for 24
hours in the presence and absence of their conditioned media (CM). Graph shows
the mean percentages of osteoblasts associated with OAB. Error bars represent ± SD.
** = p < 0.001, compared to knockout cultures (Tukey test).
A DAPI staining B Nick Translation staining
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Figure 34. Absence of Scavenger Receptor A does not affect osteoblast
apoptosis in response to OAB. Osteoblasts were isolated from SRA null mice
and incubated with OAB for 24 hours in the presence and absence of their
conditioned media (CM). Mean percentages of apoptotic osteoblasts were estimated
using A. DAPI staining and epifluorescence. Control treatment represents vehicle for
the medium in which OAB were prepared (aMEM) and percentages of apoptotic
osteoblasts are statistically indifferent from untreated cultures (1.26 ± 0.7 S.D., and
1.76 ±0.91 S.D., p > 0.05, for wild-type and knockout cultures respectively). B. Nick
Translation staining. Control treatment represents vehicle treatment for the medium
in which OAB were prepared (aMEM) and percentages of apoptotic osteoblasts are
statistically indifferent from untreated cultures (0.00 ± 0.00 S.D. and 0.25 ± 0.25
S.D. p > 0.05, for wild-type and knockout cultures respectively). Osteoblasts were
incubated with OAB and the percentage of C. osteoblasts and D. apoptotic
osteoblasts that carried none, 1, 2, 3 or > 4 OAB was determined. Error bars
represent ± SD. **=p<0.001, compared to control cultures. i= correlation coefficient.
A RT-PCR
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Figure 35. CD14-dependent uptake of OAB. Osteoblasts were isolated from
CD 14 null mice and incubated with OAB for 24 hours in the presence and absence of
their conditioned media (CM). A. RT-PCR studies showed expression of CD14
mRNA in wild-type murine osteoblasts. B. Estimation of mean percentages of
osteoblasts associated with OAB. Error bars represent ± S.D. ** = p < 0.001
compared to control cultures (Tukey test)
A DAPI staining
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Figure 36. Absence of CD14 reduces osteoblast apoptosis in response
to OAB. Osteoblasts were isolated from CD 14 null mice and incubated with OAB
for 24 hours in the presence and absence of their conditioned media (CM). Mean
percentages of apoptotic osteoblasts were estimated using A. DAPI staining and
fluorescence microscopy. Control treatment represents vehicle for the medium in
which OAB were prepared (aMEM) and percentages of apoptotic osteoblasts are
statistically indifferent from untreated cultures (1.16 ± 0.5 S.D. for wild-type and
1.34 ± 0.81 S.D. for knockout osteoblast cultures) B. Nick Translation staining of
cultures. Control treatment represents vehicle treatment for the medium in which
OAB were prepared (aMEM) and percentages of apoptotic osteoblasts are
statistically indifferent from untreated cultures (2.01 ± 0.7 S.D. for wild-type and
2.21 ± 0.3 S.D. for knockout osteoblast cultures). Osteoblasts were incubated with
OAB and the percentage ofC. osteoblasts D. apoptotic osteoblasts that carried none,
1, 2, 3 or > 4 OAB was determined. Error bars represent ± S.D. *** = p < 0.0001, **
= p < 0.001 and * = p < 0.05 compared to control cultures (Dunnetts test). +=p<0.05
and ++=p<0.001 compared to knockout cultures (Tukey test), r = correlation
coefficient
Figure 37. CD14 null osteoblasts do not undergo apoptosis in the
presence of OAB. Demonstration of representative images ofWT (upper panel)
and CD 14 null (lower panel) cultures. Osteoblasts (green Cell tracker) were fed with
OAV (Orange Cell tracker). Images show increased number of cells in CD 14 null
cultures and reduced DNA fragmentation identified by DAPI nuclear staining of
osteoblasts. Bar = 10 pm.
A Nick Translation staining of osteoblast population
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Figure 38. CD14-dependent induction of osteoblast and osteocyte
apoptosis. Murine calvariae were incubated for 24 hours in the presence and
absence of OAB. Graphs represent mean percentages of A. osteoblast and B.
osteocyte apoptosis. Control treatments represent vehicle treatments for the medium
in which OAB were prepared (aMEM). Error bars represent ± S.D. ** = p < 0.001,
compared to knockout cultures (Tukey test).
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4.4.8 Caspase-8 dependent induction of apoptosis
Osteocyte apoptotic bodies were shown in chapter 3 to induce apoptosis in osteoblast
cultures, in a caspase 3 and/or 7 dependent manner. In order to determine whether
OAB-engendered osteoblast apoptosis involved activation of death receptor
pathways, a caspase 8 inhibitor II (Martin et al. 1998) was administered and shown
to block osteoblast apoptosis as evidenced by nick Translation (Figure 39A) and
DAPI staining (Figure 39B) of cultures (p = 0.001 and p = 0.002 respectively,
compared to treatment with OAB alone), indicating the possible involvement of a
death receptor-mediated pathway in the response to OAB.
4.4.9 Upregulation of membrane-bound Fas receptor expression
Seeking a link between inhibition of osteoblast apoptosis by inhibition of caspase 8
and activation of death receptor pathways, the expression of Fas receptor on
osteoblast membrane was investigated using a FITC-labelled anti-Fas antibody.
Results indicated that the presence of OAB increased the mean percentages of
osteoblasts that were positive for Fas (p = 0.003) (Figure 40A).
Similar results were obtained for macrophage cultures (Figure 40B) in the presence
of osteocyte apoptotic bodies indicating that Fas expression on the target cells is
influenced by the interaction with apoptotic osteocytes. Flowever in macrophage
cultures the in increase in Fas presence was not associated with induction of death.
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Figure 39. Caspase-8 dependent induction of osteoblast apoptosis.
Incubation of osteoblast cultures with caspases-8 inhibitor II reduced mean
percentages of apoptosis in the presence ofOAB as estimated by A. Nick Translation
staining and B. DAPI staining of cultures. Control treatments represent vehicle
treatments for the medium in which OAB were prepared (aMEM) and percentages of
apoptotic osteoblasts are statistically indifferent from untreated cultures (0.97 ±0.1
S.D., p > 0.05) and vehicle cultures (DMSO) for caspase inhibitors (0.97 ± 0.65
S.D.). Error bars represent ± S.D. *** = p < 0.0001, compared to control cultures
(Dunnetts test)
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Figure 40. Upregulation of Fas in the presence of OAB. Mean percentages
ofA. Osteoblasts and B. Macrophages that are positive for Fas following incubation
with OAB. Control treatments represent vehicle treatments for the medium in which
OAB were prepared (aMEM). Error bars represent ± S.D. ** = p < 0.001 and * = p <
0.05 compared to control cultures.
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4.5 Discussion
As discussed in chapter 3, osteocyte apoptotic bodies deliver a specific death
inducing signal recognised only by osteoblastic cells in cultures. The aim of the
experiments outlined in this chapter was to identify the existence of phagocytic
mechanisms commonly involved in the recognition between apoptotic bodies and
phagocytes, as well as molecules that might be associated with the specific
recognition of OAB by osteoblasts, and the induction of osteoblast apoptosis.
Phagocytosis is a complex process that requires specific changes to occur on the
apoptotic cell membrane, in order to allow recognition and engulfment by
phagocytes, without disturbing neighboring living cells (Savill 1997). Several
molecules expressed on the apoptotic and/or the phagocyte cell surface have been
implicated in the recognition mechanism and the engulfment of the apoptotic cells,
which are summarized in §2.7 and are investigated in this chapter.
Having shown in the previous chapter that osteoblasts readily bind and engulf OAB
and that osteoblasts are more likely to be apoptotic if they have phagocytosed OAB, I
first undertook studies to determine the role of membrane associated
changes/activities in the phagocytosis of OAB by phagocytes, by using a range of
compounds that are known to affect, through different mechanisms, the binding,
recognition and/or internalisation of apoptotic bodies by phagocytes. Estimation of
the phagocytic index, which is the proportion of osteoblasts having phagocytosed
(bound or internalised) OAB, was followed by estimation of osteoblast apoptosis,
following treatment with these compounds, in order to identify the implication or
requirement of binding, recognition and engulfment in the death inducing response.
Glyburide is a long-acting sulfonylurea compound that has been used in the
treatment of non-insulin dependent diabetes melitus and acts as a potent inhibitor of
ATP-dependent K+ channels (Quast and Cook 1989) leading to membrane
depolarisation and insulin secretion (Luzi and Pozza 1997). Glyburide has also been
shown to block the anion flux induced by the ATP-binding cassette A-l (ABCA-1)
transporter in Xenopus oocytes at 100 pM (Becq et al. 1997). Inhibition of ABCA-1
by Glyburide at concentrations up to 100 pM has also been shown to affect
endosomal membrane trafficking by enhancing endocytosis of LDL and transferrin
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(Zha et al. 2001) and to prevent secretion of IL-lb, which is required in inflammation
and engulfment by mouse macrophages and monocytes (Hamon et al. 1997). ABCA-
1 transporter has been implicated by other studies in the ingestion of apoptotic cells
by macrophages (Luciani and Chimini 1996) and the movement of anionic
phospholipids across the plasma membrane in apoptotic cells (Hamon et al 2000).
Treatment of apoptotic thymocytes with glyburide at 50 pM was shown to decrease
their recognition by macrophages, while similar treatment of the macrophages
reduced the efficient engulfment of the apoptotic thymocytes (Marguet et al 1999),
possibly by inhibiting ABCA-1 induced phospholipid efflux and PS externalisation
in both the phagocytes and the prey. Since OAB were shown to express phosphatidyl
serine on the outer leaflet of the plasma membrane by binding to fluorescently
labelled Annexin V, while their purification was also enabled by biotinylated
Annexin V-streptavidin magnetic bead-conjugatesln the current study, glyburide was
used to determine the effect of phospholipid efflux in the recognition mechanisms
between OAB and both osteoblasts and macrophages. Treatment of phagocytes with
glyburide at 50 pM led to reduced interaction by almost 50% of OAB both with
osteoblasts and macrophages. Furthermore, reduction in the uptake of OAB by
osteoblasts was accompanied by reduced osteoblast apoptosis by more than 70%
following treatment of either OAB or osteoblasts with glyburide, indicating that
glyburide treatment affected both the recognition of the apoptotic bodies and the
phagocytic mechanisms employed by osteoblasts. Although I have not directly
blocked PS binding, these findings indicated that changes in phospholipids inducing
exposure of PS on the outer leaflet membrane of both the phagocyte and the prey is
possibly one of the mechanisms by which OAB are recognised by phagocytes. In
addition, these data pointed to a requirement for physical association between the
phagocyte and the prey in order for osteoblasts to become apoptotic or it could be
due to the loss of delivery of a signal to the inside of the cell.
Phagocyte cultures were also treated with the FoF"-ATPase inhibitor Oligomycin,
which has also been shown to inhibit Ca2+-influx by interacting directly with store-
operated channels independently of its effects on ATP production (Cho et al. 1997).
Oligomycin has been shown to impair Ca -induced transmembrane movement of
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phospholipids at 6 pM (Marguet et al. 1999), and to block recognition of apoptotic
THP-1 cells by phagocytes, by inhibiting externalization of phosphatidylserine at
concentrations of 0.1-6 pM without however affecting other apoptotic features such
as caspase-3 activation or DNA fragmentation in the apoptotic cells (Zhuang et al.
1998). In these studies Oligomycin was used in accordance to Marguet et al. and
Zhuang et al. in order to prevent the Ca2+ -dependent phospholipid exposure on the
outer leaflet of the plasma membrane of both the phagocytes and osteocyte apoptotic
bodies. Data obtained following treatment of osteoblast cultures with Oligomycin at
6 pM, indicated a significant reduction of almost 70% in osteoblast apoptosis
induced by OAB, while Oligomycin treatment of OAB also effectively reduced
osteoblast apoptosis by 70%. In addition, both in macrophage and osteoblast
cultures, phagocytosis was decreased by almost 3.7- and 2.1-fold respectively,
suggesting possibly that Oligomycin affected recognition ofOAB by the phagocytes.
2"bThese data indicated that membrane phospholipid asymmetry or Ca fluxes might be
important in the recognition between OAB and phagocytes and that the subsequent
induction of osteoblast apoptosis depends upon binding and /or engulfment of OAB.
Alternatively, it might be possible that Oligomycin prevented apoptosis by acting
through inhibition of ATP levels as shown at 1.3 pM in rat thymocytes against
Dexamethasone induced apoptosis (Stefanelli et al 1997) or release of cytochrome c
at 1.2 x 10"2M as shown in gastric epithelial cells induced in response to nitric oxide-
induced apoptosis (Dairaku et al. 2004).
Impairment of phagocytosis has also been demonstrated by reducing the availability
of Ca2+ by EDTA treatment by several studies in the past. For example, binding and
uptake of myelin derived from the central nervous system by macrophages (van der
Laan et al. 1996), phagocytosis of malaria pigment particles by monocytes and
neutrophils (Pichyangkul et al. 1997) and engulfment of apoptotic bodies by
dendritic cells (Rubartelli et al. 1997) were all inhibited following treatment with
EDTA. In addition, phagocytosis of yeast particles by Dictyostelium discoideum
cells was also reduced following treatment with EDTA at concentrations between
• • 9+
0.01-10 mM, which was however fully restored following addition of Ca (Yuan et
al. 2001), indicating the dependence of phagocytosis on the availability of Ca2+. In
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the present study, engulfment of OAB by macrophages and osteoblasts was reduced
by 1.5 and 4.5-fold respectively, following treatment with EDTA at 5 mM, indicating
94-
that phagocytosis of OAB might depend on the availability of Ca , also possibly
suggested by the phagocytic studies using Oligomycin mentioned above. In addition,
impairment of phagocytosis was accompanied by a significant reduction in osteoblast
apoptosis by more than 60%, pointing again to a requirement for physical association
between OAB and osteoblasts in order for the latter to become apoptotic.
Carbohydrate and glycoprotein moieties have also been implicated in the recognition
of the apoptotic cells by phagocytes as it has been shown that apoptotic cells loose
sialic acid moieties leading to exposure ofmannose, fucose and N-acetylglucosamine
which allows their recognition by the mannose-binding lectin receptor on phagocytes
(for review see Savill 1997 and Saevarsdottir et al 2004). Duvall et al. indicated that
the binding of apoptotic mouse thymocytes involved the recognition of N-
acetylglucosamine, N-acetylgalactosamine and galactose residues by a macrophage
lectin receptor, as shown by inhibition studies using the monosaccharides at
concentrations of 10 or 20 mM. Later studies also showed that cells undergoing
apoptosis appeared to express modified glycoprotein residues which might have
enabled their engulfment by endothelial cells expressing mannose and galactose
specific receptors on their surface, as suggested by treatment of the phagocytes with
Nacetylglucosamine, galacose and mannose at a concentration of 80 mM (Dini et al
1995). In addition, N-acetylglucosamine at 20 mM was shown to reduce
phagocytosis of apoptotic lymphocytes by activated mouse peritoneal macrophages
but not J774 macrophages (Pradhan et al. 1997). Based on these studies indicating
the involvement of sugar moieties in the recognition of apoptotic bodies by
phagocytes, N-acetylglucosamine was used to determine whether osteocytes
underwent modifications on the glycoprotein residues on their surface following
induction of apoptosis and to clarify the importance of these residues in their
recognition by the phagocytic osteoblasts and macrophages. Incubation of
phagocytes with N-acetylglucosamine reduced uptake of OAB both by macrophages
and osteoblasts by 2.4- and 3-fold respectively, indicating that recognition involved
asialoglycoprotein-like lectins on osteoblast and macrophage cell membranes. These
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molecules are likely to interact with exposed monosaccharide residues such as N-
acetylglucosamine on OAB, although further studies are required to determine the
presence of such a galactose specific receptor on osteoblast cell membranes and the
possible interaction of this receptor with monosaccharride residues on apoptotic
osteocytes. In addition, treatment with N-acetylglucosamine reduced induction of
osteoblast apoptosis by almost 70%, further indicating that apoptosis of osteoblasts
in response to OAB was dependent on interaction and possibly uptake of OAB by
osteoblasts or the implication of carbohydrate residues in the death response.
Treatment of OAB with the proteolytic enzyme trypsin also reduced the percentage
ofmacrophages and osteoblasts physically interacting with OAB by 2.5- and 1.5-fold
respectively. Furthermore, treatment with trypsin led to almost 70% reduction in the
proportion of osteoblasts that appeared apoptotic following incubation with OAB,
indicating that protein residues are implicated in recognition and binding
mechanisms of OAB with phagocytes, which are required for induction of osteoblast
apoptosis. Studies by others have shown that alteration of surface glycoporteins by
treatment with trypsin, affected recognition and uptake of microsporidians by splenic
macrophages (Leiro et al. 1997) and binding of porphyromonas gingivalis to
epithelial cells (Agnani et al. 2003). These findings have also further supported the
involvement of glycoprotein residues in the recognition and uptake of osteocyte
apoptotic bodies both by professional phagocytes such as macrophages and by
osteoblasts, although the phagocytic receptors that mediate binding to these has not
been identified in these studies.
Having investigated the effect of physical binding/recognition between osteocyte
apoptotic bodies and the phagocytes, by using compounds that possibly affect the
availability of Ca2+, externalisation of PS and modification of cell surface
glycoproteins, I then examined the effect of Nocodazole in the phagocytic response,
since phagocytosis requires the rearrangement of the actin cytoskeleton in the
phagocytes in order for engulfment to occur (for review see May and Mackesky
2001). Nocodazole is a widely used anti-neoplastic agent that disrupts microtubules
by binding to b-tubulin (Chen et al. 2002), inhibits formation of microtubules and
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subsequent binding to centromere (Burakov et al. 2003) and has been reported to
arrest the cell cycle to G2/M phase (Blajeski et al. 2002). Nocodazole has also been
used in a number of studies to affect phagocytosis due to its effects on microtubules
(Cannon and Swanson 1992). For example, Nocodazole inhibited the engulfment of
hepatocyte apoptotic bodies by primary and immortalised stellate cells and prevented
expression of the profibrogenic cytokine TGF-P and collagen-al mRNA (Canbay et
al. 2003a). Phagocytosis of L.monocytogenes by P388D1 macrophages was inhibited
by treatment with Nocodazole (Kuhn 1998) which also reduced internalization of the
pathogen Candida Albicans and mannose-rich particles by macrophages at 10 p.M
(Kaposzta et al. 1999) and the uptake of the pathogen Yersinia pseudotuberculosis by
affecting the organization of microtubules in FleLa cells at doses up to 10 pM
(McGee et al. 2002). Incubation of osteoblast and macrophage cultures in the present
study with 7 pM Nocodazole reduced engulfment of OAB by the phagocytes by 6-
and 4-fold respectively, compared to control cultures. In addition, Nocodazole
treatment also managed to effectively decrease the proportion of osteoblasts that
appeared apoptotic by almost 80% following incubation with OAB. Although I have
not directly investigated the effect of Nocodazole on the arrangement of
microtubules by using epifluorescence and antibodies against tubulin or the
phagocyte cell cycle progression and the influence that it might have on the
engulfment of OAB, these studies suggested that Nocodazole inhibits uptake ofOAB
by osteoblasts and macrophages, and that internalisation ofOAB is possibly required
for the induction of osteoblast apoptosis.
Having shown both a close physical association of OAB with apoptotic osteoblasts
and the involvement of peptide-containing molecules in the response, I went on to
study the possible role of phagocytic recognition receptors using knockout animal
models. Several receptors have been identified so far on the phagocytes that enable
binding and engulfment of apoptotic cells, including the phosphatidylserine receptor
(Fadok et al. 2000), the scavenger receptors A (Piatt et al. 1996) and CD36 (Savill et
al. 1992), ABCA-1 (Luciani and Chimini 1996) and CD14 (Devitt et al. 1998), as
reviewed in more detail in §2.7. Here I have used animal models that are deficient in
scavenger receptor A (SRA) (Suzuki et al. 1997) in order to study the possible
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involvement of this receptor in the uptake of OAB by osteoblasts, since osteoblasts
have been shown to express a variety of scavenger receptors (Roman-Roman et al.
2003). The scavenger receptor A is a membrane glycoprotein that has a high affinity
for interacting with acetylated LDL and has been suggested to contribute in the
pathologic accumulation of cholesterol during vascular diseases (Goldstein et al.
1979). More recently, SRA was shown to mediate the uptake of apoptotic
thymocytes by macrophages by using a monoclonal antibody against SRA which
managed to reduce phagocytosis by 50% compared to control (Piatt et al. 1996).
Suzuki et al. developed in 1997 mice that were deficient in SRA and were shown to
develop smaller atherosclerotic lesions. In addition, macrophages isolated from these
animal models displayed a 50% reduced ability to phagocytose apoptotic
thymocytes, while the remaining phagocytic capacity was attributed to the possible
involvement of other scavenger receptors as shown by treatment with ligands, which
could interact with more than one class of SR (Terpsra et al. 1997).
Using SRA knockout models for the purpose of this study, I observed a reduction by
almost 50% in the uptake of OAB by osteoblasts, compared to cells derived from
wild-type models, indicating a significant role for SRA in the uptake of OAB, but
also the involvement of other phagocytic mechanisms compensating for the residual
phagocytosis. Alhtough the absence of SRA reduced the proportion of osteoblasts
physically interacting with OAB, there was no reduction in the percentage of
apoptotic osteoblasts in the presence of OAB in cells from scavenger receptor-null
mice, pointing to the possible requirement for a threshold amount of reduction in
phagocytosis in order to reduce osteoblast apoptosis. In addition, there appeared to
be no difference between the wild-type and knockout cultures in the average number
of OAB interacting with osteoblasts and the likelihood of these cells to be apoptotic,
which as discussed in chapter 3 indicated that it was more likely for osteoblasts to be
apoptotic having interacted with more than four apoptotic bodies. These findings
suggested that induction of osteoblast apoptosis also dependent on the amount of
apoptotic bodies interacting with osteoblasts and pointed to the possible existence of
another mechanism that is associated with recognition of OAB and induction of the
specific response in the osteoblast.
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During phagocytosis, multiple mechanisms may co-operate in order for engulfment
to occur (Savill 2002), indicating that inhibition of a single phagocytic receptor will
not achieve complete inhibition of phagocytosis. It has been suggested that
professional phagocytes usually enable different receptors to become implicated at
different phases of the apoptotic program by employing a variety of first-line
molecules involved in the initial tethering followed by tight binding receptors to
ensure rapid clearance of apoptotic cells (Gregory 2000). In order to determine the
possible existence of such additional mechanisms that might be employed by
osteoblasts in order to phagocytose OAB I used animal models that are deficient in
CD14. CD 14 is a glycosylphosphatidylinositol-linked plasma membrane
glycoprotein that acts as a bacterial pattern recognition receptor (Pugin et al. 1994)
and comprises part of the lipopolysaccharride (LPS) receptor complex along with
Toll-like receptors (TLR) and MD2 (da Silva et al. 2001). Following interaction
with LPS, CD 14 needs to interact with TLR-4 in order to initiate inflammatory
responses as part of the innate immune response, since CD 14 lacks a cytoplasmic
domain and cannot transmit a signal on its own (for review see Miyake 2003). In
addition, CD 14 has been shown to mediate uptake of apoptotic cells (Devitt et al.
1998, Fadok et al. 1998) and has been proposed to interact with apoptotic-cell
associated molecular patterns (ACAMPs) displayed by apoptotic cells (Gregory
2000). Devitt et al. suggested that CD14 interacts with apoptotic cells through a
region that is very similar to the LPS-binding site, and that CD 14 co-operates with
additional molecules in order to achieve the binding and phagocytosis of apoptotic
cells (Devitt et al. 1998). Generation of CD 14 knockout animal models (Haziot et al
1996) led to increased resistance to shock induced by LPS; however there is no
evidence available to date regarding the efficient clearance of apoptotic cells from
CD 14 deficient animal models.
Initially I went on to examine the presence of CD 14 mRNA on primary mouse
osteoblasts, since there are contradictory reports concerning the ability of osteoblasts
to express CD14 (Kondo et al. 2001, Reyes-Bottela et al. 2000). RT-PCR studies
clearly indicated the existence of CD 14 on primary mouse osteoblasts, while the
demonstration of TLR4 mRNA on osteoblasts (Kikuchi et al. 2001) recently
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suggested that these cells are capable of interacting with LPS and initiate a cellular
response. Knock out studies for CD 14 showed that uptake of OAB by osteoblasts
was reduced by almost 50% compared to osteoblasts derived from wild-type mice,
indicating that the residual phagocytosis might be attributed to other phagocytic
mechanisms, as yet unidentified. More interestingly however, was that reduction in
phagocytosis in CD 14 null osteoblasts was associated with more than 60% reduction
in apoptosis of osteoblasts in response to OAB. The absence of CD 14 also prevented
the pro-apoptotic signals induced by OAB in ex vivo experimental conditions, using
calvaria obtained from CD14 null mice, compared to osteoblast apoptosis estimated
from wild-type calvarial sections. Findings by others have shown that CD 14 might
suppress LPS-induced monocyte apoptosis (Heidenreich et al. 1997) or negatively
regulate cell survival by mediating LPS-induced endothelial cell apoptosis (Frey et al
1998), demonstrating that CD14 could act both as a phagocytic receptor enabling
interaction with apoptotic cells and as surface molecule regulating survival, although
no association has been established so far between the presence of apoptotic cells and
CD14-mediated induction of apoptosis.
Here, absence of CD 14 reduced the proportion of osteoblasts, within the total
population of cells in culture, interacting with more than 4 OAB as well as the
proportion of apoptotic osteoblasts interacting with more than 4 OAB, reducing
therefore the likelihood of osteoblasts being apoptotic in response to increased
uptake of OAB. These findings indicated that the CD 14 glycoprotein might be
implicated in the osteoblast death response, supporting the reduction both in
osteoblast apoptosis and phagocytosis obtained by proteolytic treatment, which
pointed to the involvement of peptide-containing molecules in the ensuing response.
Furthermore, these data suggested that CD 14 might be somehow, specifically
associated with induction of osteoblast death, since SRA which is also a glycoprotein
did not appear to contribute to the death process as discussed above. Findings in this
chapter do not mean however that the presence of CD 14 alone on phagocytes is
sufficient for the induction of apoptosis in the phagocyte in the presence of OAB,
since as described in chapter 3, other phagocytes, such as macrophages that are
expressing CD 14 (Lee et al. 1988), did not undergo apoptosis having ingested OAB.
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These data suggest that the presence of CD 14 and some other factor specifically
associated with the osteoblastic lineage are both required for the induction of
osteoblast apoptosis.
Seeking to identify potential molecules that might be implicated in the induction of
osteoblast apoptosis in response to OAB, I studied the effects of nitric oxide (NO)
that is physiologically produced by all three bone cell types and participates in the
regulation of bone turnover (for review see van't Hof and Ralston 2001). Production
of NO at low concentrations by osteoblasts has been shown to positively regulate
osteoblast proliferation and differentiation (Hikiji et al. 1997, Buttery et al. 1999).
Others have shown that high concentrations of NO might be associated with the
induction of osteoblast apoptosis (Chen et al. 2002) in response to pro-inflammatory
cytokines (Damoulis and Hauschka 1997) and might be associated with increased
production of Bax protein (Chen et al. 2002). Several studies have also shown that
NO is produced in response to mechanical stress both by osteoblasts and osteocytes
(Klein-Nulend et al 1995, Zaman et al. 1999), while NO production by osteocytes
has also been suggested to regulate osteoclastic activity by directing depth and
orientation of the resorption process (Burger et al. 2003), indicating that NO is an
important regulator of bone remodelling.
In this study, both osteoblast cultures and osteocytes, prior to production of OAB,
were incubated with the nitric oxide synthase inhibitor L-NAME. Inhibition of NO
production by osteocytes had no effect in the engulfment ofOAB by osteoblasts or in
the induction of osteoblast apoptosis in response to OAB. However, inhibition ofNO
production by osteoblasts reduced both the phagocytosis of OAB by 1.6-fold and the
apoptotic death of osteoblasts by almost 70%. In addition, Griess assay showed a
3.5-fold increased production of nitrate and nitrite in osteoblast cultures in the
presence of OAB, which was decreased to control levels following pre-treatment of
osteoblasts with L-NAME. These findings suggested that the presence of OAB
induced production of NO by osteoblasts, which was associated with increased
induction of osteoblast apoptosis, however, without necessarily indicating a direct
role for NO in the apoptotic response. Reduced phagocytosis of OAB both by
osteoblasts and macrophages following treatment with L-NAME could possibly be
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attributed to altered recognition mechanisms on the phagocyte, since it has been
shown that anti-oxidant enzymes reduce phagocytosis by blocking oxidative stress
and PS oxidation (Kagan et al. 2003), although I have not further investigated this
phenomenon.
Further experiments involved the blockade of osteoblast apoptosis in response to
OAB by using an inhibitor of caspase 8 in order to identify the dependency of the
apoptotic response on death receptor pathways, since caspase 8 is mainly recruited
by death receptors (Muzio et al. 1996, Medema et al. 1997) (for review see
Thornberry et al. 1998). Inhibition of caspase 8 in osteoblast cultures efficiently
managed to reduce the apoptotic response, indicating that osteoblast apoptosis
induced by OAB is mediated both by upstream caspases such as caspase 8 and
downstream effector caspases such as caspases 3 and 7, as shown in chapter 3.
Activation of caspase 8 in osteoblasts in response to OAB could lead to activation of
caspases 3 and 7 through two distinct pathways involving direct activation (Hirata et
al. 1998), or it could activate the Bcl-2 family member Bid which then translocates
into the mitochondria, inducing cytochrome c release and eventually leads to caspase
3 activation (Li et al. 1998), although the involvement of the mitochondria in the
apoptotic response has not been investigated in this study.
Furthermore, the presence of OAB in osteoblast cultures increased the percentage of
cells that were positive for the Fas death receptor on their membranes, which were in
most cases associated with OAB. In fact, expression of Fas on the surface of
osteoblasts was found to be associated with induction of apoptosis as demonstrated
by dual labelling of osteoblasts in order to reveal both the Fas positive cells and the
cells undergoing apoptosis in response to OAB, indicating possibly that Fas could be
mediating the apoptotic response in osteoblasts (Kawakami et al. 1997, Ozeki et al.
2002) leading to activation of caspases 8, -3 and -7 although no direct association has
been shown in this study between Fas recruitment and activation of caspase 8.
Further work is required however to identify the signals that could be mediating
activation of the Fas death receptor, since MLO-Y4 osteocytes have been shown not
to express Fas Ligand (Kogianni et al. 2004, Ahuja et al. 2003) and to determine
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whether Fas activation is indeed responsible for induction of osteoblast apoptosis.
Similar increase in Fas expression on the cell surface was observed in macrophage
cultures indicating that the presence of OAB is inducing Fas receptor aggregation
that results possibly in the cytotoxicity mediated by macrophages (Nissen-Meyer et
al. 1988), and might support the observation that macrophages appeared
morphologically activated, as discussed in chapter 3, indicating that OAB induce a
pro-inflammatory response that could possibly be targeting the activity of
macrophages at particular sites on bones.
In conclusion, osteoblast apoptosis was shown to depend upon interaction with or
internalisation of OAB, and was reduced by interfering with the production or
presentation of molecules associated with changes that occurred in the apoptotic
osteocytes and/or the phagocytes, such as phospholipid, carbohydrate and
cytoskeletal changes. However, binding and phagocytosis alone did not produce an
apoptotic response since other cell types that had phagocytosed OAB did not die.
Recognition and tight binding of OAB to osteoblasts was also shown to depend on
phagocyte receptors such as SRA and CD 14. The finding that CD 14 was also shown
to be associated with induction of osteoblast apoptosis could possibly provide very
useful information in identifying the nature of the specific signals delivered by
apoptotic osteocytes that only induce apoptosis in osteoblasts and not in other
phagocytes investigated in this study. Identification of this specific signal implicated
in the induction of osteoblast apoptosis could be of extreme importance in the bone
microenvironment, since it might be modulating the removal of osteoblasts from a
particular site in order to signal the initiation of bone resorption by osteoclasts,
regulating therefore the bone turnover process. In addition, it was shown that
apoptosis of osteoblasts was associated with the Fas death receptor pathway,
involving possibly the caspases 8 and 3 or 7 in the execution of apoptosis, while both
osteoblast apoptosis and phagocytosis of OAB were impaired by inhibition of NO
production in osteoblasts. Furthermore, it might be interesting to identify possible
links between activation ofNO and Fas (Fukuo et al. 1996) or CD 14 in the osteoblast
death response, in order to determine whether these molecules form part of a
common signaling pathway or different pathways all leading to the induction of
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osteoblast apoptosis in response to OAB. In addition, since deficiency in CD14
prevented osteoblast apoptotic death both in vitro and ex vivo systems, it would be
very important to identify potential implication of CD 14 in the development of
pathologic bone diseases, characterised by excess osteoblast and/or osteocyte
apoptosis, such as in postmenopausal or glucocorticoid induced osteoporosis.
136
SECTION 3
Blockade of osteocyte apoptosis
137
Introduction to Section 3
As discussed in section 2, osteocytes are thought to regulate bone remodelling, while
osteocyte apoptosis might target resorption to particular areas, indicating that the
incidence of osteocyte apoptosis is in line with the description of apoptosis as an
essential homeostatic mechanism for the healthy maintenance of tissues and that
deregulation of apoptosis could give rise to several pathological conditions.
Increased osteocyte apoptosis in relation to age has been described in the femoral
head and might account for hip fractures in the elderly (Dunstan et al. 1993), while
increased osteocyte death also appears following treatment with agents such as
glucocorticoids (Weinstein et al. 1998). Glucocorticoid therapy induces an imbalance
in bone formation and resorption processes, leading initially to osteopetrosis,
osteocyte death and osteonecrosis, followed by rapid bone loss and osteoporosis
(Glade and Krook 1982). These observations indicate that it is likely to be beneficial
to develop therapeutic approaches that might prevent excess osteocyte apoptosis,
which might lead to pathologic bone conditions. This section investigates potential
molecules implicated in pathways that might lead to osteocyte death, such as
Dexamethasone or survival such as inhibitors of intracellular signalling pathways
and Bisphosphonates, in order to maintain a balance between osteocyte viability and
death, which ultimately leads to better bone quality.
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CHAPTER 5




This work is the subject of a published manuscript (Appendix). Prolonged use of
glucocorticoids is associated with decreased bone formation, increased resorption
and osteonecrosis, through direct and indirect effects on the activity and viability of
bone effector cells, osteoblasts and osteoclasts, and osteocytes. This study has
investigated molecular pathways implicated in Dexamethasone-induced apoptosis of
osteocytes, using a cell line and primary chicken cells. MLO-Y4 osteocytes were
pre-treated with several bisphosphonates representing a range of anti-resorptive
activities and conformation/structure relationships, and were subsequently
challenged with Dexamethasone. Apoptotic cells were detected at various times after
treatment using morphological and biochemical criteria. Dex was shown to induce
apoptosis associated with the Fas/CD95 death receptor in a caspase 8 dependent
manner. The apoptotic response was inhibited by all variants of the BP molecules,
indicating that Dex-induced apoptosis is independent of anti-osteoclastic activity.
Dex-induced apoptosis was associated with a transient increase in phosphorylated
ERK 1/2 and was blocked by the ERK inhibitor U0126. In addition, both U0126
and BPs decreased localization of Fas to the cell membrane. ERK activation by PMA
did not induce death or Fas upregulation, suggesting that Fas may be important for
the induction of apoptosis and the existence of an additional factor activated by Dex
which enables the cooperation between the Dex-activated ERK and Fas pathways,
during apoptosis of osteocytes. Furthermore, upregulation of death and Fas was not
accompanied by upregulation of FasL, pointing to the possible existence of FasL-
independent Fas-associated death in these cells.
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5.2 Introduction
Glucocorticoids (GCs) have been extensively used as anti-inflammatory agents due
to their ability to modulate immune responses (Ashwell et al. 2000), by repression of
many inflammatory cytokines and chemokines that perpetuate inflammation (Tao et
al. 2001). Glucocorticoids offer an effective treatment available for the control of
allergic diseases such as asthma and allergic rhinitis, as well as rheumatoid arthritis,
hepatitis, organ transplant and premature birth (Bijlsma 1997, Epstein 1997,
Compston 1997, Dekhuijzen and Bootsma 1997). GCs exert their effects commonly
through activation of the Fas pathway, one of the best-characterised apoptotic
pathways (Schmidt et al. 2001). Binding of FasL to FasR causes receptor
oligomerisation and recruitment of an adapter protein, FADD, which interacts with
caspase-8, initiating a caspase cascade leading to apoptosis (Figure 5). (Ashkenazi et
al. 1998).
As a side effect to their clinical applications, GCs are responsible for rapid and
profound bone loss and osteonecrosis, which increase with dose and duration of
treatment (Epstein 1997). GCs have been shown to exert anti-mitotic effects on
osteoblast precursor cells, induce apoptosis of mature osteoblasts and increase the
resorptive activity of osteoclasts (Flamdy 1997). Studies by Weinstein et al.
identified the presence of a high proportion of apoptotic osteocytes in mice,
compared to healthy controls, following chronic administration of prednisolone
(Weinstein et al. 1998). It would be of benefit clinically to develop a concurrent
prescription capable of reducing the unwanted side effects associated with GC-
treatment.
BPs are non-hydrolysable analogs of pyrophosphate in which the oxygen linking the
phosphates has been replaced by a carbon atom, with two side chains R1 and R2
(Rodan 1998). BPs inhibit the precipitation of calcium phosphate and were initially
used in industry as anticorrosive and antiscaling agents (Menschutkin 1865). In later
studies, they were found to strongly bind to hydroxyapatite crystals and to affect
bone mineralization (for review see Fleisch 2000). In addition, BPs have been shown
to act as potent competitive inhibitors of the soluble mammalian, yeast and bacterial
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and the membrane-bound plant inorganic pyrophosphatases (Smirnova et al 1988,
Zhen et al 1994). The beneficial effects of Bisphosphonates (BPs) on bone have long
been demonstrated against Paget's disease, post-menopausal osteoporosis and GC-
induced osteoporosis, by decreasing the resorptive activity of osteoclasts (Rodan
1998). BPs are classed as nitrogen-containing (such as PAM and ALN) and non N-
BPs (such as CLO). In osteoclasts, N-BPs inhibit farnesyl diphosphate (FPP)
synthase and prevent prenylation of small GTPases, such as Ras and Rho that are
required for osteoclast polarization, resorption and cell survival, whereas non N-BPs
are metabolized into cytotoxic analogues of ATP, that probably act as inhibitors of
various ATP-dependent enzymes (Rodan 1998, Rogers et al. 1999). Changes in
structure and conformation have allowed the development of various N-BPs, which
differ in their anti-resorptive activity since they differ in their ability to inhibit FPP
synthase (Dunford et al. 2001).
In contrast to osteoclasts, the effect of BPs on osteocytes, which are considered the
mechanosensors and transducers in bone, has not been well characterised. BPs have
variously been shown to both decrease and increase ERK (Nishida et al. 2003,
Plotkin et al. 1999). Studies by Plotkin et al. have implicated the ERK 1/2 pathway in
the ability of BPs to prevent pro-apoptotic effects of Dex on MLO-Y4 osteocyte-like
cells (Plotkin et al. 1999).
This study attempts to identify pro-apoptotic pathways employed by Dex as well as
compounds that could potentially protect osteocytes from glucocorticoid-induced
apoptosis. BPs and the MEK inhibitor U0126 were shown to protect against Dex-
induced apoptosis, while upregulation of the Fas receptor appeared to be important in
the induction of apoptosis.
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5.3 Materials and Methods
All chemicals were purchased from Sigma, UK, all tissue culture reagents were
purchased from Invitrogen, UK and tissue culture well plates and petri dishes were
purchased from Corning, UK unless otherwise stated. Tissue culture procedures were
performed in a laminar flow hood (class 2) receiving HEPA-filtered air, using sterile
equipment.
5.3.1 Cell culture
5.3.1.1 Culture of MLO-Y4 osteocytes
The murine osteocyte-like MLO-Y4 cell line was cultured as described in §3.3.1.
Briefly, cells were maintained in a-Modified Essential Medium (aMEM)
supplemented with 5% fetal bovine serum (FBS), 5% newborn calf serum (NCS),
1% Penicillin/Streptomycin (P/S) and 1% L-glutamine. Subculturing was performed
twice weekly upon reaching 90% of confluency, maintaining the cells in the log
phase of proliferation.
5.3.1.2 Isolation and culture of primary chicken osteocytes
Primary osteocytes were isolated by P. Nijweide as previously described (Nijweide
and Mulder, 1986) and were subjected to immunomagnetic isolation by use of the
chicken osteocyte-specific monoclonal antibody (MAb) OB7.3 bound to magnetic
beads (DYNAL, Norway), which reacts specifically with osteocytes.
5.3.2 Cell treatment
Cells were plated in growth medium at a density of lxlO4 cells/ml in 24 multi-well
plates or 1x10s cells/ml in 60 mm petri dishes for 24 hours, prior to experimentation.
Following appropriate treatment, cells were returned to the incubator at 37 °C for the
time points indicated in the figure legends. Experiments were carried out a minimum
of 3 times, and each treatment group was represented by 3 wells in each independent
experiment. Cells were observed in 3 fields per well resulting in 9 fields per
treatment group. Identical magnifications were used for all apoptosis estimates
allowing similar numbers of cells to be counted per field in all experiments. Control
treatments represent vehicle treatments for the different agents, which were subjected
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to identical dilutions to the agents. Vehicle treatments were carried out on a routinely
basis and were identical in terms of cell number and percentages of apoptotic
osteocytes with untreated control cultures.
5.3.3 Induction of Cell Death
Cells were incubated in growth medium supplemented with 10~7 to 10° M Dex
(Calbiochem, UK) and 0.4 pM to 0.4 mM H2O2 for 1-24 hours.
5.3.4 Prevention of Cell Death
5.3.4.1 Bisphosphonates
Cells were pre-treated for 1 hour with pamidronate (PAM), alendronate (ALN),
clodronate (CLO) (kind gift from Prof. M. Rogers) diluted in phosphate buffer saline
(PBS) at concentrations of 10"8 to 10"6 M, followed by Dex treatment or H2O2.
5.3.4.2 Inhibitors of intracellular signalling proteins.
Caspase inhibitors
Osteocytes were incubated with caspase 3/7-selective inhibitors (GlaxoSmithKline,
USA) and caspase 8 substrate II inhibitor Z-IETD-FMK (Calbiochem, UK),
described in §3.3.11 and 4.3.15, respectively at 1CT6M in DMSO for 1 hour, prior to
Dex treatment to evaluate the role of the Fas pathway in Dex-induced apoptosis.
MAPK inhibitors
Cells were incubated for 30 minutes with the MEK 1/2 inhibitor, U0126
(Calbiochem, UK), at concentrations of 10 to 30 pM in DMSO (Favata et al. 1998),
the p38 inhibitor SB203580 (Calbiochem, UK) at concentrations of 5 to 15 pM in
DMSO (Cuenda et al. 1995) and PMA (phorbol 12-myristate 13-acetate) at 2 ng/ml-
200 pg/ml for 1 to 5 hours. All pre-treatment agents were maintained in cultures in
the presence of Dex or H2O2.
5.3.5 Determination of Apoptotic State
A range of techniques were used to assess the apoptotic state, for all the independent
experimental culture setups, as described in §3.3.10. Cells were observed in 3 fields
per well resulting in 9 fields per treatment group.
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5.3.5.1 DAPI staining for healthy and apoptotic cell morphology
Cells were incubated with DAPI (4',6-Diamidin»2-phenylindole) at 2.5 ng/ml in
water for 10 minutes and examined by fluorescence microscopy as described in
§3.3.10.3.
5.3.5.2 Acridine orange (AO) staining for healthy and apoptotic cell
morphology.
Acridine orange (3,6-bis(dimethylamino)acridinium chloride) is a cell permeable dye
that stains DNA and RNA having excitation approximately at 280 nm and emission
at 530 nm. When it intercalates into double-stranded DNA, it fluoresces green, while
binding to the phosphate groups of denatured single-stranded DNA or to RNA,
produces orange fluorescence (Abrams et al. 1993). Following treatment, cells were
immediately incubated in Walpole's acetate buffer pH 4.2 (10:7, 1 M NaAc: 1 M
HC1) for 5 min. Cells were stained with AO for 25 minutes, washed twice and
examined under fluorescence microscopy. Healthy cells were characterised by intact
nucleus and normal cytoplasmic appearance, while apoptotic cells were characterised
by nuclear or cytoplasmic condensation, DNA fragmentation or blebbing. Large
multinuclear cells occasionally present in MLO-Y4 cultures were ignored.
5.3.5.3 DNA fragmentation using in situ Nick Translation
The percentage of target cells demonstrating DNA breaks was investigated using in
situ nick translation staining (Noble et al. 1997), which allows the determination of
DNA breaks following the incorporation of DIG-labelled dUTP as described in
§3.3.10.2. The ratio of total cells (PI positive) to apoptotic (FITC positive) was
determined using fluorescence microscopy and digital image capture.
5.3.5.4 Annexin-V-FITC Assay
Cells were incubated with Annexin-V-FITC to detect exposure of phosphatidyl
serine on the outer leaflet of the membrane bilayer followed by propidium iodide (PI)
as described in §3.3.10.1 in order to distinguish between viable (FITC negative, PI
negative), early apoptotic (FITC positive, PI negative) and late apoptotic or necrotic
cells (FITC negative, PI positive).
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5.3.6 Determination of Fas expression by immunocytochemical
staining.
The Fas/CD95 death receptor was detected on the surface of MLO-Y4 osteocytes as
described in §4.3.16. Briefly, cells were incubated with anti-Fas monoclonal
antibody (BD Transduction labs, UK) followed by secondary anti-mouse FITC
antibody and were counterstained with PI. Cells were visualised by fluorescence
microscopy and digital image capture. The ratio of total (PI positive) to Fas positive
(FITC positive) was detected based on 3 fields from a total of 3 wells.
5.3.7 Reverse Transcription-polymerase chain reaction
Total RNA was isolated from cultures of MLO-Y4 cells using RNA-B™
(Biogenesis) according to the manufacturers instruction, as described in §4.3.17.
Briefly, cDNA was synthesised from total RNA using oligo dT primers, and RNA
was converted into cDNA by Superscript II RNaseFF reverse transcriptase first
strand synthesis system for RT-PCR (Invitrogen). The PCR reaction was performed
using Qiagen Taq PCR core kit. Mouse Fas specific primers were designed against
sequence accession number M83649, Fas Ligand primers against sequence accession
number U10984 and mouse (3-Actin specific primers against sequence accession
number X03765 from HGMP database as shown below. The resulting PCR products
for Fas and Actin were 220 bp and 290 bp respectively. The PCR reaction was
carried out for 33 cycles with PTC-200 Peltier thermal cycler (MJ Research). PCR
conditions were denaturation at 94 °C for 50 seconds, annealing at 50.5 °C for 1
minute and extension at 72 °C for 1 minute 30 seconds. The PCR products were
analysed in 1.5% agarose gel containing ethidium bromide.
Fas forward 5'- CATGCTGTGGATCTGGGCTGT-3'
Fas reverse 5' -GTGTACCCCCATTCATTTTGC-3'
FasL forward 5'-ATGCAGCAGCCCGTGAATTAC-3'
FasL reverse 5'-CCATATCTGGCCAGTAGTGC-3'
Actin forward 5'- CAAGGTGTGATGGTGGGAATG-3'
Actin reverse 5 -GCTACGTACATGGCTGGGGTG-3'
5.3.8 Preparation of cell lysates
Following appropriate treatment, the medium was removed and the cells were
washed twice in ice-cold PBS. Cells were left to lyse on ice (Figure 41) for 45
minutes by addition of 500 pi of lysis buffer (50 pM Tris-FICl, pH 7.4, 1% (v/v)
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Novidet P-40, 6 mM sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM
PMSF, 1 mM Na3VC>4 and 1 mM NaF and a protease cocktail tablet (Roche, UK)).
The cells were then scraped into chilled microcentrifuge tubes and the lysate cleared
by centrifugation at 4 °C (13,000 g for 10 minutes). The cell pellets were thrown
away and the supernatants were transferred to fresh tubes and either used
immediately or stored at -20 °C.
5.3.9 Determination of protein concentration
Protein concentrations were estimated based on the method described by Bradford
(Bradford 1976). Samples and standards were diluted in water to give a final volume
of 200 pi. Protein standards were bovine serum albumin (BSA) within a range of 0-
20 pg/ml. Bio-Rad protein acid reagent (50 pi) (Bio-Rad, UK) was added and
samples were mixed thoroughly. Sample and standards were prepared in triplicate by
addition of 200 pi into a well on a 96 multi-well plate. The protein concentration was
then determined using an Athos 2001 automated plate reader (Athos Labtec
Instruments) which measured the absorbance of the dye:protein complex at 570 nm
and calculated the protein concentration relative to the BSA standards. The results
were modified to compensate for dilutions incurred during the procedure.
5.3.10 Protein gel electrophoresis
Protein extracts were separated by electrophoresis through a polyacrylamide gel
containing sodium dodecyl sulphate (SDS) (Figure 41). Proteins were denatured to
form random coils and given a net negative charge by heating them in a reducing
buffer containing SDS. Proteins were then separated on the basis of molecular weight
with small proteins migrating more quickly than large proteins due to lower steric
hindrance imposed by the gel crosslinks. SDS PAGE was performed on denaturing
stacking/resolving gels with a gel thickness of 0.1 mm.
5.3.10.1 Electrophoresis reagents.
Tris resolving buffer: 1.5 M Tris base, pH 8.9 and 13.9 mM SDS.
Tris stacking buffer: 0.5 M Tris-HCl, pH 6.8 and 13.9 mM SDS.
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Acrylamide/bisacrylamide (Protogel) solution: 30% (w/v) acrylamide and 0.8%
(w/v) bisacrylamide.
Ammonium persulphate (APS) solution: 10% (w/v) APS in dfEO.
Blue loading buffer (2x): 10% (v/v) glycerol, 10% (v/v) p-mercaptoethanol, 0.1 M
SDS, 6% (w/v) urea, 0.125 M Tris and 0.02% bromophenol blue.
Tris running buffer: 190 mM glycine, 25 mM Tris base and 17 mM SDS.
5.3.10.2 Preparation of resolving gel.
Gel plates were washed sequentially with detergent, distilled water and methanol.
Composition of resolving gel (ml)
Percentage polyacrylamide gel
8% 10% 12%
Tris resolving buffer 1.5 1.5 1.5
dH20 2.69 2.6 2.24
Protogel 1.44 1.8 2.16
Polymerisation of the gel mixture was initiated by addition of 90pl freshly prepared
10% ammonium persulphate and 6 pi of N,N,N',N'-tetramethylethylenediamine
(TEMED). The gel mixture was pippeted into the gel cast, layered with water and
allowed to polymerise for 30 minutes at room temperature.
5.3.10.3 Preparation of stacking gel
Composition of stacking gel (for 2 gels)
Tris stacking gel 1.25 ml
dH20 3 ml
Protogel 0.75 ml
Polymerisation was initiated by addition of 75 pi ammonium persulphate and 5 pi of
TEMED. The stacking gel was poured onto the surface of the polymerised resolving
gel. A spacer comb was inserted into the gel cast and the gel was allowed to
polymerise for 30 minutes at room temperature. The gel cast was then placed into a
gel tank containing running buffer in both upper and lower chambers to submerge the
gel and the spacer comb was removed.
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Figure 41. SDS PAGE electrophoresis and Western blot analysis. Cells in
culture were incubated in lysis buffer and proteins were collected, which were
denatured with SDS to acquire their primary structure and a net negative charge.
Proteins were then separated on a polyacrylamide gel based on SDS, according to
their molecular weight, and were transferred onto a membrane blot. Finally the blot
was hybridised with primary and secondary antibodies and exposed on a film
enabling the detection of the protein of interest.
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5.3.10.4 Electrophoresis.
Protein samples and coloured molecular weight rainbow markers (Bio-Rad, UK)
were mixed with an equal volume of reducing buffer and were denatured by boiling
for 5 minutes prior to loading into the sample wells. The gel was then subjected to
electrophoresis at a constant current of 20 mAmps (Figure 41) (Power Pac 3000,
Bio-Rad, UK). Fractionation was terminated when the bromophenol blue in the
reducing buffer reached the bottom of the gel.
5.3.11 Western Blot analysis.
5.3.11.1 Transfer of proteins to polyvinylidene difluoride (PVDF) membrane.
After electrophoresis, proteins were transferred from the gel onto a PVDF membrane
(Figure 41). The membrane (cut to the dimensions of the gel) was soaked in
methanol and then in transfer buffer (48 mM Tris-base, 38 mM glycine, 1.3 mM SDS
and 20% (v/v) methanol, pFl 9.0-9.4) for 15 minutes, along with the gel and layers of
filter paper and fibre pads. A fibre pad was placed on the gel holder cassette,
followed by filter paper, gel, PVDF membrane and by another filter paper and a fibre
pad. The cassette was placed in the Mini trans-Blot Cell Assembly, which has the
capacity to hold two cassettes between parallel electrodes only 4cm apart, along with
a bio-ice cooling unit, which was kept frozen at -20 °C (Trans-blot SD, Bio-Rad,
UK). Proteins were transferred onto the membrane at 30 V for 1 hour.
5.3.11.2 Detection of proteins on PVDF.
The membrane was incubated in Tris-buffered saline/Tween (25 mM Tris-base pH
8.0, 150 mM NaCl and 0.1% (v/v) Tween 20, (TBS-T) containing 3% (w/v) BSA)
for 24hrs at room temperature to block non-specific binding sites. The proteins were
then probed with the appropriate primary antibody (rabbit polyclonal antibodies
against phosphorylated p44/42 MAPK, p90rsk, MEK 1/2 and c-Raf kinases, New
England Biolabs, UK ) in TBS-T containing 0.3% BSA overnight at 4 °C. The
membrane was washed for 45 minutes in TBS-T and was incubated with a species-
specific secondary antibody, at room temperature for 1 hour. The membrane was
washed again in TBS-T for 45 minutes and the bound-antibody complexes were
visualised using the Enhanced Chemiluminscence (ECL) (Amersham, UK) system,
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according to the manufacturer's instructions. The membrane was exposed to
autoradiograph film and developed (Figure 41).
5.3.11.3 Stripping and reprobing membranes
Once developed, the membrane could be stripped and reprobed for other proteins.
The membrane was incubated in stripping buffer (100 mM p-mercaptoethanol, 69
mM SDS and 62.5 mM Tris-HCl, pH 6.7) at 56 °C for 30 minutes and washed
extensively in TBS-T for 45 minutes at room temperature. The membrane was then
blocked in TBS-T containing 3% BSA overnight and immunological detection of
proteins performed as described in 5.3.11.2.
5.3.12 Immunoprecipitation
Protein extracts (1 mg) from cell lysates were diluted to lmg/ml and added to
microcentrifuge tubes containing 15 pi of protein A/G agarose conjugate bead slurry
(50% conjugate/ 50% PBS) and 4 pi of Jo2 hamster monoclonal antibody against
murine Fas (Pharmigen, USA). The reaction mixture was rotated overnight at 4 °C.
The agarose beads were collected by centrifugation at 4 °C (13,000 g for 20
minutes), washed four times with 1ml of ice-cold lysis buffer and were then
subjected to electrophoresis as described above.
5.3.13 Statistical analysis
Statistical analysis was performed using quantitative data analysis with SPSS release
ll.5 for Windows, as described in §3.3.12, using Analysis of Variance (ANOVA),
Tukey test and Dunnett test for comparison between the treatment groups. Results
are expressed as means ± S.D. p < 0.05 was considered to be statistically significant.
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5.4 Results
5.4.1 Dexamethasone induces MLO-Y4 cell apoptosis in a time- and
dose-dependent manner.
ML0-Y4 osteocytes were cultured with Dex at 10"7 to 10° M for various times
between 1 and 24 hours (Figure 42A and 42B). Apoptotic osteocytes appeared
irregularly shaped and smaller in size, as shown by AO staining, while DAPI staining
(Figure 43) revealed chromatin condensation, shrinkage of nuclei and the
fragmentation of the nuclear material into smaller blebs. Estimation of apoptotic
osteocytes revealed that maximal levels of death accompanied by cell loss, were
reached at 5 hours of incubation with concentrations of 10"3 M and 10~6 M (p =
0.0001 and p = 0.001 compared to control respectively). At 24 hours numbers of
osteocytes in culture recovered somewhat, while apoptotic levels decreased,
suggesting that Dex-induced death of osteocytes is transient (Figure 42A and 42B).
At concentrations of 10"7 M, Dex did not induce apoptosis in these cells. At 10"3 M a
small proportion of cells were noted to have expanded and burst characteristics of
necrosis. Based on the apoptotic criteria in response to the different concentrations
and time points investigated, the dose of 10"6 M, which did not induce necrosis, was
selected for future experiments, reaching a peak at 5 hours incubation.
5.4.2 Assessment of Dex-induced apoptosis by Annexin-V-FITC and
Nick Translation assays.
AO and DAPI staining allowed the observation of plasma membrane blebbing,
cytoplasmic condensation and nuclear blebbing, respectively, which are considered
to occur during final stages of apoptosis, following the proteolytic cleavage of
cytoplasmic and nuclear cytoskeletal factors (Thornberry et al. 1998). In order to
characterise further the osteocytes following incubation with Dex at 10" M for 5
hours, externalisation of PS and fragmentation of DNA were examined, which occur
at earlier apoptotic stages than nuclear and cytoplasmic blebbing, by Annexin-V-
FITC binding (Figure 44A) (<1% necrotic cells identified by PI counter-staining),
and by Nick Translation assay (Figure 44B), respectively. This indicated that
osteocytes underwent apoptosis with plasma membrane changes and fragmentation
ofDNA in the presence ofDex.
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Figure 42. Dexamethasone induces apoptosis in MLO-Y4 osteocytes in
a concentration-dependent manner. MLO-Y4 osteocytes were incubated in
the presence ofDex at 10"7 to 10"5 M for 1-24 hours and apoptosis was determined by
Acridine Orange and DAPI staining and fluorescence microscopy, by examining 3
fields per well and 3 wells per treatment group. A. Mean percentages of apoptotic
osteocytes and B. Mean number of osteocytes in culture. Control cultures represent
vehicle (ethanol) cultures and are similar to untreated cultures in percentages of





Figure 43. Dexamethasone induces cytoplasmic and nuclear
condensation, DNA fragmentation and formation of osteocyte apoptotic
bodies. Representative images of untreated (top panel) and Dex-treated MLO-Y4
osteocytes (bottom panel) at 10"6 M for 5 hours stained with DAPI. White arrows
indicate nuclear condensation and fragmentation. Black arrows indicate cytoplacmic





























Figure 44. Dexamethasone induces apoptotic changes in MLO-Y4
osteocytes. MLO-Y4 osteocytes were incubated with Dex at 10"6 M for 5 hours.
Mean percentages of apoptotic osteocytes were characterised by A. Annexin V FITC
binding and B. DNA fragmentation. Results are expressed as means ± S.D.
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5.4.3 Dexamethasone upregulates the Fas pathway
RT-PCR studies revealed that MLO-Y4 osteocytes express Fas receptor both in basal
state and following treatment with Dex (Figure 45A). However, FasL expression
was not detected in both treated and untreated samples. Quantification of osteocytes
that exhibited binding with an anti-Fas receptor antibody showed that Dex increased
the percentage of cells staining positive for Fas (Figure 45B) as early as 3 hours by
7-fold (Figure 45C). In addition, western blot analysis demonstrated a time-
dependent increase in Fas protein upon treatment with Dex (Figure 45D).
The involvement of Caspase 8, which lies downstream of Fas, was then investigated
in Dex-induced apoptosis. Pre-treatment with the caspase 8 inhibitor Z-IETD-FMK
reduced the induction of death at 5 hours, up to 5-fold, compared to cultures treated
with Dex, as shown by Annexin-V-FITC assay and DAPI nuclear staining,
suggesting that caspase 8 is involved in the apoptotic machinery activated by Dex in
MLO-Y4 osteocytes (Figure 46). In addition, pre-treatment with a selective inhibitor
against caspases 3 and 7 reduced the percentage of apoptotic osteocytes up to 6-fold
(Figure 46).
5.4.4 Bisphosphonates prevent Dex-induced apoptosis in MLO-Y4
osteocytes.Dose response studies were used to identify concentrations of the non
N-containing CLO and the N-BPs PAM and ALN (Figure 47) that did not increase
apoptosis above control levels (Figure 48). Mean percentages of osteocytes
displaying apoptotic morphology were statistically different compared to control
following treatment with all BPs at 10"6 M, after 6 hours of treatment (p = 0.03),
whereas the lowest concentration of 10"8 M did not increase apoptosis above control
levels for all BPs (p > 0.05). BPs were then used to treat osteocytes prior to addition
of Dex in cultures. Estimation of apoptosis showed that BPs at the lowest effective
dose of 10"8 M significantly decreased the pro-apoptotic effect of the corticosteroid in
osteocytes (Figure 49). The apparent lack of saving from death using doses higher
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Figure 45. Dex upregulates Fas expression in MLO-Y4 osteocytes. MLO-
Y4 osteocytes were incubated with Dex at 10"6 M for 5 hours and Fas expression was
confirmed using A. RT-PCR analysis B. Immunocytochemistry using anti-Fas mAb
for 1 to 5 hours. The graph represents the percentage of osteocytes, expressing Fas
per number of cells ± S.D., determined by fluorescence microscopy. Control cultures
represent vehicle (ethanol) cultures for Dex and are similar to untreated cultures in
percentages of apoptotic osteocytes. C. Representative images of Fas positive cells
identified by Fas mAb conjugated to FITC-labelled secondary antibody (green) and
counter-stained with PI (red) using fluorescence microscopy (20x magn.) Untreated
osteocytes (left panel) and Dex-treated osteocytes (right panel). D. Detection of Fas
protein levels following Dex treatment for 1 to 5 hours using western blot analysis.
Changes in band densitometry were quantified using NHI image analysis system and
expressed as percentage change relative to zero time control ± S.D. (Graphs
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Figure 46. Inhibitors of caspases 8 and 3,7 reduce pro-apoptotic stimuli
induced by Dex. MLO-Y4 osteocytes were incubated with inhibitors of caspase-8
(Z-IETD-FMK) and a caspase 3/7 selective inhibitor for 1 hour, followed by Dex
treatment at 10"6 M for 5 hours. Cells were stained with A. Annexin-V FITC and B.
DAPI and examined by fluorescence microscopy for phosphatidylserine detection
and chromatin condensation, respectively. Graphs represent percentage means of
apoptotic osteocytes ± S.D. (*** = p < 0.0001, ** = p < 0.001, * = p < 0.05). Control
cultures represent vehicle (ethanol) cultures for Dex and are similar to untreated
cultures (0.98 ± 0.58 S.D., p > 0.05 estimated by Annexin-V FITC and 1.27 ± 0.33














Figure 47. Chemical structures of CLO, PAM and ALN. All BPs are
characterised by two phosphonate groups attached to a central carbon atom. The R2
side chain in CLO, which is a first generation BP, is a CI- atom, while PAM and
ALN are second generation BPs and both contain a N-group but different lengths in
the R2 side chain. The presence or absence of a N-group accounts for differences in
anti-osteoclastic activity and anti-resorptive potency. Image adapted from Dunford et
al. J.Pharm.Exper.Therap 2001, page 238.
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Figure 48. Dose-response studies of PAM, ALN and CLO. MLO-Y4
osteocytes were incubated with PAM, ALN and CLO to identify concentration that
did not induce osteocyte apoptosis over a period of 6 hours. Cells were stained with
AO and examined by fluorescence microscopy. Graphs represent percentage means
of apoptotic osteocytes, per number of cells ± S.D (*** = p < 0.0001, ** = p < 0.001,
* = p < 0.05).□control cultures,□ =untreated control. Control cultures represent
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Figure 49. Bisphosphonates prevent MLO-Y4 osteocyte apoptosis
induced by Dexamethasone in a concentration-dependent manner.
O A
Osteocytes were incubated with BPs at 10" to 10 M for 1 hour prior to Dex
treatment, for 5 hours. A. Mean percentages of apoptotic osteocytes were
statistically different compared to control following treatment with all BPs at 10"6M,
o
in the presence of Dex. B. The lowest concentration of 10" M for all BP molecules
reduced percentages of apoptotic osteocytes to levels similar to control. Cells were
stained with AO and examined by fluorescence microscopy (*** = p < 0.0001, ** =
p < 0.001, * = p < 0.05) Control cultures represent vehicle (ethanol) cultures for Dex
and are similar to untreated cultures in percentages of apoptotic osteocytes (1.42 ±
0.11 S.D., p > 0.05).
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5.4.5 Inhibitors of MAP kinase signalling molecules prevent Dex-
induced apoptosis in MLO-Y4 osteocytes.
The effect of Dex on MLO-Y4 osteocytes was further characterised in the presence
of protein inhibitors such as the MEK 1/2 inhibitor U0126 and the p38 inhibitor
SB203580. Dose response studies identified optimal concentrations ofU0126, which
did not significantly increase apoptosis above control levels either for the compound
alone, or the vehicle in which it was delivered, within the range of concentrations
known to inhibit ERK 1/2 (Favata et al. 1998) (Figure 50A). Quantification of
apoptosis showed that concentrations of U0126 at 10 and 20 |_iM exerted protective
effects on osteocytes following 5-hour incubation period with Dex (Figure 50B). In
contrast, SB203580 at concentrations of 5 to 15 pM known to inhibit p38 (Cuenda et
al. 1995), did not prevent GC-induced apoptosis, while doses above 10 pM induced
significant apoptosis when added alone to osteocyte cultures (Figure 51).
5.4.6 BPs and protein kinase inhibitors do not protect osteocytes from
oxidant-induced death.
To evaluate the role of the BP and ERK pathways in the induction of osteocyte
apoptosis by other agents, MLO-Y4 cells were pre-treated with PAM and U0126
prior to their exposure to EfCE. MLO-Y4 osteocytes were cultured with H2O2 at
concentrations shown to induce apoptosis (0.08 mM to 0.4 mM), for various times
between 1 and 24 hours (Figure 52A). Maximal levels of death accompanied by cell
loss were reached at 24 hours of incubation by all different concentrations (Figure
52B). At 0.8 mM a small proportion of cells were noted to have expanded and burst
characteristics of necrosis. Based on the apoptotic criteria, the dose of 0.4 mM,
which did not induce necrosis, at 5 hours incubation, was selected to induce
apoptosis in cultures pre-treated with BPs and the ERK 1/2 inhibitor (Figure 53).
Mean percentages of apoptotic osteocytes revealed that EfOi-induced osteocyte
death was not reduced in the presence of either U0126 or PAM.
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Figure 50. The MEK 1/2 inhibitor U0126 prevents Dex-induced
apoptosis. MLO-Y4 osteocytes were incubated with U0126 for 30 minutes at 10-
30 pM in the presence and absence of Dex at 10"6 M for 5 hours. A. Dose-response
studies of U0126 at 10-30 pM. and B. U0126 prevents MLO-Y4 osteocyte
apoptosis induced by Dex, at 10 and 20 pM at 5 hours. Cells were stained with AO
and examined by fluorescence microscopy. Graphs represent the mean percentages
of apoptotic osteocytes ± SD (*** = p < 0.0001, ** = p < 0.001, * = p < 0.05)
Control cultures represent vehicle (DMSO) cultures and are similar to untreated
cultures in percentages of apoptotic osteocytes.
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Figure 51. The p38 inhibitor SB203580 induces apoptosis in the
presence or absence of Dex. MLO-Y4 osteocytes were incubated with
SB203580 at 5-15 pM for 30 minutes in the presence and absence ofDex at 10"6 M,
for 5 hours. A. Dose-response studies of SB203580 at 5-15 pM. B. SB203580 at 5-
15 pM does not prevent Dex-induced osteocyte apoptosis at 5 hours. Cells were
stained with AO and examined by fluorescence microscopy. Graphs represent mean
percentages of apoptotic osteocytes ± S.D. (*** = p < 0.0001, ** = p < 0.001, * = p <
0.05). Control cultures represent vehicle (DMSO) cultures and are similar to
untreated cultures in percentages of apoptotic osteocytes.
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Figure 52. H202 induces apoptosis in MLO-Y4 osteocytes in a
concentration-dependent manner. MLO-Y4 osteocytes were incubated with
H2C>2 at 0.08-0.8 mM for 1-24 hours. Cells were stained with AO and examined by
fluorescence microscopy. A. Mean percentages of apoptotic osteocytes and B. Mean
number of osteocytes in culture. Graphs represent mean percentages of apoptotic
osteocytes ± SD (*** = p < 0.0001, ** = p < 0.001, * = p < 0.05).
165
% Apoptotic osteocytes in response to H2O2, PAM and U0126 treatment
a Presence of H202














Figure 53. BPs and U0126 do not protect osteocytes from oxidant-
induced death. MLO-Y4 osteocytes were incubated with PAM at 10"8 M and
U0126 at 20 pM prior to H2O2 treatment, for 5 hours. Cells were stained with AO
and examined by fluorescence microscopy. Graphs represent percentage of apoptotic
osteocytes, per number of cells ± S.D. (*** = p < 0.0001)
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5.4.7 Primary osteocytes are protected from Dex-induced death by BPs
and the MEK1/2 inhibitor.
Primary cultures of chicken osteocytes were also used to observe responses to
inducers of osteocyte death. AO staining revealed that in a similar way to that seen in
the MLO-Y4 cell line, both BPs and the MEK inhibitor U0126 were capable of
blocking Dex-induced death in these primary cells (Figure 54).
5.4.8 Dexamethasone activates the MEK/ERK kinase signaling pathway.
Incubation with Dex, increased the amount of activated ERK 1/2 protein in
osteocytes, compared to vehicle, in a time dependent manner, as evidenced by
western blot analysis, using an anti-phospho ERK 1/2 antibody (Figure 55A).
Activation of ERK 1/2 protein by Dex was acute, since it was detected as soon as 1
minute following treatment and was decreased to basal control levels, after 1 hour of
treatment. BPs transiently increased ERK 1/2 phosphorylation within 1 minute of
treatment, returning to baseline by 5 minutes, as shown previously by Plotkin et al.
(Plotkin et al. 1999). In this treatment group baseline levels were maintained for all
subsequent time points investigated, up to 5 hours (Figure 55B). Addition of Dex to
cells pre-treated for 1 hour with BPs resulted in a reduced activation of ERK 1/2
relative to samples treated with Dex alone (Figure 56). The MEK 1/2 protein
inhibitor, U0126 blocked Dex and/or BP-induced ERK 1/2 activation in all cases.
In order to characterize further the role of ERK 1/2 pathway in Dex-induced
apoptosis, the presence of proteins lying both upstream (MEK 1/2 and c-Raf) and
downstream (p90rsk) of ERK 1/2 protein, was investigated. Western blot analysis
showed that MEK (Figure 57A) and p90rsk (Figure 57B) activation by Dex
coincided with ERK 1/2 activation, while pre-treatment with ALN slightly reduced
phosphorylated levels of both proteins. In addition, U0126 prevented activation of
p90rsk by Dex, but did not affect phosphorylated MEK 1/2 protein, in accordance
with previous reports (Favata et al., 1998). Levels of c-Raf remained constant and
similar to vehicle levels, during all different treatments and time points investigated
(Figure 57C).
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Figure 54. BPs and MEK 1/2 inhibitor reduce apoptotic stimuli induced
by Dex, in primary chicken osteocytes. Primary osteocytes were incubated
with PAM at 10"8M for 1 hour and U0126 at 20 pM for 30 minutes prior to addition
of Dex at 10"6 M for 5 hours. Cells were stained with AO and examined by
fluorescence microscopy. Graph represents percentage of apoptotic osteocytes per











0 0.01 0.5 1 3 5 Time (h)
Band densitometry
0.01 0.5 1 3
Time (h)
Time (h)
Figure 55. Dex activates the ERK 1/2 protein kinase. A. Dex activates the
ERK 1/2 protein kinase, in a time dependent manner. B. ALN activates the ERK 1/2
protein kinase, only during the first five minutes of addition to the cultures. MLO-Y4
cell lysates were subjected to Western blot analysis using an anti-phospho MAPK
p44/42 antibody. The blots were stripped and reprobed with a total anti-MAPK
p44/p42 antibody, to verify equal loading of samples. Changes in band densitometry
were quantified using NHI image analysis system from 3 independent experiments
and expressed as percentage change relative to control samples, representing either
vehicle control or zero time control ± S.D. (*** = p < 0.0001, * = p < 0.05 compared
to control)
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Figure 56. ALN reduces the Dex-induced ERK 1/2 activation. ALN was
shown to reduce Dex-induced activation of ERK 1/2, at 5 minutes, whereas U0126
blocked Dex-induced ERK 1/2 activation. Lysates were subjected to Western Blot
analysis, using an anti-phospho MAPK p44/p42 antibody. The blots were stripped
and reprobed with a total anti-MAPK p44/p42 antibody, to verify equal loading of
samples. Changes in band densitometiy were quantified using NHI image analysis
system from 3 independent experiments and expressed as percentage change relative
to control samples, representing either vehicle control or zero time control ± S.D. **
= p < 0.001, * = p < 0.05 compared to control, + = p < 0.05 compared to Dex
treatment
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Figure 57. Dexamethasone activates the ERK 1/2 pathway. Lysates
prepared from MLO-Y4 cells treated with Dex, ALN and U0126, were subjected to
Western Blot analysis, using A. anti-phospho MEK 1/2 antibody, B. anti-phospho
p90rsk and C. anti-phospho c-Raf antibody. Changes in band densitometry were
quantified using NHI image analysis system from 3 independent experiments and
expressed as percentage change relative to vehicle sample ± S.D. ** = p < 0.001, * =
p < 0.05 compared to control, + = p < 0.05 compared to Dex treatment
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5.4.9 Suppression of Dex-induced Fas activation by MEK 1/2 inhibitor
and BPs.
The role of BPs and ERK1/2 protein kinase in Dex-induced activation of Fas was
investigated by immunocytochemistry studies (Figure 58A). Previous studies have
shown interaction between ERK and Fas protein pathways in the induction of
apoptosis (Goillot et al. 1997). Pre-treatment of osteocytes with EI0126 at 20 pM,
prevented activation of Fas by Dex (p = 0.0001, compared to Dex-treated samples).
In a similar manner to U0126, pre-treatment ofMLO-Y4 cells with both N- and non
N-BPs at 10~8 M, reduced activation of Fas by Dex (p = 0.0001).
5.4.10 PMA-induced ERK1/2 activation is not associated with osteocyte
apoptosis
PMA when administered alone at concentrations of 2 ng/ml to 200 pg/ml for 1 to 5
hours (Figure 58B) did not increase Fas, while prior to Dex treatment PMA did not
enhance Dex-induced Fas upregulation, in contrast to Dex treated cultures (Figure
58B). In addition, PMA did not induce osteocyte apoptosis (Figure 59B), despite
demonstrating a clear increase in phosphorylated ERK in MLO-Y4 osteocytes as
determined by western blotting (Figure 59A).
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Figure 58. BPs and U0126 suppress Dex-induced Fas activation. Cells
were probed with an anti-Fas antibody and examined by fluorescence microscopy. A.
N- and non N-BPs reduce Dex-induced Fas expression as shown by
immunocytochemistry and western blot analysis. Changes in band densitometry were
quantified using NHI image analysis system and expressed as percentage change
relative to vehicle sample ± S.D. from 3 independent blots. B. U0126 suppressed
Dex-induced Fas expression while PMA did not increase Fas expression, compared
to control, when administered at a range of concentrations and time points. Graphs
represent mean percentages of osteocytes, expressing Fas per number of cells ± S.D.
(*** = p < 0.0001, ** = p < 0.001, * = p < 0.05 compared to control, + = p < 0.05
compared to Dex treatment)
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Figure 59. PMA-induced ERK1/2 activation is not associated with
osteocyte apoptosis. Cells treated with PMA followed by Dex were A. subjected
to western blot analysis to reveal pERK 1/2 and p90rsk activation and B. treated to
reveal DNA breaks using the Nick Translation assay. PMA did not affect osteocyte
apoptosis, compared to control. Graphs represent percentage of apoptotic osteocytes,
per number of cells ± S.D. (*** = p < 0.0001, compared to control, + = p < 0.05
compared to Dex treatment)
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5.5 Discussion
Death of the osteocytes, and therefore interruption of the sophisticated network that
they form within the bone, could account for the increased bone fragility and
osteonecrosis associated with patients affected by glucocorticoid-induced
osteoporosis (Glade and Krook 1982, Weinstein et al. 1998).
Data in this chapter investigate molecular pathways implicated in Dex-induced death
of osteocytes, the mechanosensors and transducers in bone, and on molecules that
might provide therapeutic approaches to combat this death. Induction of osteocyte
apoptosis by Dex was characterised by several classical apoptotic features, including
chromatin and cytoplasmic condensation, DNA fragmentation, exposure of
phosphatidylserine and formation of apoptotic bodies, and was concentration- and
time-dependent. In addition, apoptosis was caspase-dependent since inhibition of
caspases -3 and -7 (Lee et al. 2000), which are responsible for chromatin
condensation, DNA fragmentation and membrane blebbing, suppressed Dex-induced
death.
Dex-induced apoptosis has been associated with the Fas/FasL apoptotic pathway in
several different cell types, in relation to its action as an immunosuppressive agent
(Schmidt et al. 2001). Fas receptor mRNA was detected in MLO-Y4 osteocytes both
in response to Dex treatment and in untreated cultures. However, Dex treatment
upregulated localisation of Fas protein on the osteocyte plasma membranes, in a
time-dependent manner compared to untreated controls, indicating a possible
association between Fas recruitment and the incidence of osteocyte apoptosis in the
presence of Dex. Indeed, inhibition of caspase 8, the upstream caspase participating
in the Fas pathway, using a peptide inhibitor (Martin et al. 1998), blocked Dex-
induced apoptosis, further supporting a possible association between Dex and the Fas
pathway in osteocyte apoptosis. However, expression of Fas Ligand in both Dex-
treated and untreated cultures was not detected, suggesting that if indeed there is
activation of the Fas-related pathway in the presence of Dex it is FasL independent.
Similar phenomenon has been observed in tumour cell studies, showing that
anticancer agents directly promote Fas receptor trimerisation and activation of the
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FADD/caspase 8 pathway, independently of FasL (Misceau et al. 1999). Other
studies by Ahuja et al, have also reported expression of Fas receptor on MLO-Y4
osteocytes, while the authors also failed to detect FasL expression (Ahuja et al 2003).
BPs suppressed Dex-induced apoptosis in MLO-Y4 osteocytes after 5 hours
treatment with Dex, in accordance to previous reports (Plotkin et al. 1999). Although
the half-life of BPs in vitro experimental conditions is not known, the
pharmacokinetics of these molecules in vivo, might allow them to suppress GC-
induced apoptosis of osteocytes for longer periods of time, since they can be retained
active in the skeleton until their release, following resorption of the multiple sites in
which they were deposited (Fleisch 2000).
Dex-induced apoptosis was prevented by both non N-BPs (CLO), which are
metabolized into cytotoxic analogues of ATP and N-BPs (PAM and ALN), which
inhibit prenylation through inhibition of FPP synthase (Rogers et al. 1999). Both
groups of BPs were equally effective inhibitors of death, indicating that prevention of
Dex-induced osteocyte apoptosis by BPs does not depend on the presence of a N-
group (Figure 47) and hence on inhibition of FPP synthase.
Activation of the ERK pathway is generally associated with the induction of
proliferative and survival signals. In osteoblasts, activation of the ERK cascade has
been shown to regulate growth, differentiation, function and integrin expression,
whereas in T cells it protects from GC-induced apoptosis and exerts negative effects
on the pro-apoptotic signals induced by death receptors such as Fas and TNF (Lai et
al. 2001, Jamieson and Yamamoto 2000, Tran et al. 2001). However, in contrast to
the known pro-survival effects, the ERK pathway has also been associated with the
induction of pro-apoptotic signals. Activation ofERK appears to be important for the
induction of cisplatin-induced apoptosis in HeLa cells and activation-induced cell
death of T cells, whereas other evidence suggest that increased levels of ERK
contribute to brain injury during focal cerebral ischemia. (Wang et al. 2000, van den
Brink et al. 1999, Alessandrini et al. 1999).
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Recently, Nishida et al. have reported that YM529, a new bisphosphonate, decreases
phosphorylation of ERK1/2 during apoptosis of HL60 cells (Nishida et al. 2003).
Nevertheless, Plotkin et al. observed an acute activation of ERK by BPs, which was
sustained for 5 minutes during the pre-treatment period (Plotkin et al. 1999), and
suggested that activated ERK is involved in the protective effects of BPs on Dex-
induced apoptosis. Data in this study have shown activation of ERK by BPs, which
peaked at 5 minutes of addition of BPs to osteocyte cultures. However, this study did
not measure possible ERK production in response to Dex, as has been noted in other
cell types (Jamieson and Yamamoto 2000). Following on from both studies, this
work has investigated the course of ERK activation in order to characterize the effect
of Dex on the ERK pathway, during osteocyte apoptosis. In contrast to activation of
ERK by BPs during the pre-treatment period, Dex transiently increased the amount
of activated ERK1/2 in osteocytes, which remained elevated for the first hour of
incubation, and was suggestive of a specific non-genomic effect, involving
membrane-bound GC receptors, since activation of cytosolic receptors requires at
least 30 minutes (Patschan et al. 2001). Inhibition of ERK by U0126 suppressed
Dex-induced osteocyte apoptosis, both in the presence and absence of BPs,
indicating that induction of death signals by Dex-activated ERK compared to non-
damaging BP-activated ERK is due to either differences in the timing and duration of
activation or to the generation of secondary factors by Dex, which render ERK pro-
rather than anti-apoptotic. Furthermore, in the presence of BPs, ERK
phosphorylation in response to Dex was significantly reduced.
Variance between the findings of Plotkin et al. in which ERK appears as an anti-
apoptotic signal and the current conclusion in this chapter regarding its positive role
in apoptotic death, may be due to differences in experimental conditions between the
two studies. Plotkin et al. studied apoptosis in serum-replete conditions and ERK
under serum free conditions, while in this study both apoptosis (the phenomenon)
and ERK phosphorylation in these cells were investigated under identical serum-
replete conditions. On the other hand, PMA treatment failed to increase the
proportion of apoptotic osteocytes when added alone, and did not prevent or enhance
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the pro-apoptotic stimuli in the presence of Dex, indicating that activation of ERK
through other pathways is not sufficient to induce osteocyte apoptosis.
Dex treatment also increased MEK and p90rsk activation at identical times to the
activation of ERK, which was however reduced in cultures pre-treated with BPs,
whereas levels of c-Raf were not altered, compared to control levels, suggesting that
Dex is acting downstream of c-Raf or through another isoform of Raf in the
signalling pathway involving Raf, MEK and ERK. In contrast to ERK, p38 inhibition
did not reduce osteocyte apoptosis, indicating specificity in the pro-apoptotic effects
ofMAPK family members. In neuroblastoma cells transfection with activated MEK1
upregulated Fas activity (Goillot et al. 1997), while in T cells, during activation-
induced cell death, transfection of a dominant negative MEK1 inhibited FasL
expression (van den Brink et al. 1999). In this study, inhibition of ERK in
experiments using the Fas/CD95 antibody reduced the Dex-induced Fas activation,
whereas upregulation of ERK by PMA did not affect Fas levels, indicating that
production of Fas is closely associated to the pro-apoptotic signals induced by Dex.
In addition, prevention of Dex-induced apoptosis by non N-BPs and N-BPs also
decreased Fas expression, supporting the importance of Fas in the death response and
pointing to the existence of an additional factor associated with Dex-treatment that
might enable the co-operation between ERK and Fas pathways during the induction
of osteocyte apoptosis.
In conclusion, this study has shown that Dex-induced apoptosis in osteocytes is
associated with activation of the ERK and Fas pathways and could be prevented by
BP molecules in a manner that is independent of their chemical structure and the
ability to inhibit FPP synthase. These findings might have important applications for
the management of patients affected by glucocorticoid-induced osteoporosis, since
death of osteocytes, which are considered to be the mechanosensors and transducers
in bone, might lead to impairment of the adaptive response to mechanical loading
and to increased bone fragility.
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CHAPTER 6




This work is the subject of a published manuscript (Appendix). Bisphosphonates
like PAM, ALN and CLO prevent osteocyte apoptosis following treatment with
Dexamethasone, as shown in chapter 5. This study has used additional BP molecules
that have minor structural and conformational changes compared to CLO, PAM and
ALN, in order to determine whether the anti-apoptotic effects of BPs on osteocytes
correlate with their anti-resorptive potency.
NE11808 and NE11809 are structurally similar N-containing BPs, which differ in the
presence of a methyl group in NE11809. However NE11809 is associated with
decreased anti-resorptive activity and reduced ability to inhibit FPP synthase,
compared to NE11808, indicating an association between the activity of BPs to
inhibit osteoclast resorption and the three-dimensional structure of the molecules.
Osteocyte cultures were incubated with Dexamethasone in the absence or presence of
NE11808 and NE11809. Estimation of apoptotic osteocytes showed that both BPs
were equally effective inhibitors of death. In addition both BPs reduced the Dex-
induced ERK 1/2 activation, in a manner similar to the BPs described in chapter 5.
Results in this chapter have indicated that the protective effects of BP on osteocytes
against Dex-induced apoptosis are independent of their structure and activity against
osteoclasts. These findings suggest that alterations in the three-dimensional structure
might provide BP molecules that could be independently applied to affect osteoclast




BPs are non-hydrolysable pyrophosphate analogs, in which the oxygen linking the
phosphates (P-O-P) has been replaced by carbon (P-C-P), which has two side chains,
R1 and R2 (Rodan 1998). BPs, such as etidronate were initially used as early as 1897
as anticorrosive and antiscaling agents in industrial procedures (Menschutkin 1865).
BPs were subsequently found to have a high affinity for hydroxyapatite crystals and
to affect calcium phosphate formation and were designed to prevent calcification of
bone mineral, which depends both on the presence of a hydroxy1 group in the R1
chain and on the dose of the bisphosphonate (Papapoulos 1997). Finally, BPs were
shown to be very effective anti-resorptive agents in vivo and to exert direct effects on
osteoclasts and were used in the treatment of glucocorticoid-induced osteoporosis,
post-menopausal osteoporosis, Paget's disease, hypercalcemia, osteogenesis
imperfecta, and tumor-associated bone diseases (Adami and Zamberlan 1996).
The anti-resorptive property of BPs depends mostly on the structure and
conformation of the R2 side chain, whereas the R1 side chain participates mainly in
the binding to mineralised matrix (Rogers et al. 1999) (Figure 60). First generation of
BPs have a short R2 side chain, and are characterised by an alkyl or halide side
chains, such as etidronate and clodronate respectively. Second generation BPs
contain a primary amino group in the R2 chain and they are 10- to 1,000-fold more
potent than first generation. Third generation BPs were developed in the 1980s and
contain a tertiary amino group or a nitrogen atom within a heterocyclic ring and are
10,000-fold more potent than first generation BPs (Sietsema et al. 1989, Rogers et al.
1999). The presence of two phosphonate groups is also important, although the
structure and conformation of the R2 side chain is the major determinant of the
antiresorptive activity (Dunford et al. 2001).
In the previous chapter, Bisphosphonates were shown to prevent osteocyte apoptosis
following treatment with Dexamethasone. The BPs that were administered included
the first generation non N- containing CLO and the second generation N-BPs PAM
and ALN (Figure 61), indicating that the absence or presence of the nitrogen group
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in the R2 side chain did not affect the anti-apoptotic activity of BPs against
Dexamethasone-induced osteocyte death.
NE11808 and NE11809 are both N-containing third generation BPs characterised by
the presence of a heterocyclic ring. NE11808 and NE11809 have a similar chemical
composition (Figure 62); however they have minor conformational changes and also
differ in the presence of a methyl group in NE11809 in the R2 side chain, which
accounts for differences in their potency against bone resoprtion (Dunford et al.
2001). This study has investigated the effect of NE11808 and NE11809 on
osteocytes against Dexamethasone-induced apoptosis, in order to identify a











Figure 60. Basic chemical structure of BP molecules. BPs consist of two
phosphonate groups attached to a central carbon atom and two side chains, R1 and
R2, responsible for attachment to bone mineral and anti-resorptive activity
respectively. Image adapted from van Beek et al. Bone 1998, page 438.
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Figure 61. Chemical structures of BPs belonging to first (CLO) and
second (PAM and ALN) generation of BPs. All molecules are characterised by
two phosphonate groups attached to a central carbon atom which has a R1 side chain
(-H or -OH) and different R2, which account for differences in anti-resorptive




Figure 62. Chemical structures of third generation bisphosphonates
NE11808 and NE11809. NE11808 and NE11809 are N-BPs that contain a
heterocyclic-group in the R2 side chain; however they differ in the presence of a
methyl group in NE11809, which dramatically reduces the anti-resorptive potency
and ability to inhibit FPP synthase of NE11809, compared to NE11808. Image
adapted from Dunford et al. J.Pharm.Exper.Therap. 2001, page 238.
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6.3 Materials and Methods
All chemicals were purchased from Sigma, UK; all tissue culture reagents were
purchased from Invitrogen, UK and tissue culture well plates and petri dishes were
purchased from Corning, UK unless otherwise stated. Tissue culture procedures were
performed in a laminar flow hood (class 2) receiving HEPA-filtered air, using sterile
equipment.
6.3.1 MLO-Y4 cell culture
The MLO-Y4 osteocyte cell line was cultured as described in §3.3.1. Briefly, cells
were maintained in a-Modified Essential Medium (aMEM) supplemented with 5%
FBS, 5% newborn calf serum (NCS), 1% Penicillin/Streptomycin and 1% L-
glutamine. Subculturing was performed twice weekly upon reaching 90% of
confluency, maintaining the cells in the log phase of proliferation.
6.3.2 Cell treatment
Cells were plated in growth medium at a density of lxlO4 cells/ml in 24 multi-well
plates or lxl05 cells/ml in 60 mm petri dishes for 24 hours, prior to experimentation,
as described in §5.3.2. Experiments were carried out a minimum of 3 times, and each
treatment group was represented by 3 wells in each independent experiment. Control
treatments represent vehicle treatments for the different agents, which were subjected
to identical dilutions to the agents.
6.3.3 Induction of Cell Death
8 6Cells were incubated in growth medium supplemented with 10" to 10" M Dex in
DMSO (Calbiochem, UK)
6.3.4 Prevention of Cell Death
6.3.4.1 Bisphosphonates
Cells were treated for 1 hour with the heterocyclic-containing N-BPs, NEII808 and
NEII809 (Procter & Gamble) at concentrations of 10"8 to 10"6 M in PBS, followed by
Dex treatment.
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6.3.4.2 Inhibitors of intracellular signalling proteins.
MAPK inhibitors
Cells were incubated for 30 minutes with U0126 (Promega, UK), at concentrations
of 20 pM in DMSO (Favata et al. 1998) in order to inhibit MEK 1/2 protein kinase.
6.3.5 Determination of Apoptotic State
6.3.5.1 DAPI staining for healthy and apoptotic cell morphology
Cells were fixed in 4% paraformaldehyde and incubated with DAPI at 2.5 ng/ml in
water for 10 minutes, as described in §3.3.10.3.
6.3.5.2 Acridine orange (AO) staining for healthy and apoptotic cell
morphology.
Acridine Orange staining was performed as described in §5.3.5.2. Briefly, cells were
incubated in Walpole's acetate buffer, stained with AO and examined on an inverted
fluorescence microscope.
6.3.5.3 DNA fragmentation using in situ Nick Translation
The percentage of target cells demonstrating DNA breaks was investigated using in
situ nick translation staining (Noble et al. 1997), which allows the determination of
DNA breaks following the incorporation of DIG-labelled dUTP as described in
§3.3.10.2. The ratio of total cells (PI positive) to apoptotic (FITC positive) was
determined using fluorescence microscopy and digital image capture.
6.3.6 Preparation of cell lysates
Cell lysates were prepared as described in §5.3.8 (Figure 41). Briefly, cells were
lysed on ice and the lysates were either used immediately or stored at -20 °C.
6.3.7 Determination of protein concentration
Protein concentrations in samples were estimated as described in §5.3.9, against
standards of BSA within a range of 0-20 pg/ml using an automated plate reader,
which measured the absorbance at 570 nm.
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6.3.8 Protein gel electrophoresis
Protein extracts were separated by electrophoresis through a polyacrylamide gel
containing sodium dodecyl sulphate (SDS), on the basis of molecular weight, as
described in § 5.3.10 (Figure 41).
6.3.8.1 Electrophoresis reagents.
Tris resolving buffer: 1.5 M Tris base, pH 8.9 and 13.9 mM SDS.
Tris stacking buffer: 0.5 M Tris-HCl, pH 6.8 and 13.9 mM SDS.
Acrylamide/bisacrylamide (Protogel) solution: 30% (w/v) acrylamide and 0.8%
(w/v) bisacrylamide.
Ammonium persulphate (APS) solution: 10% (w/v) APS in dFEO.
Blue loading buffer (2x): 10% (v/v) glycerol, 10% (v/v) P-mercaptoethanol, 0.1M
SDS, 6% (w/v) urea, 0.125 M Tris and 0.02% bromophenol blue.
Tris running buffer: 190 mM glycine, 25 mM Tris base and 17 mM SDS.
Resolving and stacking buffers were prepared and allowed to polymerise on gel
plates as described in § 5.3.10.2-3.
6.3.8.2 Electrophoresis.
Electrophoresis was carried out as described in §5.3.10.4 at a constant current of 20
mAmps (Power Pac 3000, Bio-Rad, UK).
6.3.9 Western Blot analysis.
6.3.9.1 Transfer of proteins to a polyvinylidene difluoride (PVDF) membrane.
Proteins were transferred onto a PVDF membrane (Figure 41) as described in
§5.3.11.1 using a Mini trans-Blot Cell Assembly, (Bio-Rad, UK) at 30 V for 1 hour.
6.3.9.2 Detection of proteins on PVDF.
Proteins were detected on PVDF as described in §5.3.11.2. Briefly, proteins were
probed with the appropriate primary antibody (rabbit polyclonal antibodies against
phosphorylated p44/42 MAPK, p90rsk and c-Raf kinases) followed by a species-
specific secondary antibody, and were detected using the Enhanced
188
Chemiluminscence (ECL) system and autoradiograph film, according to the
manufacturer's instructions. (Figure 41).
6.3.10 Statistical analysis
Statistical analysis was performed using quantitative data analysis with SPSS release
11.5 for Windows, as described in §3.3.12, using Analysis of Variance (ANOVA),
Tukey test and Dunnett test for comparison between the treatment groups. Results
are expressed as means ± S.D. p < 0.05 was considered to be statistically significant.
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6.4 Results
6.4.1 NE11808 and NE11809 prevent Dex-induced apoptosis in ML0-Y4
osteocytes.
Dose response studies were used to identify concentrations of NE11808 and
NE11809 that did not increase apoptosis above control levels. (Figure 63). Mean
percentages of apoptotic osteocytes were statistically different compared to control
following treatment with NE11808 at 10~6 M, after 5 hours of treatment (p = 0.03).
The lowest concentration of 10"x M, which did not increase osteocyte apoptosis
above control levels for both NE11808 and NE11809 (p > 0.05), was chosen to treat
osteocytes prior to addition of Dex in cultures. The optimum concentration and
incubation period for induction of apoptosis by Dex was identified through
concentration- and time-dependent studies, as described in chapter 5 (Figure 42 and
43).
Estimation of apoptotic osteocytes based on morphological criteria showed that both
NE11808 and NE11809 at 10"8 M significantly decreased the pro-apoptotic effect of
the corticosteroid at 10~6 M, following 5 hours incubation in osteocyte cultures
(Figure 64 and 65).
6.4.2 NE11808 and NE11809 reduce the Dex-induced activation of
ERK1/2 protein kinase.
As described in chapter 5, Dex increased the amount of phosphorylated ERK 1/2 in
osteocytes, compared to vehicle, in a time dependent manner, as evidenced by
western blot analysis, using an anti-phospho ERK1/2 antibody (Figure 55).
Activation of ERK 1/2 protein by Dex was detected as soon as 1 minute following
treatment and was decreased to basal control levels after 1 hour of treatment.
Addition of Dex to cells pre-treated for 1 hour with NE11808 and NE11809 resulted
in a reduced activation of ERK 1/2 relative to samples treated with Dex alone
(Figure 66). The MEK 1/2 protein inhibitor, U0126, blocked Dex-induced ERK 1/2
activation in all cases.
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Figure 63. Dose-response studies of NE11808 and NE11809. Osteocytes
were incubated with NE11808 and NE11809 at 10~8 M tolO"6 M in order identify
concentrations that did not induce osteocyte apoptosis over a period of 6 hours.
Graph represents mean percentage of apoptotic osteocytes ± SD, estimated by AO
nuclear staining and fluorescence microscopy. Q= control cultures, □ =untreated
cultures. Control cultures represent vehicle (PBS) cultures and are similar to
untreated cultures in percentages of apoptotic osteocytes.
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Figure 64. NE11808 and NE11809 prevent MLO-Y4 osteocyte apoptosis
induced by Dexamethasone in a concentration-dependent manner.
Osteocytes were incubated with BPs at 10"8 to 10"6 M for 1 hour prior to Dex
treatment, for 5 hours. A. Percentages of apoptotic osteocytes were statistically
different compared to control following treatment with all BPs at 10"6 M, in the
presence of Dex. B. The lowest concentration of 10"8 M for both BPs reduced
percentages of apoptotic osteocytes to levels similar to control. Graphs represent
mean percentages of apoptotic osteocytes ± SE, estimated by AO staining and
fluorescence microscopy.Q =control cultures,■ =Dexamethasone treated cultures in
absence or presence of NE11808 and NE11809. Control cultures represent vehicle
(ethanol) cultures for Dex and are similar to untreated cultures in percentages of
apoptotic osteocytes (1.42 ± 0.11 % S.D., p > 0.05).
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Figure 65. NE11808 and NE11809 prevent Dex-induced apoptosis in
ML0-Y4 osteocyte cultures. Representative images of osteocyte cultures treated
with NE11808 and NE11809 for 1 hour followed by Dex treatment for 5 hours and
stained with Acridine Orange. NE11808 (top right panel) and NE11809 (lower right
panel) reduce Dex-induced apoptosis in osteocytes (lower left panel). Bar =10 pm.
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Figure 66. NE11808 and NE11809 reduce Dex-induced ERK 1/2
activation. A. Western blot of phosphorylated ERK 1/2 activity in response to Dex,
U0126, NE11808 and NE11809. B. Mean percentages of changes in ERK 1/2
phosphorylation in response to the different treatments, compared to control.
Changes in band densitometry were quantified using NHI image analysis system
from 3 independent experiments and expressed as percentage change relative to
control samples ± S.D.
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6.4.3 NE11808 and NE11809 reduce the Dex-induced activation of
p90rsk protein kinase.
In order to characterize further the role of ERK 1/2 pathway in Dex-induced
apoptosis, the presence of proteins lying both upstream (c-Raf) and downstream
(p90rsk) of ERK 1/2 protein, was investigated. Western blot analysis showed that
p90rsk (Figure 67) activation by Dex coincided with ERK 1/2 activation, while pre-
treatment with NE11808 and NE11809 slightly reduced phosphorylated levels of
p90rsk. In addition, U0126 prevented activation of p90rsk by Dex. Levels of c-Raf
remained constant and similar to vehicle levels, during all different treatments
investigated (Figure 68).
6.4.4 Suppression of Dex-induced Fas activation by NE11808 and
NE11809.
The role of NE11808 and NE11809 in Dex-induced activation of Fas was
investigated by immunocytochemistry studies using an anti-Fas monoclonal antibody
(Figure 69). Pre-treatment of MLO-Y4 cells with both NE11808 and NE11809 at
10~8 M, reduced activation of Fas by Dex (p = 0.0001).
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Figure 67. NE11808 and NE11809 reduce Dex-induced p90rsk activation.
A. Western blot of phosphorylated ERK 1/2 activity in response to Dex, U0126,
NE11808 and NE11809. B. Mean percentages of changes in p90rsk phosphorylation
in response to the different treatments, compared to control. Changes in band
densitometry were quantified using NHI image analysis system from 3 independent
experiments and expressed as percentage change relative to control samples ± S.D.
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Figure 68. c-Raf activity is not altered in the presence of NE11808,
NE11809, Dex and U0126. A. Western blot of phosphorylated ERK 1/2 activity
in response to Dex, U0126, NE11808 and NE11809. B. Mean percentages of
changes in c-raf phosphorylation in response to the different treatments, compared to
control. Changes in band densitometry were quantified using NHI image analysis
system from 3 independent experiments and expressed as percentage change relative
to control samples ± S.D.




Figure 69. NE11808 and NE11809 suppress Dex-induced Fas
expression. NE11808 and NE11809 reduce Dex-induced Fas expression as shown
by immunocytochemistry. Cells were probed with an anti-Fas antibody and
examined by fluorescence microscopy. Graph represents mean percentages of
osteocytes, expressing Fas per number of cells ± S.D (*** = p < 0.0001, + = p < 0.05
compared to Dex treatment)
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6.5 Discussion
This study has shown that NE11808 and NE11809 prevented the pro-apoptotic
effects of Dexamethasone in a manner that implicated the ERK 1/2 pathway in
osteocyte cultures. Pre-treatment of osteocyte cultures with NE11808 and NE11809
reduced the proportion of osteocytes that displayed chromatin and cytoplasmic
condensation and membrane blebbing induced by Dex treatment.
Investigation of the ERK 1/2 pathway revealed that NE11808 and NE11809 reduced
the amount of phosphorylated ERK 1/2 and p90rsk protein kinases in osteocytes
treated with Dex, pointing to a pro-apoptotic role for the ERK pathway in osteocytes
in the presence of Dexamethasone. These findings are in agreement with results from
chapter 5, which demonstrated that PAM, ALN and CLO were equally effective
inhibitors of Dex-induced apoptosis in osteocytes and reduced activation of ERK and
p90rsk proteins, as described in detail in chapter 5.
Bisphosphonates are stable analogues of naturally occurring pyrophosphate
compounds, characterised by two C-P bonds located on the same carbon atom which
also has two side chains, R1 and R2 (Rodan 1998) (Figure 60 and Table 1). All the
BP molecules adhere to hydroxyapatite crystals and display anti-resorptive actions.
Binding to bone mineral is dependent on the R1 side chain, which acts as a bone
hook, while the presence of a -OH group increases the affinity possibly due to
tridentate configuration (van Beek et al. 1998). In addition it has been shown that R1
with the phosphonate groups might contribute to the anti-resorptive activity as well,
which is however determined mainly by the R2 side chain (Ibbotson et al. 1989)
(Figure 61).
At the cellular level, the action of BPs is primarily dependent on the presence or
absence of a nitrogen group in the R2 side chain. (Fleisch 2000). BPs that do not
contain a nitrogen group, like CLO and ETI become metabolised into non-
hydrolysable analogues of ATP, initially demonstrated in the cellular slime mould
Dictyostelium discoideum (Rogers et al. 1992), which accumulate in the cytoplasm

















Table 1. R1 and R2 side chains of commonly used Bisphosphonates.
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In particular it has been shown that CLO becomes metabolised into AppCC12p,
which inhibits the mitochondrial electrogenic ATP/ADP translocase, inducing
membrane depolymerisation, cytochrome c release, caspase activation (Benford et al.
2001) and finally apoptosis (Lehenkari et al. 2002).
N-containing BPs appear to inhibit farnesyl diphosphate (FPP) synthase, an enzyme
in the mevalonate pathway, leading to a decrease in the synthesis of geranylgeranyl
diphosphate (GPP) (Benford et al. 1999). This enzyme is responsible for the
production of cholesterol and isoprenoid lipids, which are required for the post-
translational modification and hence function of small GTPases, such as Ras, Rho
and Rac, which regulate several functions including membrane ruffling, morphology
and survival in osteoclasts and macrophages (Coxon et al. 1998, Rogers et al.l999).
Similar action by N-BPs which results in apoptotic cell death through inhibition of
the mevalonate pathway has been shown both in vitro (Shipman et al.l998) and in
vivo (Gordon et al. 2002) in myeloma cells, demonstrating an important anti-tumour
activity by BPs (Croucher et al. 2003), while induction of apoptosis in Caco-2 human
epithelial cells, might account for the gastrointestinal toxicity observed by N-BPs
(Suri et al. 2001). Interestingly, however, it has been demonstrated that unlike the
non N-BPs, induction of apoptosis by N-BPs is not necessary to prevent osteoclastic
resorption, since at lower doses they have been shown to potently inhibit bone
resorption without inducing osteoclast apoptosis (Halasy-Nagy et al. 2001).
Recently N-BPs have been developed that are more potent inhibitors of bone
resorption and in addition to inhibiting FPP synthase, they also prevent isopentenyl
diphosphate isomerase (Thompson et al. 2002), indicating that small modifications in
the structure and conformation of the R2 side chain can dramatically affect the anti-
resorptive activity of N-BPs and suggest that the nitrogen group and the R2 side
chain have an important role in the interaction between BPs and the pharmacological
target (Ebetino et al. 1996). These observations have allowed the conclusion that
there is a clear correlation between the activity of BPs to inhibit osteoclast resorption
and the three-dimensional structure of the molecules.
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This study has used the third generation N-BPs NE11808 and NE11809 for which
clear structure/activity relationships have been observed in the past (Rogers et al.
1995). NE11808 and NE11809 contain a heterocyclic-group in the R2 side chain,
while they lack a -OH group in the R1 side chain (Figure 62) which confers
increased binding affinity to bone minerals, possibly due to tridentate configuration
(van Beek et al. 1998). This might indicate that these two BPs do not adhere strongly
to hydroxyapatite crystals; however no relationship has been reported between anti-
resorptive activity and decreased binding to bone mineral. NE11808 and NE11809
have similar chemical structures (Figure 62); however they differ in the presence of
a methyl group in NE11809, which dramatically reduces the anti-resorptive potency
of NE11809, compared to NE11808, in rodents in vivo (Rogers et al. 1995). In
addition, recent studies by Dunford et al. have shown that NE11809 has a reduced
ability, compared to NE11808 to inhibit farnesyl diphosphate (FPP) synthase, which
correlates with the reduced anti-resorptive activity of the molecule (Dunford et al.
2001). Furthermore, it has been observed for strong anti-resorptive BPs, such as RIS
and NE11808, that there is a close overlap between the nitrogen group in their three-
dimensional structures, in contrast to NE11809, which has a weak anti-osteoclastic
activity, indicating that location of the nitrogen group at a fixed position provides
strong anti-resorptive potency to BPs (Ebetino et al. 1995).
Both NE11808 and NE11809 were equally effective inhibitors of death at doses of
o
#
10" M, in this study, indicating that prevention of Dex-induced osteocyte apoptosis
by BPs does not depend on inhibition of FPP synthase or on structure/activity
relations of BP molecules. Although it has not been investigated in this thesis, it
might be possible that both BPs reduce the availability of Ca2+ by acting as Ca2t
chelators or the protective effects might be due to an as yet unidentified mechanism
of bisphosphonate action. These findings confirm the protective role of BPs on
osteocytes as demonstrated in chapter 5 and open up new areas of research in the
field of glucocorticoid-induced osteoporosis as minor modifications in the structure
or conformation of the R2 side chain might enable BP molecules to be independently
applied to affect osteoclast activity or osteocyte survival.
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SECTION 4
Conclusions and Future work
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Conclusions and Future work
Bone adapts to changes in its form and function by inducing alterations in its structure
and shape, through the targeted activity of the bone remodelling process. Since the
osteocyte is located within the bone matrix and forms an extensive network of
canalicular processes, it has been proposed to act as the cell that senses mechanical
strains and accordingly transmits signals to osteoblasts and osteoclasts that direct the
remodeling process.
Co-localization has been established between apoptosis of the osteocytes and the
targeted activity of specific bone resorbing cell types. (Noble et al. 1997, Noble et al.
2003). However, previously no specific behavior of osteoclasts or osteoblasts had been
linked with the process of osteocyte apoptotic death. This thesis has provided evidence
that demonstrate for the first time a direct effect on osteoblasts following interaction
with products derived from apoptotic osteocytes. Osteocyte apoptotic bodies induced the
apoptotic death of osteoblasts, while ingestion of apoptotic bodies derived from a range
of other cell types did not affect osteoblast viability. In addition, osteocyte apoptotic
bodies did not induce an apoptotic response to cells other than osteoblasts.
These findings provide a functional role for osteocyte apoptosis in bone and imply that
osteocyte apoptosis occurs in order to target a specific area that requires remodelling,
according to mechanical stimuli, by inducing the apoptotic death of osteoblasts lining
the bone surface, which possibly provides the signals that attract osteoclasts to that area
and initiate bone resorption. Although these data point to a biological significance for
osteocyte apoptosis in bone, certain questions remain to be answered as to the events
that occur downstream of interaction of apoptotic osteocytes with osteoblasts. Further
studies are required to identify factors released during osteoblast apoptosis, including
cytokines and growth factors, which possibly attract osteoclasts into that specific area,
targeting the resorption process. In addition, it appears very important to understand the
identity of osteocyte apoptotic bodies, that is the molecular signature that enables them
to induce specific responses to some cells but not others. Evidence provided in this
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thesis point to the existence of a specific osteocytic marker, since vesicles from cells of
osteoblastic and other lineages did not induce similar phenomena, indicating that this
marker is responsible for the functional identity of osteocytes. Characterisation of this
factor could be possible through the use of 2-D gel electrophoresis and proteomics
analysis, which will enable the production of extensive protein maps unique to
osteocytes. This approach will involve comparison of the membrane-associated and
cytoplasmic protein composition between OAB and apoptotic products derived from
different cell types. Based on data provided in this thesis, it appeared that a membrane
associated protein on OAB might be mediating the OAB-induced osteoblast apoptotic
response. Therefore, the proteomics analysis in combination with appropriate treatment
of the samples, will allow the identification of this factor, whether it is unique to OAB,
or whether it contains different glycosylation patterns for example, compared to
apoptotic bodies from different cell types. Based on the results obtained using this
approach it might be possible to raise functional antibodies against this factor or to
silence target genes in osteocyte cultures, in order to determine their role in
physiological and pathological conditions.
Having identified biological significance I also looked at ways to control the apoptosis
of osteocytes. Data in this thesis have provided evidence on some of the pathways that
Dexamethasone possibly engages to induce apoptosis in osteocytes. In addition it has
been demonstrated that Bisphosphonates protect osteocytes from the adverse effects of
glucocorticoid use in a manner that is independent of their activity and potency against
osteoclasts and bone resorption. Further studies are required to determine whether all
bisphosphonates use a common signalling pathway in osteocytes that also interacts at
some point with pathways used by Dexamethasone during induction of osteocyte
apoptosis. This information could allow manipulation of the apoptotic and survival
pathways engaged by BPs and Dex in order to maintain the osteocyte population and/or
control osteocyte apoptosis.
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Most bone-related diseases arise due to imbalances between the processes of bone
formation and bone resorption. Previous findings which have shown that osteocyte
apoptosis might be directing the activity of osteoclasts to particular sites in bone
requiring remodeling, along with the findings provided in this thesis that osteocyte
apoptosis directly influences the behaviour of osteoblasts by inducing their apoptotic
death, might provide the basis for the development of novel therapeutic interventions in
bone pathology. Such novel approaches could involve the targeting of pathways that
mediate apoptosis in osteocytes in order to induce or prevent apoptosis by using
functional apoptosis-related antibodies or by applying mechanical loading as it has been
shown previously. It might also be possible having characterised the unique osteocytic
factor that is responsible for inducing osteoblast apoptosis to directly influence the
behaviour of osteoblasts at particular sites in order to initiate the turnover process. In
addition, further work is required to understand the functional significance of apoptosis
itself and how it relates to the physiological function of tissues.
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Abstract
Prolonged use of glucocorticoids is associated with decreased bone formation, increased resorption and
osteonecrosis, through direct and indirect effects on the activity and viability of bone effector cells, osteoblasts
and osteoclasts, and osteocytes. This study has investigated molecular pathways implicated in Dexamethasone-
induced apoptosis of osteocytes, using a cell line and primary chicken cells. MLO-Y4 osteocytes were pre-
treated with several bisphosphonates representing a range of anti-resorptive activities and conformation/structure
relationships, and were subsequently challenged with Dexamethasone. Apoptotic cells were detected at various
times after treatment using morphological and biochemical criteria. Dex was shown to induce apoptosis
associated with the Fas/CD95 death receptor and in a caspase 8 dependent manner. The apoptotic response was
inhibited by all variants of the BP molecules, including those with reduced anti-resorptive activity, indicating
that Dex-induced apoptosis is independent of anti-osteoclastic activity. Dex-induced apoptosis was associated
with a transient increase in phosphorylated ERK 1/2 and was blocked by the ERK inhibitor U0126. In addition,
both U0126 and BPs decreased localization of Fas to the cell membrane. ERK activation by PMA did not
induce death or Fas upregulation, suggesting that Fas may be important for the induction of apoptosis and the
existence of an additional factor activated by Dex which enables the cooperation between the Dex-activated
* Corresponding author. Tel.: +44 131 6502964; fax: +44 131 6513077.
E-mail address: Brendon.Noble@ed.ac.uk (B. Noble).
0024-3205/$ - see front matter © 2004 Elsevier Inc. All rights reserved,
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ERK and Fas pathways, during apoptosis of osteocytes. Furthermore, upregulation of death and Fas was not
accompanied by upregulation of FasL, pointing to the possible existence of FasL-independent Fas-associated
death in these cells.
© 2004 Elsevier Inc. All rights reserved.
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Introduction
Glucocorticoids (GCs) have been extensively used as anti-inflammatory agents due to their
ability to modulate immune responses (Ashwell et al., 2000), commonly through activation of the
Fas pathway, one of the best-characterised apoptotic pathways (Schmidt ct al., 2001). Binding of
FasL to FasR causes receptor oligomerisation and recruitment of an adapter protein, FADD, which
interacts with caspase-8, initiating a caspase cascade leading to apoptosis. (Ashkenazi and Dixit,
1998).
As a side effect to their clinical applications, GCs are responsible for rapid and profound bone loss
since they exert anti-mitotic effects on osteoblast precursor cells, induce apoptosis ofmature osteoblasts
and increase the resorptive activity of osteoclasts (Hamdy, 1997). Studies by Weinstein et al. identified
the presence of a high proportion of apoptotic osteocytes in mice, compared to healthy controls,
following chronic administration of prednisolone (Weinstein et al., 1998). It would be of benefit
clinically to develop a concurrent prescription capable of reducing the unwanted side effects associated
with GC-treatment.
The beneficial effects of Bisphosphonates (BPs) on bone have long been demonstrated against Paget's
disease, post-menopausal osteoporosis and GC-induced osteoporosis, by decreasing the resorptive
activity of osteoclasts (Rodan, 1998). BPs are classed as nitrogen-containing (such as PAM and ALN)
and non N- BPs (such as CLO). In osteoclasts, N-BPs inhibit famesyl diphosphate (FPP) synthase and
prevent prenylation of small GTPases, such as Ras and Rho that are required for osteoclast polarization,
resorption and cell survival, whereas non N-BPs are metabolized into cytotoxic analogues of ATP, that
probably act as inhibitors of various ATP-dependent enzymes (Rodan, 1998; Rogers et al., 1999).
Changes in structure and conformation have allowed the development of various N-BPs, which differ in
their anti-resorptive activity since they differ in their ability to inhibit FPP synthase (Dunford et al.,
2001).
In contrast to osteoclasts, the effect of BPs on osteocytes, which are considered the mechanosensors
and transducers in bone, has not been well characterised. BPs have variously been shown to both
decrease and increase ERK (Nishida et al., 2003; Plotkin et al., 1999). Studies by Plotkin et al have
implicated the ERK 1/2 pathway in the ability of BPs to prevent pro-apoptotic effects of Dex on MLO-
Y4 osteocyte-like cells (Plotkin et al., 1999).
This study attempts to identify pro-apoptotic pathways employed by Dex as well as compounds that
could potentially protect osteocytes from glucocorticoid-induced apoptosis. BPs and the MEK inhibitor
U0126 were shown to protect against Dex-induced apoptosis, while upregulation of the Fas receptor
appeared to be important in the induction of apoptosis.




Unless otherwise stated, chemicals were purchased from Sigma, UK. MLO-Y4 murine osteocyte cell
line was obtained from L. F. Bonewald (San Antonio, USA) and grown in collagen coated flasks in
aMEM (Invitrogen, UK) supplemented with 5% fetal bovine serum, 5% newborn calf serum, 1% L-
glutamine and 1% antibiotics, according to previously described methods (Kato et al., 1997). Cells were
cultured until 90% confluence, before passage for experimental use.
Primary chicken osteocytes
Primary osteocytes were obtained and characterised as previously described (Nijweide and Mulder,
1986; Van der Plas and Nijweide, 1992; Aardcn et al., 1996). Briefly, a mixture of osteoblasts and
osteocytes was isolated by sequential collagenase-EDTA digestion from calvariae of 18-day-old chicken
fetuses. Cell fractions were pooled and cultured for 1 day in MEM containing 2% chicken serum, 1.4
mM L-glutamine, 0.3 mM L-ascorbic acid (Merck, UK), 5.6 mM glucose (Invitrogen, UK), and 0.5 pg/
ml gentamycin (Invitrogen, UK). Cell fractions were harvested by trypsin-EDTA, subjected to
immunomagnetic isolation of osteocytes (OCY) by use of the chicken OCY-specific monoclonal
antibody (MAb) OB 7.3, bound to magnetic beads (DYNAL, Oslo, Norway), which reacts specifically
with OCY. A magnetic field was used to separate cells bound to beads, (1-8 beads/cell), used as isolated
OCY. More than 95% of the cell population were OCY, as shown by staining with MAb OB 7.3. Then
2.5 x 104 OCY with beads were seeded onto glass slides and used for experiments the next day.
Cell treatment
For experimental manipulations, cells were plated in growth medium at a density of 1 x 104, in 24
multiwell plates for 24 hours, prior to experimentation. Experiments were carried out a minimum of 3
times, and each treatment group was represented by 3 wells in each independent experiment. Cells were
observed in 3 fields per well (x20 magnification lens, approximately 40-100 cells per field) resulting in
9 fields per treatment group. Identical magnifications were used for all apoptosis estimates allowing
similar numbers of cells to be counted per field in all experiments. For western blot analysis, cells were
plated at a density of 1 x 105 in 60 mm petri dishes.
Induction of cell death
Cells were incubated in growth medium supplemented with 10~8 to 10~6 M Dex (Calbiochem, UK)
and 0.4 pM to 0.4 mM H202 for 1-24 hours.
Prevention of cell death using BPs and inhibitors of intracellular signaling proteins
Osteocytes were pre-incubated with caspase 8 substrate II inhibitor Z-IETD-FMK (Calbiochem, UK)
and caspase 3/7-selective inhibitors (GlaxoSmithKline, USA) at 10"6 M for 1 and 24 hours, to evaluate the
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role of the Fas pathway in Dex-induced apoptosis. Cells were also pre-treated for 1 hour with PAM, ALN,
CLO (kind gift form Prof. Mike Rogers, University ofAberdeen, UK) and the heterocyclic-containing N-
BPs, NEII808 andNEII809 (Procter and Gamble, USA), at concentrations of 1CU8 to 10~6 M, followed by
Dex treatment. In addition, cells were pre-incubated for 30 minutes with U0126, a MEK 1/2 inhibitor
(Promega, UK) at concentrations of 10 to 30 pM (Favata ct al., 1998), SB203580 (Calbiochem, UK), a
p38 inhibitor at concentrations of 5 to 15 pM (Cucnda ct al., 1995) and with PMA at 2 ng/ml-200 pg/ml for
1 to 5 hours. All pre-treatment agents were maintained in cultures in the presence of Dex or H202.
Determination of apoptotic state
A range of techniques were used to determine the presence of apoptotic cells, for all the independent
experimental culture setups, but only representative examples of each technique are shown throughout
the manuscript:
1) DAPI staining for healthy and apoptotic cell morphology
Following treatment, cells were fixed in 4% paraformaldehyde, washed in PBS and air dried. Cells
were then incubated with DAPI at 2.5 ng/ml for 10 minutes, washed in PBS and examined by
fluorescence microscopy and digital image capture.
2) Acridine orange (AO) staining for healthy and apoptotic cell morphology.
Following treatment, cells were immediately incubated in Walpole's acetate buffer pH 4.2 (10:7, 1 M
NaAc: 1 M HC1) for 5 minutes, followed by AO staining for 25 minutes. Cells scored as apoptotic were
characterised by nuclear or cytoplasmic condensation, two or more nuclear fragments, single crescent-
shaped nucleus or blebbing.
3) DNA fragmentation using in situ Nick Translation (NT)
Cells demonstrating DNA breaks were investigated in samples fixed in 4% paraformaldehyde, using a
previously described DNA nick translation technique (Noble et al., 1995, 1997). Positive controls were
established through pre-treatment with DNasel at 0.2 mg/ml for 30 minutes. Cells were exposed to NT
mixture which consisted of 3 pM Digoxigenin (DIG) labelled dUTP (DIG-11-dUTP), 3 pM each of
dATP, dGTP, dCTP, 50 mM Tris HC1, pH 7.5, 5 mM MgCl2 and 0.1 mM dithiotreitol and 0.5 pl/100 pi
DNA polymerase for 1 hour at 37 °C, in a humidified chamber (Roche, UK). Wells were incubated for 1
hour at RT with fluorescein isothiocyanate (FITC)-labelled anti-DIG antibody and 5% normal sheep
serum. Wells were then washed in PBS and counter stained with propidium iodide (PI). Cells containing
fragmented DNA stained positive for FITC label and PI, as determined using fluorescence microscopy
and digital image capture, based on 3 fields from a total of 3 wells per treatment.
4) Annexin-V-FITC Assay
During apoptosis, PS exposure on the outer leaflet of the membrane bilayer can be detected with
fluorescently labelled Annexin V. Cells were incubated with Annexin-V-FITC at 1 pg/ml for 15 minutes
at RT, followed by PI to identify necrotic cells in the culture. Fluorescence microscopy, allowed
discrimination between viable (FITC negative, PI negative), apoptotic (FITC positive) or necrotic cells
(FITC negative, PI positive).
Determination ofFas expression by immunocytochemical staining
Following incubation with various agents, cells were fixed in 4% paraformaldehyde and
subsequently washed in PBS. Cells were incubated for 5 minutes with 0.1% SDS, and were washed
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in PBS thoroughly. Cells were then blocked for 20 minutes in goat serum followed by 1 hour
incubation with anti-Fas mAb at RT. After washing in PBS, cells were incubated with secondary anti-
mouse FITC antibody for 1 hour and were counterstained with PI. Cells staining positive for FITC
label and PI, were considered as cells expressing Fas on the plasma membrane, as determined using
fluorescence microscopy and digital image capture, based on 3 fields from a total of 3 wells per
treatment.
Reverse transcription-polymerase chain reaction
Total RNA was isolated from cultures of MLO-Y4 cells using RNA-B™ (Biogenesis) according to
the manufacturers instruction. cDNA was synthesized from 3 pg of total RNA using oligo dT primers,
and RNA was converted into cDNA by Superscript II RNaseH" reverse transcriptase first strand
synthesis system for RT-PCR (Invitrogen). The PCR reaction was performed using Qiagen Taq PCR
core kit (10X reaction buffer, Taq 5 u/pl, Q buffer and dNTP 10 mM each) in a total of 25 pi reaction
containing 5 pM each forward and reverse primers. Mouse Fas specific primers were designed against
sequence accession number M83649 and mouse (3-Actin specific primers against sequence accession
number X03765 from HGMP database as shown below. The resulting PCR products for Fas and Actin
were 220 bp and 290 bp respectively. The PCR reaction was carried out for 33 cycles with PTC-200
Peltier thermal cycler (MJ Research). PCR conditions were denaturation at 94 °C for 50 seconds,
annealing at 50.5 °C for 1 minute and extension at 72° for 1 minute 30 seconds. The PCR products were
analysed in 1.5% agarose gel containing ethidium bromide.
Primer Sequences:
Fas forward 5' -CATGCTGTGGATCTGGGCTGT-3'
Fas reverse 5' -GTGTACCCCCATTCATTTTGC-3'
Actin forward 5' -CAAGGTGTGATGGTGGGAATG-3'
Actin reverse 5' -GCTACGTACATGGCTGGGGTG-3'
The Accession number for the primers used for FAS ligand PCR is U10984. The identity of all PCR
products was confirmed on DNA sequencing.
Western blot analysis of intracellular signalling proteins
Cells were maintained in identical culture conditions (presence of serum) to those used to study
effects on apoptosis. Lysates were prepared (lysis buffer: 20 mM Tris-HCl, pH 7.5, 0.1% (v/v) Igepal, 6
mM sodium deoxycholate, 150 mM NaCl, 2 mM EGTA, 2 mM EDTA, 0.1 mM Na3V04 and 20 mM
NaF and a protease inhibitor cocktail tablet (Roche, UK)), and protein concentrations were estimated
using a commercially available kit (Bio-Rad, UK). Lysates (30 pg/lane) were resolved on SDS-PAGE
gels, transferred onto PVDF membranes and blocked with TBST solution (10 mM Tris-HCl, pH 7.4, 150
mM NaCl, 0.1% Tween 20) supplemented with 3% BSA, and then hybridized with rabbit polyclonal
antibodies against phospho-p44/42MAPK, phospho-MEK 1/2, phospho-cRaf, phospho-p90rsk and total
MAPK p44/42 (New England Biolabs, UK). Proteins were detected using ECL reagents according to the
manufacturers instructions. Blots were stripped (100 mM (3-mercaptoethanol, 69 mM SDS and 62.5 mM
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Tris-HCl, pH 6.7) and rehybridised with an antibody that recognises total p44/42 MAPK, to verify equal
loading of samples.
Immunoprecipitation and western blot analysis ofFas
Protein extracts (1 mg) from cell lysates were diluted to 1 mg/ml and incubated with 15 pi of
protein A agarose conjugate bead slurry (50% conjugate/ 50% PBS) and 4 pi of Jo2 hamster anti-Fas
monoclonal antibody (BD Transduction Laboratories, USA) overnight at 4 °C. The agarose beads
were collected by centrifugation at 4 °C, washed four times in lysis buffer and were then subjected
to electrophoresis as described above. Proteins on PVDF membranes were hybridized with Jo2
antibody followed by secondary anti-hamster antibody (Abeam, USA) and were detected using ECL
reagents.
Statistical analysis
All statistical analyses were performed using quantitative data analysis with SPSS release 11.5 for
Windows. Analysis of Variance (ANOVA), Tukey test and Dunnett test were performed for comparison
between the treatment groups. The Tukey test allows comparison ofmore than two means at once since
this reduces the error associated with multiple t-tests (Zar, 1984). The Dunnett test allows comparison
between the control mean and every other mean in the group (Zar, 1984). Results are expressed as
means ± S.D. p<0.05 was considered to be statistically significant.
Results
Dexamethasone induces MLO-Y4 cell apoptosis in a time- and dose-dependent manner
MLO-Y4 osteocytes were cultured with Dex at 10~7—10~5 M for various times between 1 and 24
hours (Fig. 1A and B). Apoptotic osteocytes appeared irregularly shaped and smaller in size, as shown
by AO staining, while DAPI staining revealed chromatin condensation, shrinkage of nuclei and the
fragmentation of the nuclear material into smaller blebs (Fig. 1C). Maximal levels of death
accompanied by cell loss were reached at 5 hours of incubation with concentrations of 10"5 M and
10~6 M, whereas, at 24 hours, numbers of osteocytes in culture recovered somewhat, while apoptotic
levels decreased, suggesting that Dex-induced death of osteocytes is transient (Fig. 1A and B). At
concentrations of 10~7 M, Dex did not induce apoptosis in these cells. At 10~5 M a small proportion
of cells were noted to have expanded and burst characteristics of necrosis. Based on the apoptotic
criteria in response to the different concentrations and time points investigated, the dose of 10-6 M,
which did not induce necrosis, was selected for future experiments, reaching a peak at 5 hours
incubation.
Assessment ofDex-induced apoptosis by Annexin-V-FITC and nick translation assays
Early apoptotic features induced by Dex at 5 hours, were detected by both Annexin-V-FITC, which
resulted in 12.35% ±1.14 osteocytes expressing PS (<1% necrotic cells identified by PI counter-
G. Kogianni et at. /Life Sciences 75 (2004) 2879-2895 2885
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Fig. 1. Dexamethasone induces apoptosis in MLO-Y4 osteocytes in a time- and dose-dependent manner. MLO-Y4 cells were
then stained with A.O. and examined by fluorescence microscopy to determine (A) Number of cellsand (B) Percentage of
apoptotic osteocytes per number of cells ± S.D., in response to different doses of Dex and time. (C) Representative images of
untreated (top panel) and Dex-treated MLO-Y4 osteocytes (bottom panel) at 10~6 M for 5 hours stained with DAP1. Bar = 5
pm. (*** = p < 0.0001, ** = p < 0.001, * = p < 0.05).
staining), and by Nick Translation assay, which resulted in 12.83% ±1.00 osteocytes positive for
DNA breaks, compared to 1.33 ± 0.67 and 1.85 ± 1.38 in control cultures, respectively (data not
shown).
Dexamethasone upregulates the Fas pathway
RT-PCR studies revealed that MLO-Y4 osteocytes express Fas receptor either in basal state or
following treatment with Dex (Fig. 2A). Flowever, FasL expression was not detected in both treated or
untreated samples (data not shown). Immunocytochemistry showed that Dex increased the percentage of
cells staining positive for Fas as early as 3 hours by 7-fold and at 5 hours by 22-fold compared to control
(Fig. 2B and D). In addition, western blot analysis demonstrated time-dependent increase in Fas protein
upon treatment with Dex (Fig. 2D).

























Fig. 2. Dex upregulates Fas expression in MLO-Y4 osteocytes. (A) Fas expression was confirmed using RT-PCR with RNA
extracted from MLO-Y4 cultures treated with Dex. (B) Fas protein was detected following Dex treatment for 1 to 5 hours using
a Fas mAb and fluorescence microscopy. Graph shows percentage of cells expressing Fas ± S.D. (C) Detection of Fas protein
levels following Dex treatment for 1 to 5 hours using western blot analysis. Changes in band densitometry were quantified
using NHI image analysis system and expressed as percentage change relative to zero time control ± S.D. (D) Representative
images of fluorescence microscopy (20x magn.). Untreated osteocytes (left panel) and Dex-treated osteocytes (right panel).
(*** = p < 0.0001, ** = p < 0.001, * = p < 0.05 compared to control).
The involvement of Caspase 8/FL1CE, which lies downstream of Fas, was then investigated,
in Dex-induced apoptosis. Pre-treatment with the caspase 8 inhibitor Z-IETD-FMK reduced the
induction of death at 5 hours, up to 5-fold, compared to cultures treated with Dex, as shown
by Annexin-V-FITC assay, suggesting that caspase 8 is involved in the apoptotic machinery
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Fig. 3. Inhibitors of caspases 8 and 3,7 reduce pro-apoptotic stimuli induced by Dex. MLO-Y4 osteocytes were incubated with
inhibitors of caspase-8 (Z-1ETD-FMK) and a caspase 3/7 selective inhibitor for 1 hour, followed by Dex treatment for 5 hours.
Cells were incubated with Annexin-V F1TC and examined by fluorescence microscopy for PS detection. Graphs represent
percentage of apoptotic osteocytes per number of cells ± S.D. (*** = p < 0.0001, ** = p < 0.001, * = p < 0.05).
activated by Dex in MLO-Y4 osteocytes (Fig. 3). In addition, pre-treatment with caspase 3/7 -
selective inhibitors for identical times reduced the percentage of apoptotic osteocytes up to 6-
fold (Fig. 3).
Bisphosphonates prevent Dex-induced apoptosis in MLO-Y4 osteocytes
BPs were used at concentrations that did not increase apoptosis above control levels (data not shown),
to treat osteocytes prior to addition of Dex in cultures. Estimation of apoptosis showed that N-BPs
(PAM, ALN and the heterocyclic-containing NEII808 and NEII809) and non N- BPs (CLO) at 10-8 M
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Fig. 4. BPs prevent MLO-Y4 osteocyte apoptosis induced by Dex. MLO-Y4 osteocytes were incubated with BPs at 10~8M
prior to Dex treatment, for 5 hours. Cells were stained with AO and examined by fluorescence microscopy. Graphs represent
percentage of apoptotic osteocytes, per number of cells ± S.D. (*** = p < 0.0001, ** = p < 0.001, * = p < 0.05).
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Inhibitors ofMAP kinase signalling molecules prevent Dex-induced apoptosis in ML0-Y4 osteocytes
The effect of Dex on MLO-Y4 osteocytes was further characterised in the presence of protein
inhibitors such as the MEK1/2 inhibitor U0126 and the p38 inhibitor SB203580. Dose response studies
identified optimal concentrations of U0126, which did not significantly increase apoptosis above control
levels either for the compound alone, or the vehicle in which it was delivered, within the range of
concentrations known to inhibit ERK 1/2 (Favata et al., 1998) (Fig. 5). Quantification of apoptosis
showed that concentrations of U0126 at 10 and 20 pM exerted protective effects on osteocytes
following 5-hour incubation period with Dex (Fig. 5). In contrast, SB203580 at concentrations of 5 to 15
pM known to inhibit p38 (Cuenda et al., 1995), did not prevent GC-induced apoptosis, while doses
above 10 pM induced significant apoptosis when added alone to osteocyte cultures (data not shown).
Primary cultures of chicken osteocytes were also used to observe the Dex induced death response in
primary cells. Evaluation of apoptosis after a 5 hour-culture period, revealed that in a similar way to that
seen in the MLO-Y4 cell line, both BPs and the MEK inhibitor U0126 were capable of blocking Dex-
induccd death in these primary cells (data not shown).
BPs and protein kinase inhibitors do not protect osteocytes from oxidant-induced death
To evaluate the role of the BP and ERK pathways in the induction of osteocyte apoptosis by other
agents, MLO-Y4 cells were pre-treated with PAM and U0126 prior to their exposure to H2O2, at
concentrations shown to induce apoptosis (0.08 mM to 0.4 mM). Examination of apoptotic morphology
by AO staining revealed that PAM and U0126 did not protect MLO-Y4 osteocytes against H2O2
induced death stimuli (data not shown).
Dexamethasone activates the MEK/ERK protein signaling pathway
Incubation with Dex, increased the amount of activated ERK 1/2 protein in osteocytes, compared
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Fig. 5. The MEK 1/2 inhibitor U0126 prevents Dex-induced apoptosis. (A) U0126 prevents MLO-Y4 osteocyte
apoptosis induced by Dex, in a dose dependent manner, and (B) in the presence of PAM. Cells were stained with AO and
examined by fluorescence microscopy. Graphs represent the percentage of apoptotic osteocytes per number of cells ± S.D.
(*** = p < 0.0001, ** = p < 0.001, * = p < 0.05).
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Fig. 6. (A) Dex activates the ERK 1/2 protein kinase, in a time dependent manner. ERK phosphorylation induced by Dex was
statistically different from control during all time points investigated. (B) ALN reduces the Dex-induced ERK1/2 activation,
at 5 minutes, whereas U0126 blocks Dex-induced ERK 1/2 activation. MLO-Y4 cell lysates were subjected to Western Blot
analysis, using an anti-phospho MAPK p44/p42 antibody. The blots were stripped and reprobed with a total anti-MAPK p44/
p42 antibody, to verify equal loading of samples. Changes in band densitometry were quantified using NH1 image analysis
system and expressed as percentage change relative to control samples, representing either vehicle control or zero time
control ± S.D., from 3 independent blots. ** = p < 0.001, * = p < 0.05 compared to control, + = p < 0.05 compared to Dex
treatment.
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Fig. 7. Dexamethasone activates the ERK 1/2 pathway. Lysates prepared from MLO-Y4 cells treated with Dex, ALN and
U0126, were subjected to Western Blot analysis, using (A) anti-phospho MEK 1/2 antibody, (B) anti-phospho p90rsk and (C)
anti-phospho c-Raf antibody. Changes in band densitometry were quantified using NH1 image analysis system and expressed as
percentage change relative to vehicle sample ± S.D., from 3 independent blots. ***=p < 0.0001, **=p < 0.001, * = p < 0.05,
compared to control +++ = p < 0.0001, + = p < 0.05 compared to Dex treatment.
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phospho ERK 1/2 antibody (Fig. 6A). Activation of ERK 1/2 protein by Dex was acute, since it was
detected as soon as 1 minute following treatment and was decreased to basal control levels, after 1
hour of treatment.
BPs transiently increased ERK 1/2 phosphorylation within 1 minute of treatment, returning to
baseline by 5 minutes, as shown previously by Plotkin et al. (Plotkin et al., 1999). In this treatment group
baseline levels were maintained for all subsequent time points investigated, up to 5 hours (data not
shown). Addition of Dex to cells pre-treated for 1 hour with BPs resulted in a reduced activation of ERK
1/2 relative to samples treated with Dex alone (Fig. 6B). The MEK 1/2 protein inhibitor, U0126,
blocked Dex and/or BP-induced ERK 1/2 activation in all cases.
In order to further characterize the role ofERK 1/2 pathway in Dex-induced apoptosis, the presence of
proteins lying both upstream (MEK 1/2 and C-Raf) and downstream (p90rsk) of ERK 1/2 protein, was
investigated. Western blot analysis showed that MEK (Fig. 7A) and p90rsk (Fig. 7B) activation by Dex
coincided with ERK 1/2 activation, while pre-treatment with ALN slightly reduced phosphorylated levels
of both proteins. In addition, U0126 prevented activation of p90rsk by Dex, but did not affect
phosphorylated MEK1/2 protein, in accordance with previous reports (Favata ct al., 1998). Levels of c-
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Fig. 8. BPs and U0126 suppress Dex-induced Fas expression. Cells were probed with an anti-Fas antibody and examined by
fluorescence microscopy. (A) N- and non N-BPs reduce Dex-induced Fas expression as shown by immunocytochemistry and
western blot analysis. Changes in band densitometry were quantified using NHI image analysis system and expressed as
percentage change relative to vehicle sample ± S.D. from 3 independent blots (B) PMA alone did not increase Fas expression,
compared to control. Graphs represent percentage of osteocytes, expressing Fas per number of cells ± S.D. (*** = p < 0.0001,
compared to control, ++ = p < 0.001, + = p < 0.05 compared to Dex treatment).
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Fig. 9. PMA-induced ERK 1/2 activation is not associated with osteocyte apoptosis. Cells treated with PMA followed by Dex
were (A) subjected to western blot analysis to reveal pERKl/2 and p90rsk activation and (B) treated to reveal DNA breaks
using the Nick Translation assay. PMA did not affect osteocyte apoptosis, compared to control. Graphs represent percentage of
apoptotic osteocytes, per number of cells ± S.D. (*** = p < 0.0001, ** = p < 0.001, * = p < 0.05).
Suppression ofDex-induced Fas activation by MEK 1/2 inhibitor and BPs
The role of BPs and ERK 1/2 protein kinase in Dex-induced activation of Fas was investigated by
immunocytochemistry studies and western blot analysis (Fig. 8). Previous studies have shown
interaction between ERK and Fas protein pathways in the induction of apoptosis (Goillot et al., 1997).
Pre-treatment of osteocytes with U0126 at 20 pM, prevented activation of Fas by Dex (p=0.0001,
compared to Dex-treated samples). In a similar manner to U0126, pre-treatment of MLO-Y4 cells with
both N- and non N-BPs at 1CT8 M, reduced activation of Fas by Dex (p=0.0001).
PMA-induced ERK1/2 activation is not associated with osteocyte apoptosis
PMA did not induce osteocyte apoptosis (Fig. 8), despite demonstrating a clear increase in
phosphorylated ERK in MLO-Y4 osteocytes as determined by western blotting (Fig. 9A). Furthermore,
PMA when administered alone at concentrations of 2 ng/ml to 200 pg/ml for 1 to 5 hours did not
increase Fas, while prior to Dex treatment PMA did not enhance Dex-induced Fas upregulation, in
contrast to Dex treated cultures (Fig. 9B).
Discussion
Prolonged administration of glucocorticoids leads to bone loss and osteoporosis, through stimulation
of resorption and induction of osteoblast and osteocyte apoptosis (Weinstein et al., 1998). This study has
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attempted to investigate molecular pathways implicated in Dex-induced death of osteocytes, the
mechanosensors and transducers in bone, and on molecules that might provide therapeutic approaches to
combat this death. Dex induction of osteocyte apoptosis characterised by several classical apoptotic
features, including chromatin and cytoplasmic condensation, DNA fragmentation, exposure of
phosphatidylserine and formation of apoptotic bodies, was concentration- and time-dependent. In
addition, apoptosis was caspase-dependent since inhibition of caspases —3 and —7 (Lee ct al., 2000),
which are responsible for chromatin condensation, DNA fragmentation and membrane blebbing,
suppressed Dex-induced death.
Dex-induced apoptosis has been associated with the Fas/FasL apoptotic pathway in several different
cell types, in relation to its action as an immunosuppressive agent (Schmidt et al., 2001). Fas receptor
mRNA was detected in MLO-Y4 osteocytes both in response to Dex treatment and in untreated
cultures. However, Dex treatment upregulated localisation of Fas protein on the osteocyte plasma
membranes, in a time-dependent manner compared to untreated controls, indicating a possible
association between Fas recruitment and the incidence of osteocyte apoptosis in the presence of Dex.
Indeed, inhibition of caspase 8 using a peptide inhibitor (Martin ct al., 1998), the upstream caspase
participating in the Fas pathway, blocked Dex-induced apoptosis, further supporting a possible
association between Dex and the Fas pathway in osteocyte apoptosis. However, we failed to detect
expression of Fas Ligand in both Dex-treated and untreated cultures, suggesting that if indeed there is
activation of the Fas-related pathway in the presence of Dex it is FasL independent. Similar
phenomenon has been observed in tumour cell studies, showing that anticancer agents directly
promote Fas receptor trimerisation and activation of the FADD/caspase 8 pathway, independently of
FasL (Misceau et al., 1999).
BPs suppressed Dex-induced apoptosis in MLO-Y4 osteocytes after 5 hours treatment with Dex, in
accordance to previous reports by Plotkin, et al. (Plotkin et al., 1999). Although we do not know the half-
life of BPs in in vitro experimental conditions, the pharmacokinetics of these molecules in vivo, might
allow them to suppress GC-induced apoptosis of osteocytes for longer periods of time, since they can be
retained active in the skeleton until their release, following resorption of the multiple sites in which they
were deposited.
Dex-induced apoptosis was prevented by both non N-BPs (CLO), which are metabolized into
cytotoxic analogues of ATP and N-BPs (PAM and ALN), which inhibit prenylation through
inhibition of FPP synthase (Rogers et al., 1999). The third generation heterocyclic-containing
NE11808 was used as well as the structurally similar NE11809 which differs in terms of having a
methyl group, which confers reduced inhibition of FPP synthase (Dunford et al., 2001). Both BPs
were equally effective inhibitors of death, indicating that prevention of Dex-induced osteocyte
apoptosis by BPs does not depend on inhibition of FPP synthase or on structure/activity relations of
BP molecules.
ERK 1/2 is associated variously with the induction of proliferative and survival signals (Robinson and
Cobb, 1997; Lai et al., 2001; Jamieson and Yamamoto, 2000; Tran et al., 2001). However, in contrast to
the known pro-survival effects, ERK is also implicated in cisplatin-induced apoptosis in HeLa cells,
brain injury during focal cerebral ischemia and activation-induced cell death of T cells (Wang et al.,
2000; Alessandrini et al., 1999; Van den Brink et al., 1999).
Recently, Nishida, et al have reported that YM529, a new bisphosphonate, decreases
phosphorylation of ERK1/2 during apoptosis of HL60 cells (Nishida et al., 2003). Nevertheless,
Plotkin, et al observed an acute activation of ERK by BPs, which was sustained for 5 minutes during
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the pre-treatment period (Plotkin et al., 1999), and suggested that activated ERK is involved in the
protective effects of BPs on Dex-induced apoptosis. Our study has also shown activation of ERK by
BPs, which peaked at 5 minutes of addition of BPs to osteocyte cultures. However, Plotkin, et al did
not measure possible ERK production in response to Dex, as has been noted in other cell types
(Jamieson and Yamamoto, 2000). Following on from both studies, our work has investigated the
course of ERK activation in order to characterize the effect of Dex on the ERK pathway, during
osteocyte apoptosis. In contrast to activation of ERK by BPs during the pre-treatment period, Dex
transiently increased the amount of activated ERK1/2 in osteocytes, which remained elevated for the
first hour of incubation, and was suggestive of a specific non-genomic effect, involving membrane-
bound GC receptors, since activation of cytosolic receptors requires at least 30 minutes (Patschan et
al., 2001). Inhibition of ERK by U0126 suppressed Dex-induced osteocyte apoptosis, both in the
presence and absence of BPs, indicating that induction of death signals by Dex-activated ERK
compared to non-damaging BP-activated ERK is due to either differences in the timing and duration
of activation or to the generation of secondary factors by Dex, which render ERK pro- rather than
anti-apoptotic. Furthermore, our data indicated a significant reduction in ERK phosphorylation
induced by Dex, in the presence of BPs. Variance between the findings of Plotkin et al., in which
ERK appears as an anti-apoptotic signal and our current conclusion regarding its positive role in
apoptotic death, may be due to differences in experimental conditions between the two studies.
Plotkin et al studied apoptosis in serum-replete conditions and ERK under serum free conditions,
while we studied both apoptosis (the phenomenon) and ERK phosphorylation in these cells under
identical serum-replete conditions. On the other hand, PMA treatment failed to increase the
proportion of apoptotic osteocytes when added alone, and did not prevent or enhance the pro-
apoptotic stimuli in the presence of Dex, indicating that activation of ERK through other pathways is
not sufficient to induce osteocyte apoptosis.
Dex treatment also increased MEK and p90rsk activation at identical times to the activation of ERK,
which was however reduced in cultures pre-treated with BPs, whereas levels of c-Raf were not altered
compared to control levels, suggesting that Dex is acting downstream of c-Raf or through another
isoform of Raf in the signalling pathway involving Raf, MEK and ERK. In contrast to ERK, p38
inhibition did not reduce osteocyte apoptosis, indicating specificity in the pro-apoptotic effects ofMAPK
family members.
In neuroblastoma cells transfection with activated MEK1 upregulated Fas activity (Goillot et al.,
1997), while in T cells, during activation-induced cell death, transfection of a dominant negative MEK1
inhibited FasL expression (Van den Brink et al., 1999). In our study, inhibition of ERK in experiments
using the Fas/CD95 antibody reduced the Dex-induced Fas activation, whereas upregulation of ERK by
PMA did not affect Fas levels, indicating that production of Fas is closely associated to the pro-
apoptotic signals induced by Dex. In addition, prevention of Dcx-induced apoptosis by non N-BPs and
N-BPs also decreased Fas expression, supporting the importance of Fas in the death response and
pointing to the existence of an additional factor associated with Dex-treatment that might enable the co¬
operation between ERK and Fas pathways during the induction of osteocyte apoptosis. In conclusion,
inhibition of Dex-induced osteocyte apoptosis by BPs was independent of the FPP synthase pathway
associated with strongly anti-resorptive molecules, suggesting that BPs might in principal by modifying
the structure or conformation of the R2 side chain, be independently applied to affect osteoclast activity
or osteocyte survival, providing therapeutic approaches for various bone diseases induced by
glucocorticoids.
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